

Supplementary Online Content 1

FAST Uveitis Trial original protocol, final protocol, and summary of changes

NEI U10 EY021125-01

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

Data Safety and Monitoring Committee (DSMC) Meeting

September 11, 2012

Manual of Operations (MOP)

Elizabeth Proctor Library, Room S-318
F.I. Proctor Foundation for Research in Ophthalmology
513 Parnassus Avenue
University of California, San Francisco

TABLE OF CONTENTS

INVESTIGATORS, PERSONNEL AND STUDY SITES	5
DATA SAFETY AND MONITORING COMMITTEE (DSMC) MEMBERS.....	6
BACKGROUND.....	7
1. INTRODUCTION TO TRIAL	8
1.1 RESEARCH QUESTION	8
1.2. Specific Aims.....	8
2. TRIAL DESIGN	9
2.1 DESIGN SUMMARY	9
2.2 STUDY TIMELINE	10
2.3 ELIGIBILITY	10
2.3.1 Anatomical Location of Inflammation.....	10
2.3.2 Inclusion Criteria	11
2.3.3 Exclusion Criteria	12
2.4 RANDOMIZATION AND MASKING.....	12
2.5 DEFINITIONS FOR PRIMARY ENDPOINT.....	14
2.5.1 Treatment Success	14
2.5.2 Treatment Failure.....	14
2.5.3 Primary Endpoint Flowchart	17
3. TREATMENT PLAN	18
3.1 STUDY DRUGS.....	18
3.1.1 Methotrexate.....	19
3.1.2 Mycophenolate mofetil	19
3.1.3 Folic acid.....	20
3.1.4 Packaging and distribution of study medications	20
3.1.5 Adherence to the treatment plan	20
3.2 CORTICOSTEROID THERAPY	21
3.2.1 Oral prednisone	21
3.2.2 Supplements.....	23
3.2.3 Topical corticosteroid	23
3.2.4 Other adjunctive treatments	23
3.3 STUDY PROCEDURES	24
4. STUDY VISITS.....	25
4.1 VISIT SCHEDULES	25
4.1.1 Phase I: First-line Treatment.....	25
4.1.2 Phase II: Rescue Treatment.....	26
4.1.3 Non-study visits.....	26
4.2 STUDY FORMS COMPLETION SCHEDULE	27
4.3 ENROLLMENT AND BASELINE-I VISIT	28
4.3.1 Consent and eligibility evaluation	28
4.3.2 Randomization	28
4.3.3 Procedures for data collection.....	28
4.3.4 Specimens	29
4.3.5 Forms for data collection.....	29
4.4 FOLLOW-UP VISITS	29
4.4.1 Procedures for data collection	29
4.4.2 Specimens.....	29

4.4.3 Forms for data collection.....	30
4.5 BASELINE-II	30
4.5.1 Eligibility.....	30
4.6 NON-STUDY VISITS	30
4.6.1 Procedures for data collection	30
4.6.2 Specimens.....	31
4.6.3 Forms for data collection.....	31
5. STUDY EXAMINATIONS AND PROCEDURES	31
5.1 QUALITY OF LIFE QUESTIONNAIRE ADMINISTRATION.....	31
5.2 REFRACTION AND VISUAL ACUITY	32
5.2.1 Refraction Procedure	32
5.2.2 Visual acuity procedure.....	39
5.2.3 Visual acuity training and certification	43
5.3 OPHTHALMIC PROCEDURES.....	43
5.3.1 Grading inflammation	43
5.3.2 Inter-observer variation of ocular inflammation.....	46
5.4 OPTICAL COHERENCE TOMOGRAPHY	46
5.4.1 Required patient assessments – Heidelberg Spectralis.....	46
5.4.2 Scan procedures – Heidelberg Spectralis	47
5.4.3 Obtaining retinal thickness data – Heidelberg Spectralis.....	48
5.4.4 Saving/Exporting data – Heidelberg Spectralis	48
5.4.5 Required patient assessments – Zeiss Cirrus	49
5.4.6 Scan procedures – Zeiss Cirrus.....	49
5.4.7 Obtaining retinal thickness data –Zeiss Cirrus	50
5.4.8 Saving/Exporting data – Zeiss Cirrus	50
5.4.9 OCT operator qualifications.....	50
5.5 FUNDUS PHOTOGRAPHY.....	50
5.6 LABORATORY MEASUREMENTS	51
6. ADVERSE EVENTS.....	51
6.1 NON-SERIOUS ADVERSE EVENT (AE)	51
6.2 SERIOUS ADVERSE EVENT (SAE)	52
6.3 ADVERSE EVENT REPORTING	52
6.4 PATIENT DEATH	52
7. DATA COLLECTION AND MANAGEMENT	52
7.1 DATA COLLECTION FORMS	53
7.2 DATA REVIEW	53
7.3 DATA ENTRY.....	53
7.3.1 Data Entry Errors	53
7.3.2 Data Consistency and Validity.....	54
7.3.3 Data Preparation and Cleaning.....	54
7.3.4 Monitoring.....	54
7.4 DATA ANALYSIS	55
7.5 DATA STORAGE AND SECURITY.....	55
8. QUALITY CONTROL.....	55
8.1 MEDICATION STORAGE AND EXPIRY	56
8.2 PERIODIC REPORTS	56
8.3 DATA MANAGEMENT, SECURITY, AND QUALITY ASSURANCE	56
8.4 MONITORING COMPLIANCE	56

8.5 CERTIFICATION	56
8.6 DATA AUDITS	56
9. DUTIES AND RESPONSIBILITIES OF STAFF	56
9.1 OPHTHALMOLOGIST	56
9.2 CLINICAL TRIAL MANAGER	57
9.3 STUDY COORDINATOR.....	57
9.4 DATA ANALYST	57
9.5 DATA ENTRY OPERATOR	57
9.6 BIOSTATISTICIAN.....	57
9.7 OPHTHALMIC ASSISTANTS	58
9.8 REFRACTIONISTS	58
9.9 OCT OPERATORS.....	58
9.10 FUNDUS PHOTOGRAPHERS.....	58
9.11 FUNDUS GRADERS.....	58
10. STUDY ORGANIZATION.....	58
10.1 EXECUTIVE COMMITTEE	58
10.2 CLINICAL COORDINATING CENTER (CCC).....	58
10.3 DATA COORDINATING CENTER (DCC)	59
10.4 DATA ANALYSIS CENTER (DAC).....	59
10.5 DATA SAFETY AND MONITORING COMMITTEE (DSMC)	59
10.6 EDITORIAL COMMITTEE.....	60
10.7 STUDY SITES	60
10.8 PHARMACY	60
10.9 STUDY COMMUNICATIONS	60
11. BIBLIOGRAPHY.....	61
APPENDIX A: STUDY FORMS	63
APPENDIX B: CERTIFICATION FORMS	118
APPENDIX C: UPRC MANUAL.....	121

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

Investigators, Personnel and Study Sites

Nisha Acharya, MD, MS ¹	Principal Investigator Site Director San Francisco Study Ophthalmologist San Francisco
SR Rathinam, MD, PhD ²	Site Director Aravind Eye Hospitals Study Ophthalmologist Madurai
N Radhika, MD ²	Study Ophthalmologist Madurai
VK Anuradha, MD ³	Study Ophthalmologist Coimbatore
Eric Suhler, MD, MPH ⁴	Site Director Casey Eye Institute Study Ophthalmologist Oregon
Todd Margolis, MD, PhD ¹	Medical Monitor
Thomas Lietman, MD ¹	Data Coordinating Center
Dr. Travis Porco, MPH, PhD ¹	Data Coordinating Center, Principal statistician
Dr. Wayne Enanoria, PhD ¹	Data Coordinating Center, Research epidemiologist
Salena Lee, OD ¹	Refraction Certification Manager
Natalie Nardone, PhD ¹	Study Coordinator San Francisco
Gobinath Kanagaraj ²	Study Coordinator Madurai
Mr. Meenakshi Sundaram ³	Study Coordinator Coimbatore
Ms. Tracy Giles ⁴	Study Coordinator Oregon

Francis I. Proctor Foundation, University of California San Francisco¹; Aravind Eye Hospital, Madurai, India²; Aravind Eye Hospital, Coimbatore, India³; Casey Eye Institute, Oregon Health and Science University⁴

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

Data Safety and Monitoring Committee (DSMC) Members

Maureen Maguire, PhD	Chair of DSMC, biostatistics Carolyn F. Jones Professor of Ophthalmology University of Pennsylvania
William Barlow, PhD	Biostatistics Research Professor, Biostatistics University of Washington
Jackie Glover, PhD	Ethics Professor of Pediatrics University of Colorado
Debra Goldstein, MD	Uveitis Professor of Ophthalmology Northwestern University
Steven Yeh, MD	Uveitis Assistant Professor of Ophthalmology Emory University
Narsing Rao, MD	Uveitis Professor of Ophthalmology and Pathology Doheny Eye Institute
Donald Everett, MA	Program officer National Eye Institute National Institutes of Health

Background

In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, we propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uveitis. Uveitis, a set of conditions defined by intraocular inflammation, is a significant cause of vision loss and morbidity in the United States and the world.^{1, 2} The incidence was recently estimated to be more than 50 cases per 100,000 person-years, with a prevalence of approximately 115 per 100,000 persons.³ Additionally, uveitis is believed to be the cause of up to 10% of cases of legal blindness in the United States, or approximately 30,000 new cases of blindness per year.^{1, 3, 4} In contrast to common age-related eye disorders, uveitis may have a stronger socio-economic impact because it disproportionately affects younger working-age patients.⁵ Although the etiology of uveitis is varied, most cases are presumed to be immune-mediated and lack a known infectious cause.⁶⁻⁹ Even in developing countries such as India that have a larger burden of infection, the vast majority of cases are non-infectious.^{10, 11}

The current mainstay of treatment for non-infectious uveitis is corticosteroids (topical, systemic, locally injected, or corticosteroid-eluting implants). Due to the well documented local and systemic side effects associated with corticosteroid therapy, other immunosuppressive therapies are frequently used as corticosteroid-sparing agents in patients who need long-term therapy. These include antimetabolites, calcineurin inhibitors, alkylating agents, and biologic drugs.¹² Cost and morbidity associated with uncontrolled inflammation make the selection of an effective initial steroid-sparing agent extremely important.

When corticosteroid-sparing therapy is required, the two most commonly used first-line immunosuppressive agents are methotrexate and mycophenolate mofetil.¹³ Because of cost and potentially dangerous long-term side effects, other classes of drugs such as biologics are typically reserved for refractory cases in which other treatments have failed.¹² It is common practice for patients requiring a steroid-sparing agent to be treated first with the less expensive methotrexate and then switched to mycophenolate mofetil in the event of treatment failure. However, results from non-comparative retrospective case series indicate that uveitis patients may be much more likely to achieve controlled inflammation and tolerate treatment with mycophenolate mofetil.¹³⁻²⁸ Furthermore, approximately half of the patients who fail treatment with methotrexate go on to successful treatment with mycophenolate mofetil.²⁹ Unlike in rheumatology, where clinical trials have demonstrated differential efficacy of antimetabolites for systemic inflammatory diseases, there have been no prospective randomized, controlled trials in uveitis to systematically determine which antimetabolite is more clinically efficacious as initial corticosteroid-sparing therapy. This makes it difficult for clinicians to make informed, evidence-based decisions about first-line immunosuppressive treatment. In addition, if patients fail one antimetabolite, there is no evidence basis for deciding whether to switch to another antimetabolite, or to move on to another class of immunosuppressives, including biologics.

1. Introduction to trial

The proposed study is a randomized comparative effectiveness trial to determine which treatment, methotrexate or mycophenolate mofetil, is more effective as first-line corticosteroid-sparing treatment for patients with non-infectious intermediate, posterior and panuveitis requiring corticosteroid-sparing therapy.

Two hundred sixteen patients with non-infectious uveitis in need of corticosteroid-sparing therapy will be randomized to receive either oral methotrexate or oral mycophenolate mofetil at Aravind Eye Hospitals (Madurai and Coimbatore, South India), Casey Eye Institute (Oregon Health and Science University, Portland) and the F.I Proctor Foundation (University of California, San Francisco). They will be followed monthly for 6 months after enrollment or until treatment failure. Patients who achieve success at 6 months will continue for another 6 months on the same medication. Patients who fail at 6 months will switch treatments and be followed for an additional 6 months or until failure of the second treatment.

1.1 Research question

Which treatment—methotrexate or mycophenolate mofetil—is more effective as a first-line immunosuppressive treatment for patients with non-infectious intermediate, posterior and panuveitis requiring corticosteroid-sparing therapy?

1.2. Specific aims

Aim 1: Establish which immunosuppressive treatment, methotrexate or mycophenolate mofetil, results in a higher rate of corticosteroid-sparing treatment success. As a primary outcome, rates of successful corticosteroid-sparing control of inflammation will be compared at 6 months after enrollment. We will also evaluate differences in secondary outcomes, such as visual acuity, macular thickness, time to control of inflammation, efficacy within various anatomic locations of uveitis, tolerability, quality of life, and adverse events.

Aim 2: Evaluate the clinical efficacy of switching agents after initial treatment failure. Patients who are recorded as a treatment failure on the initial randomized drug will be switched to the other treatment. These patients will be followed an additional 6 months from the date of treatment failure, following the same protocol with the same primary and secondary outcomes as in Aim 1.

2. Trial design

2.1. Design summary

Study type

- Randomized, observer-masked comparative effectiveness trial
- Block randomization by site: Aravind Eye Hospitals, Casey Eye Institute, F.I Proctor Foundation
- Sample size: 216 patients, 108 patients per arm (Table 1)

Treatment arms

- Oral methotrexate
- Oral mycophenolate mofetil

Treatment timeline

- Phase I
 - Initial treatment from 0-6 months. If treatment success (i.e. achieving corticosteroid-sparing control of inflammation at 6 months), treatment extended to 12 months.
- Phase II
 - Second therapy initiated after failure to achieve corticosteroid-sparing control of inflammation in Phase I (0-6 months).

Outcomes

- **Primary outcome (Specific Aim 1):**
 - Rate of overall treatment success at 6 months, where treatment success is defined as controlled ocular inflammation (Table 2) with ≤ 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate
- **Secondary outcomes**
 - **Specific Aim 2:** Rate of corticosteroid-sparing treatment success at 6 months after switching treatments in patients who are a treatment failure in the first 6 months where treatment success is defined as in Aim 1
 - Time to control of inflammation
 - Time to treatment success
 - Proportion achieving treatment success at 5 months and sustaining, for at least 28 days, to 6 months
 - Proportion achieving treatment success at 12 months in Phase I
 - Phase I treatment success (6-12 months) with complete discontinuation of corticosteroid
 - Proportion achieving treatment success at 6 months in Phase II
 - Phase II treatment success with complete discontinuation of corticosteroids
 - Change in best spectacle-corrected visual acuity (BSCVA)
 - Presence of macular edema
 - Change in macular thickness
 - Change in vitreous haze as assessed clinically by the Davis scale.
 - Change in vitreous haze as assessed by fundus photography grading by NEI and Davis scales
 - Efficacy for intermediate, posterior and panuveitis subgroups
 - Proportion discontinuing due to intolerability
 - Rate of adverse events
 - Proportion discontinuing due to serious adverse events
 - Quality of life (Health related and vision related)
 - Tabulate the occurrence of dose reduction used in immunosuppressive treatment
 - Efficacy of treatment in patients with Vogt-Koyanagi-Harada (VKH) disease

2.2. Study timeline

Table 1: Timeline for study completion

Date	Planned Activity			
December 2011 through September 2012	Pre-study activities: refine/finalize MOP, IRB, IND, Indian Council of Medical Research approval			
September 2012 through November 2012	1st meeting of DSMC, conduct final certification of sites and study personnel, earliest project start date			
November 2012 through May 2015 (2.5 years)	Enrollment goals by site			
	Madurai	Coimbatore	San Francisco	Oregon
	100	71	15	30
Through December 2015	Finish 6 month follow-up (Phase I) + 1 month visit window			
Through July 2015	Finish follow-up (Maximum of 12 months + 1 month visit window period)			
Through April 2016	Lock database, analyze, publish, and disseminate results			

2.3. Eligibility

2.3.1. Anatomical location of inflammation

All patients must have met the criteria for intermediate, anterior and intermediate, posterior or panuveitis, as defined by the Standardization of Uveitis Nomenclature (SUN) Working Group, at any time since their diagnosis of uveitis.

The Standardization of Uveitis Nomenclature

Type	Primary Site of Inflammation	Includes
Anterior Uveitis	Anterior Chamber	Iritis Iridocyclitis Anterior cyclitis
Intermediate Uveitis	Vitreous	Pars planitis Posterior cyclitis Hyalitis
Posterior Uveitis	Retina or Choroid	Focal, multifocal, or Diffuse choroiditis Chorioretinitis Retinochoroiditis Retinitis Neuroretinitis
Panuveitis	Anterior Chamber Vitreous Retina or Choroid	

*Adapted from the SUN Working Group Anatomic Classification of Uveitis

According to SUN criteria:

“There was consensus that the term intermediate uveitis should be used for that subset of uveitis where the vitreous is the major site of inflammation, and that the presence of peripheral vascular sheathing and macular edema should not change the classification. The diagnostic term *pars planitis* should be used only for that subset of intermediate uveitis where there is snowbank or snowball formation occurring in the absence of an associated infection or systemic disease (that is “idiopathic”). The term *panuveitis* should be reserved for those situations in which there is no predominant site of inflammation, but inflammation is observed in the anterior chamber, vitreous, and retina and/or choroid (this is, retinitis, choroiditis, or retinal vasculitis). For the definition of panuveitis, structural complications such as macular edema or neovascularization should not be considered in classifying the anatomic location of uveitis. Inflammation in the anterior chamber and vitreous (this is, more vitritis than in an iridocyclitis and more anterior chamber inflammation than in intermediate uveitis) should be referred to as anterior and intermediate uveitis and not panuveitis.”³⁰

2.3.2. Inclusion Criteria

All the following criteria must be met at enrollment:

- Historical non-infectious intermediate, anterior and intermediate, posterior or panuveitis in at least one eye
- Active inflammation within the last 90 days, defined by the presence of any of the following (in at least one eye) according to SUN criteria:
 - ≥ 2+ anterior chamber cells
 - ≥ 2+ vitreous haze
 - active retinal or choroidal lesions

At least one of the following criteria must be met before or at enrollment:

- 1.) Active inflammation after 4 weeks of high-dose (1mg/kg prednisone equivalent) corticosteroid treatment
 - 2.) Treatment with oral corticosteroids resulting in a reduction of inflammation, followed by an increase in inflammation when corticosteroid is tapered, in the 14 days prior to enrollment
 - 3.) Known chronic condition* necessitating corticosteroid-sparing immunosuppressive treatment**
- At least 1+ anterior chamber cells and/or 1+ vitreous haze and/or active retinal/choroidal lesions (bullous serous retinal detachment qualifies) in at least one eye at enrollment
 - Willingness to start corticosteroid treatment at 1mg/kg or 60mg a day of prednisone, whichever is less

*According to SUN guidelines, the following uveitic syndromes are thought to require chronic immunosuppressive therapy: Behcet’s disease with posterior segment involvement, multifocal choroiditis and panuveitis, serpiginous choroidopathy and birdshot retinochoroidopathy.

**One of the chronic conditions to be considered is late phase Vogt–Koyanagi–Harada syndrome (VKH). VKH with posterior synechiae, bullous serous retinal detachments, and/or choroidal detachments may be considered in this category.

2.3.3. Exclusion criteria

Any one excludes patient:

- Any infectious cause of uveitis
- Media opacity (such as cataract and/or corneal scar) and/or extensive posterior synechiae such that examination of the posterior segment is not possible in both eyes
- Chronic hypotony (IOP < 5 mm Hg for > 3 months) in both eyes
- Prior use of any immunosuppressive drug other than prednisone
- Periocular or intravitreal corticosteroid injection in the past 2 months
- Fluocinolone acetonide implant in either eye in < 3 years
- Intraocular surgery in < 30 days
- VA of hand motions or worse in better eye
- < 16 years of age at enrollment
- Planning to conceive during the study period, pregnant or breast-feeding (blood or urine pregnancy test for all females, excluding those who are post-menopausal is mandatory)*
- Unwillingness to abstain from alcohol (2 drinks per month is okay)
- Cancer
- Systemic autoimmune disease anticipated to dictate treatment course
- Abnormal CBC (\leq 2,500 white blood cells and/or \leq 75,000 platelets and/or \leq 10 hemoglobin) within 14 days prior to randomization*
- Abnormal alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \geq 2 times the upper limit of normal for the lab and/or creatinine \geq 1.5 within 14 days prior to randomization*
- Evidence of active tuberculosis, HIV infection, syphilis, or hepatitis B or C (patients must have a tuberculin skin test, or interferon-gamma release assay, a chest radiograph, RPR/VDRL, FTA-ABS, Hepatitis B surface antigen and Hepatitis C antibody tests within 60 days prior to randomization)**

*Testing required within 14 days prior to enrollment; **Testing required within 60 days prior to enrollment.

Beyond the tests listed above, the remainder of the work-up is at the discretion of the investigator and should be tailored to the clinical situation. Distinguishing between infectious and non-infectious uveitis is part of standard of care and should be dictated by the patient's clinical exam, but at minimum, all patients must have testing for tuberculosis, syphilis and hepatitis within 60 days prior to enrollment. Given that treatment with antimetabolites is not thought to increase the risk of tuberculosis, patients with latent (but not active) tuberculosis will be eligible for this study.

2.4. Randomization and masking

Block randomization of the patients will ensure that an equal number of patients are randomized to each study arm at each site. The exact block size will vary (4, 6, or 8 with equal probability) and will only be known to the biostatistician. Randomization lists will be created by the biostatistician (Travis Porco) and distributed to the following persons:

Emergency Contact Personnel

- Dr. Lalitha Prajna *, Chief Microbiologist, Aravind Eye Hospital

- Dr. Christine Flaxel*, Retina specialist, Casey Eye Institute, Oregon
- Dr. Steven McLeod*, Chairman Department of Ophthalmology, University of California San Francisco

*Emergency contact persons who will consult the list only in case of an emergency in which unmasking is necessary for patient safety and Dr. Thomas Lietman of the DCC cannot be reached.

Data Coordinating Center (DCC) Personnel

- Dr. Thomas Lietman, Professor of Ophthalmology and Epidemiology, University of California San Francisco, Proctor Foundation
- Dr. Travis Porco, Principal statistician, Proctor Foundation
- Dr. Wayne Enanoria*, Research epidemiologist, statistical programmer/analyst, Proctor Foundation

*To be determined if Dr. Enanoria will be masked.

The study coordinators (listed below) will be aware of patient treatment assignment; however, they will not have access to the randomization lists at their site. After consenting patients for enrollment, study coordinators will contact the designated person at their site holding randomization lists to request treatment assignment by patient ID. Study coordinators will then assign patients to that treatment.

The following study coordinators will not have access to the randomization lists on site:

- Dr. Natalie Nardone*, Study Coordinator, Proctor Foundation, University of California, San Francisco
- Mr. Meenakshi Sundaram, Study Coordinator, Aravind Eye Hospital Coimbatore, India
- Mr. Gobinath Kanagaraj, Study Coordinator, Aravind Eye Hospital Madurai, India
- Ms. Tracy Giles, Study Coordinator, Casey Eye Institute, Oregon

The following personnel will hold the randomization lists and inform study coordinators of the patient assignment:

- Ms. Sally Tsang, Clinic Manager Proctor Foundation, University of California, San Francisco
- Mrs. A. Maglin Brinda Mary, Aravind Eye Hospital Coimbatore, India
- Mrs. T.S Chandravati, Aravind Eye Hospital Madurai, India
- Dr. Jennifer Petrolatti, Pharmacist Casey Eye Institute, Oregon

*Dr. Nardone will act as a study coordinator to Proctor Foundation patients, as well as a clinical trial manager for sites in India and Oregon. At these sites, she will have access to the randomization lists in India and Oregon, in order to check patient treatment assignment as a quality assessment.

All patients and study coordinators will be unmasked to treatment assignment after enrollment, as the two study drugs are different in appearance and must be administered on different weekly schedules. Study ophthalmologists performing the clinical eye exams, as well as visual acuity examiners, OCT operators, fundus photographers and fundus graders will be masked to treatment assignment to prevent bias in study outcomes. Leiter's Pharmacy will purchase and supply mycophenolate mofetil and methotrexate from Amerisource Bergen.

Leiter's pharmacy will be responsible for preparing and distributing bottles of the medications labeled with randomization codes and dosing instructions to Proctor Foundation, and to Casey Eye Institute's pharmacy where they will distribute the

medication. Leiter's will also supply medication to Aravind Eye Hospital's drug manufacturing division Aurolab, where they will bottle and label the medication with codes and dosing instructions.

The unique features on the medication bottles will be the dosing instructions which vary by drug. Patient ID numbers will be provided to each site on separate label sheets. After enrollment and randomization, the patient ID labels will be removed and placed on the medication bottles by the study coordinator. Separate labels will also be created with dose reduction instructions (at the two reduction levels) for each drug. If a dose reduction is used, the study coordinator will place the reduction labels on the medication bottles. At no time will the study doctor handle labeling or distribution of the study medication.

To maintain masking throughout the trial, steps will be taken to avoid the study doctors discovering patient assignment. Not only will the study doctors have no part in handling the medication bottles, all patients will be given dark bags to place and keep their bottles in throughout the trial. They will be instructed to bring their medication to their visits enclosed in the bags, and an extra bag will be kept at the front desk of the clinics in case they forget. This will minimize the chances of the study doctor seeing the dosing instructions on the bottles. Additionally, patients will meet with the study coordinator first, before seeing their study doctor. The study coordinator will review the patients' medication diaries with them and keep the study bottles in his/her office for the entire patient visit. Before bringing patients to the study doctor, the study coordinator will remind them to not discuss their dosing and medication name with their study doctor.

Clinical examiners, refractionists, OCT operators, fundus photographers and fundus graders will not be given any information on medication assignment. If at any time masking of these personnel is broken, a protocol deviation form must be completed, scanned and emailed to both the Medical Monitor [REDACTED] and Principal Investigator [REDACTED]. Note that these patients should still continue on in the trial.

2.5. Definitions for primary endpoint

2.5.1. Treatment success

Treatment success is defined as controlled ocular inflammation (see Table 2) in both eyes* with ≤ 7.5 mg/day of prednisone, and ≤ 2 drops/day of topical 1% prednisolone acetate at the 6 month visit, without tolerability or safety issues warranting discontinuation.

Table 2: Criteria for *controlled* inflammation

Parameter	Definition of control
Anterior chamber cells*	$\leq 0.5+$
Vitreous haze**	$\leq 0.5+$
Choroid & retina***	No active lesions

*SUN criteria³⁰; ** NEI vitreous haze grading scale³¹ ***Choroidal/retinal lesions are independent of macular edema.

2.5.2. Treatment failure

Discontinuation of study medication *at any time* due to efficacy, tolerability, or safety may result in a declaration of treatment failure.

- **Discontinuation due to efficacy:** Patients can discontinue the study medication due to lack of efficacy and be declared a treatment failure and enter Phase II **at any time during follow-up** if any of the following occur:
 1. The patient does not reach a prednisone dose of 7.5 mg/day or less and less than or equal to 2 prednisolone acetate 1% drops per day by 6 months.
 2. The treating physician determines that it is futile to continue the current study medication due to persistent, uncontrolled inflammation that appears to be non-responsive to treatment.
- **Discontinuation due to intolerability:** Patients who must discontinue the drug as a result of side effects (i.e. severe gastrointestinal upset) will be recorded as a treatment failure. In patients experiencing intolerable side effects, a dose reduction can be used at physician’s discretion. Please refer to Table 5 for dose reduction guidelines.
- **Discontinuation due to safety:** Patients who experience any serious adverse event will exit the study immediately. Patients who experience abnormal lab results meeting the designated threshold of a non-serious adverse event (i.e. AST or ALT increasing to twice the upper limit of normal) will immediately stop taking their medication. As these abnormalities are often reversible, patients whose abnormalities are classified as non-serious adverse events (see Table 3) will be allowed one month to regain eligibility. If the lab results return to normal within one month, patients may be re-administered the study drug per protocol. Otherwise, treatment failure will be declared, at which point patients will exit the study and be treated according to the best medical judgment of their clinician. For other non-serious adverse events (such as an opportunistic infection) the study drug may be stopped temporarily as per the discretion of the investigator.

Note that if discontinuation of study medication causes a patient to have uncontrolled inflammation or >7.5mg/day prednisone at the 6-month visit, treatment failure due to efficacy may still be declared. Patients with abnormalities which meet the designated threshold of a serious adverse event (SAE) will exit the study immediately and be treated according the best medical judgment of their physician.

Table 3: Thresholds for classifying non-serious and serious lab abnormalities


	Non-Serious Adverse Event	Serious Adverse Event
Leukocytes	>1,000 and <2,500/ μ L lasting less than 1 month	<2,500 lasting more than 1 month or \leq 999/ μ L
Platelets	20,000 to 75,000/ μ L lasting less than 1 month	\leq 20,000/ μ L or <75,000/ μ L lasting greater than one month
Hemoglobin	> 6.4 to < 10 g/dL	\leq 6.4 g/dL
SGOT (AST) or SGPT (ALT)	2 to 5 times the upper limit of normal of the reference range	> 5 times the upper limit of normal of the reference range
Creatinine	\geq 1.5 to < 2 mg/dL	\geq 2 mg/dL

- **Dropout from study:** Subjects will be considered to have dropped out

from study only if they declare they are no longer interested in further participation or are deceased. It should be noted that missing a visit does not mean that a patient has dropped out of the study, for example, if they missing the 1 month visit every attempt will be made to bring them back as soon as possible and to continue with subsequent visits. Also, a non-serious adverse event or discontinuation of study medication does not mean a patient has dropped out of the study, and they should continue to be followed according to the protocol, as they may be able to resume treatment. We anticipate that a few patients may drop out due to relocation, unwillingness to continue or death. In case of patient dropout, the patient dropout form should be filled out.

If death is considered to be related to the study drug, the patient will be counted as a treatment failure. If death is not related to the study drug the patient will be counted as a dropout. This would be at the discretion of the medical monitor.

2.5.3. Primary Endpoint Flowchart



*Criteria for controlled inflammation: Anterior chamber cells ≤0.5 +; Vitreous haze ≤ 0.5 +; No active choroid and retina lesions

** 2 drops/day refers to topical 1% prednisolone acetate or equivalent

3. Treatment plan

3.1. Study drugs

Patients will be randomized to receive either methotrexate or mycophenolate mofetil. In addition, folic acid supplements will be given to all patients who have been randomized to methotrexate. All study ophthalmologists, refractionists, OCT operators, fundus photographers and fundus graders will be masked to treatment assignment. For dosing schedules, see Tables 4 and 5.

Table 4: Weekly Dosing Schedule

	Drug	Day						
		1	2	3	4	5	6	7
Introductory Dose	Methotrexate	15 mg						
	Mycophenolate mofetil	500 mg/BID	500 mg/BID	500 mg/BID	500 mg/BID	500 mg/BID	500 mg/BID	500 mg/BID
	Folic Acid (if methotrexate)	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg
Weeks 1-2	Methotrexate	25 mg						
	Mycophenolate mofetil	1.5 g/BID	1.5 g/BID	1.5 g/BID	1.5 g/BID	1.5 g/BID	1.5 g/BID	1.5 g/BID
	Folic Acid (if methotrexate)	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg
Maintenance Dose	Methotrexate	25 mg						
	Mycophenolate mofetil	1.5 g/BID	1.5 g/BID	1.5 g/BID	1.5 g/BID	1.5 g/BID	1.5 g/BID	1.5 g/BID
	Folic Acid (if methotrexate)	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg

Table 5: Dose Reduction Guidelines*

	Drug	Day						
		1	2	3	4	5	6	7
Reduction Level I	Methotrexate	20 mg						
	Folic Acid	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg
	Mycophenolate mofetil	1g/BID	1g/BID	1g/BID	1g/BID	1g/BID	1g/BID	1g/BID
Reduction Level II	Methotrexate	15 mg						
	Folic Acid	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg	1 mg
	Mycophenolate mofetil	500 mg/BID	500 mg/BID	500 mg/BID	500 mg/BID	500 mg/BID	500 mg/BID	500 mg/BID

*Doses should only be reduced in response to intolerable side effects and safety concerns. If there are no tolerability/safety issues, the patient should stay on the highest maintenance dose for the duration of follow-up.

3.1.1. Methotrexate

All methotrexate doses will be taken once per week in a divided dose, one dose taken in the morning and one in the evening. For the first two weeks, an introductory dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be increased to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy.

If there are tolerability issues in the first two weeks such that the patient is not able to increase the dose, treatment failure due to intolerability should be declared. The patient would then be eligible to switch treatment in Phase II. If this occurs in Phase II, treatment failure would be declared and the patient would exit the study. If the dose is increased per protocol at two weeks, the study ophthalmologist can decide to reduce the maintenance dose if the patient experiences severe side effects. For the first dose reduction, methotrexate will be reduced to 20 mg per week. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week. After the second dose reduction, treatment can be stopped if intolerability persists and the patient can switch to Phase II. Treatment can be stopped early due to lack of efficacy or adverse events.

To maintain masking, study coordinators will review patient side effects with the patient at each visit, prior to meeting with the physician. At this time, the study coordinator will remind the patient not to speak to their study doctor regarding the name of the medication or dosing instructions. If the patient is experiencing intolerable side effects, and the study coordinator believes a dose reduction should be considered, this will be brought up with the study physician. The study coordinator and patient will talk to the physician without revealing the name of the medication or the dosing instructions. The study doctor will then decide if the dose reduction should be done. The study coordinator will then provide the patient with new dosing instructions, away from the vicinity of the study physician (see Table 5).

3.1.2. Mycophenolate mofetil

Mycophenolate mofetil will be taken twice daily. Patients will be advised by the study coordinator to take this medication on an empty stomach. For the first two weeks, an introductory dose of 500 mg BID orally will be administered to assess tolerability. After two weeks, the dose will be increased to 1.5 g BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy.

If there are tolerability issues in the first two weeks such that the patient is not able to increase the dose, treatment failure due to intolerability should be declared. The patient would then be eligible to switch treatment in Phase II. If this occurs in Phase II, treatment failure would be declared and the patient would exit the study. If the dose is increased per protocol at two weeks, the study ophthalmologist can decide to reduce the study treatment dose, if the patient experiences severe side effects. For the first dose reduction, mycophenolate will be reduced to 1g BID. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg BID. After the second dose reduction, treatment can be stopped if intolerability persists and the patient can switch to Phase II. Treatment can be stopped early due to lack of efficacy or adverse events.

To maintain masking, study coordinators will review patient side effects with the patient at each visit, prior to meeting with the physician. At this time, the study coordinator will remind

the patient not to speak to their study doctor regarding the name of the medication or dosing instructions. If the patient is experiencing intolerable side effects, and the study coordinator believes a dose reduction should be considered, this will be brought up with the study physician. The study coordinator and patient will talk to the physician without revealing the name of the medication or the dosing instructions. The study doctor will then decide if the dose reduction should be done. The study coordinator will then provide the patient with new dosing instructions, away from the study physician (see Table 5).

3.1.3. Folic acid

It is standard of care to prescribe folic acid supplements to reduce the severity of side effects in patients treated with methotrexate. All patients randomized to methotrexate will be prescribed 1 mg per day of folic acid.

3.1.4. Packaging and distribution of study medications

Patient medications will be packaged and distributed by Leiter's Pharmacy, to the two U.S. sites, Proctor Foundation and Casey Eye Institute. Medication will be distributed to Aurolab in India, and they will package and distribute it to the sites in Madurai and Coimbatore, South India.

Introductory bottles will contain 14 days of medication at the lower doses (15 mg for methotrexate and 500 mg for mycophenolate mofetil). Bottles with the maintenance dose will contain 30 days' worth of medication. At the patient's first visit (i.e. Baseline for Phase I) they will be given the 14 day introductory dose and the 30 day maintenance dose). At every monthly visit following, patients will be given an additional 30 days' worth of medication, until 5 months. If patients enter Phase II after treatment failure in Phase I, patients' medication will be dispensed following the same schedule as in Phase I. If patients enter Phase I (6-12 months) after treatment success in Phase I (0-6 months), they will be given 120 days' worth of medication at their 6 month visit. Lost bottles will be replaced.

Study medications, labeled with the appropriate dosing instructions, will be distributed to the study coordinator prior to each study visit. After randomization, before the drug is dispensed, the study coordinator will place the Study ID label on the bottles. If a dose reduction is used, the study coordinator will put a label on the bottle with the new instructions.

3.1.5. Adherence to the treatment plan

Patients will be given a treatment diary in the form of a checklist in which they can record missed doses. They will be asked to bring the diary with them to each visit. Adherence will be monitored by the study coordinator through review of the treatment diaries, and will be recorded on the Medication Adherence Log in each patient file. Pill counting will also be done for a more objective measure of adherence.

The following instructions will be given to the patients if they miss scheduled doses of their medication:

Methotrexate: If a patient misses their scheduled dose, they may take it the next day. If it is not taken the next day, they should wait until the following week.

Mycophenolate Mofetil: If the patient misses a dose, they should continue with the regular dosing schedule.

3.2. Corticosteroid therapy

3.2.1. Oral prednisone

Prednisone vs. alternative oral corticosteroid

Unless contraindicated, oral prednisone should be used. An equivalent dose of an alternative oral corticosteroid may be used only if a specific contraindication to oral prednisone is present. All references to oral corticosteroid and specific dosing schedules presented in this Manual of Procedures are given for oral prednisone.

Initial dose

All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Treatment success is dependent upon successfully tapering concomitant prednisone to ≤ 7.5 mg/day. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered¹. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study (i.e. until the end of Phase I). Further reduction of corticosteroids will be allowed in Phase II, if patients continue on the same medication as Phase I. If patients switch treatments and enter Phase II, they will follow the same protocol as the initial Phase I corticosteroid treatment. At any point, investigators have the option of reducing the prednisone dose if the patient is experiencing severe side effects, but it is strongly encouraged to follow the corticosteroid tapering guidelines.

Tapering schedule

For all patients, oral prednisone will be tapered gradually to ≤ 7.5 mg/day if possible according to Standardization of Uveitis Nomenclature (SUN) guidelines (see Table 6). As it takes 6-8 weeks for the study medications to take full effect, it is expected that inflammation may become uncontrolled with a corticosteroid taper in some patients during the first 3 months of the study. This does not necessarily mean that the randomized treatment has failed, since more time may be needed to ensure the drug has reached its full effect. However, some patients who have uncontrolled inflammation are not responding to the medication; if the study ophthalmologist believes that continued treatment is futile prior to the primary endpoint, treatment failure may be declared and the patient treated according to the best medical judgment. At any point in this tapering schedule, investigators have the option to reduce the corticosteroid dose if the patient is experiencing severe side effects.

Table 6: Tapering schedule for oral prednisone: Phase I or if starting new medication in Phase II

Dose (mg/day)	Duration (weeks)	Decrement (mg/day)
60	2 – 4 ¹	10
50	1	10
40	1	5
35	1	5
30	1	5
25	1	5
20	1	2.5
17.5	1	2.5
15	1	2.5
12.5	1	2.5
10	1	2.5
7.5	hold*	

NOTE: Begin patients at 1mg/kg or 60 mg/day, whichever is less. For Phase I hold patients at 7.5 mg/day, up to the end of 6 months.

¹ If uveitis does not improve at the end of the first 4 weeks, use best medical judgment regarding supplemental treatment (e.g. pulse dose treatment, corticosteroid injections, additional immunosuppressives).

Table 7: Optional tapering schedule Phase I (6-12 months)

Dose (mg/day)	Duration (weeks)	Decrement (mg/day)
7.5	1*	2.5
< 7.5 & ≥ 5	2 - 4	1 - 2.5
< 5 & ≥ 2.5	2 - 4	1.5 - 2.5
< 2.5 & ≥ 1	2 - 4	1
0		

NOTE: When beginning Phase I (6-12 months), hold patient at 7.5 mg/day, for at least one week.

Directions for Rescue Taper

Reactivations can be mild or severe. Mild reactivations are considered an increase in inflammation up to the 1+ level in anterior chamber cell or vitreous haze. Severe reactivations are considered an increase in inflammation up to the 2+ level or higher in anterior chamber cell or vitreous haze. Retinal/choroidal lesions may be considered mild or severe at the discretion of the study physician.

If uveitis reactivates:

- Increase oral prednisone up to a dose of 1 mg/kg for severe reactivations, or for mild reactivations, up to double the dose at which the flare occurred, until uveitis is controlled. Then re-taper according to the guidelines.

Uveitis is considered non-responsive if inflammation does not increase but does not further improve after the first 4 weeks of treatment.

If uveitis is non-responsive:

- Hold the current dose of prednisone for an additional week. If still no improvement, treatment failure due to efficacy may be declared, and patients

may proceed to Phase II.

After suppression of uveitis is once again achieved (either in the case of reactivation or non-response) follow the taper guidelines for Phase I. Patients who have failed the treatment to which they are randomized will then switch treatments, begin Phase II, and follow the same taper guidelines as Phase I (0-6 months). If patients flare during Phase II, they can follow directions for the rescue taper listed above. Patients who fail the second treatment will exit the study and be treated as per the investigators discretion.

3.2.2. Supplements

All patients will be given recommendations for supplemental treatment. This treatment is important for patients receiving oral corticosteroids, in order to minimize the incidence of osteoporosis. Recommendations will include:

- Calcium supplement, 500 mg 3 times daily (unless contraindicated)
- Vitamin D, 400-800 IU daily.

3.2.3. Topical corticosteroid

In addition to oral prednisone, patients may enter the study on varying doses of topical corticosteroid drops. Topical corticosteroids should be tapered according to the suggested guidelines (Table 8). The goal will be to completely taper off topical corticosteroids, but a dose of ≤ 2 times a day prednisolone acetate 1% or equivalent corticosteroid will be considered medically acceptable. The chronic use of two times a day prednisolone acetate was also considered to be medically acceptable in the survey we conducted of the American Uveitis Society members.

Table 8: Suggested tapering schedule for topical corticosteroid drops

Dose	Duration (weeks)
8 times a day	1-2
6 times a day	1
4 times a day	1
3 times a day	1
2 times a day	1
1 time a day	1
None	

3.2.4. Other adjunctive treatments/procedures

The protocol dictates use of oral prednisone, corticosteroid drops and study medication (methotrexate or mycophenolate). The investigator may use other topical adjunctive medications such as IOP lowering medications and cycloplegic agents. These should be recorded on the Treatment Assessment form at each visit. The protocol does not allow for corticosteroid injections, intravenous therapy, additional immunosuppressives or surgery during the study period. If it is felt to be necessary to do one of these, the Protocol Deviation form should be completed and sent to the Medical Monitor and Principal Investigator.

3.3. Study procedures

Enrollment visit

Study coordinators should adhere to the following protocol for study procedures taking place at the enrollment visit.

- The patient's eligibility for participating in the study will be determined between the study coordinator and the study physician.
- If eligible, the patient will review the consent form with the study coordinator and the study physician, and give their consent.
- After consent, the study coordinator will assign the patient a unique Patient ID (derived from the list provided to the study coordinator from the principal statistician).
- The study coordinator will then contact the designated person on site, holding the randomization list, to obtain the patient's drug assignment. This will be done away from sight of the study physician.
- The study coordinator will then label the medication with the assigned Patient ID.

Study visits

Study coordinators should adhere to the following protocol for study procedures taking place, after the patient is consented, enrolled and randomized. All study procedures should follow the schedule listed below:

- The patient comes for a study visit and meets with the study coordinator before their study doctor.
- The patient's medication bottle is immediately placed in a secure, opaque bag and left at the study coordinators desk for the remainder of the visit.
- The study coordinator will check-in with the patient and complete the following in any order:
 - Review of patient medication diaries
 - Review of adverse events since last visit*
 - Dispense new medication bottles (*if applicable*)
 - Completion of SF-36 questionnaire (All patients) (*if applicable*)
 - Completion of NEI-VFQ-25 (U.S. patients only) or IND-VFQ (Indian patients only) (*if applicable*)
 - Review with the patient that they are not to speak with their study doctor about their dosing schedule, or the name of the medication that they are currently taking.

*If the patient is experiencing intolerable side effects, and the study coordinator believes a dose reduction should be considered, this will be brought up with the study physician. The study coordinator and patient will talk to the physician without revealing the name of the medication or the dosing instructions. The study doctor will then decide if the dose reduction should be done. The study coordinator will then provide the patient with new dosing instructions, away from sight of study physician.

- The patient will then complete the following assessments, in the following order:
 - Visual Acuity Assessment
 - Slit lamp front of the eye exam and intra-ocular pressure
- The patient's eyes will then be dilated and the following assessments will be completed, in any order**:

- Posterior segment exam
- OCT measurements
- Fundus photography
- Laboratory measurements
- After completion of the study visit, the patient will meet with the coordinator, review scheduling for the next study visit, and retrieve their medication.

**It is essential that vision, front of the eye exams and intra-ocular pressure are completed *before* dilation of the eyes.

4. Study visits

4.1. Visit schedules

4.1.1. Phase I: First-line treatment

After eligibility has been evaluated and informed consent given for participation in the trial, patients will be randomized to receive either methotrexate or mycophenolate mofetil. Patients will continue with this course of treatment unless treatment failure occurs due to safety, intolerability or lack of efficacy (if a failure is recorded within the first 6 months, the treatment assignment will be switched to the drug not initially randomized to, and the patient will follow a new visit schedule). Patients who are deemed treatment failures in Aim 1 due to safety (serious adverse event) will exit the study and not proceed to Aim 2. Treatment success, according to the primary endpoint, will be assessed at 6 months. If treatment has been deemed successful for a patient at 6 months, they will be provided study medication for an additional 6 months and return for additional study visits as shown below. As long as the patient stays on the first randomized medication, Visit Schedule I will be followed.

Guidelines for Visit Schedule I

- Day 1 corresponds to the Baseline-I visit, which is also the first day the patient receives treatment.
- Visit windows are determined based on the date of randomization.
- Baseline data must be at the Baseline-I visit, with the exception of laboratory measurements which may be collected within 14 days prior to or on the date of randomization.
- There should be a minimum of 2 weeks between each study visit.
- Data for the baseline and follow-up visits may be collected anytime within the visit window.

Table 9: Visit Schedule Phase I (0-6 months) or Phase II

Visit	Code	Window (weeks)
Baseline*	BL-1 (II)	
Week 2	Wk2 (II)	
Month 1*	M1-I (II)	±15 days
Month 2	M2-I (II)	±15 days
Month 3	M3-I (II)	±15 days
Month 4	M4-I (II)	±15 days
Month 5	M5-I (II)	±15 days
Month 6	M6-I (II)	-15 to +30 days

*Every visit scheduled will be from the baseline visit date (Phase 1). **Every monthly visit will be calculated from the baseline visit, using the average amount of days per month.

Table 10: Visit Schedule Phase I (6-12 months)

Visit	Code	Window (weeks)
Month 6*	M6-I	±15 days
Month 9*	M9-I	±15 days
Month 12*	M12-I	-15 to +30 days

* since baseline/treatment administration (Phase 1)

4.1.2. Phase II: Rescue treatment

In case of the first randomized treatment failure due to intolerability or lack of efficacy within the first six months of treatment, the treatment assignment will be switched to the alternate treatment. At this point, the patient will receive the antimetabolite not originally randomized to and will be followed an additional 6 months or until failure of the second treatment.

Guidelines for Visit Schedule II

- Day 1 corresponds to the Baseline-II visit, which is also the first day the patient receives rescue treatment with the medication not initially received.
- Visit dates are determined based on the date of the Baseline-II visit (which may also be the same date as the Phase I treatment failure date), and may not be changed.
- The Baseline-II visit form should be completed to gather information on any changes in health status or medications.
- There should be a minimum of 2 weeks between each study visit.
- Data for the follow-up visits may be collected anytime within the visit window.

4.1.3. Non-study visits

Despite the regular follow-up outlined in the visit schedules above, it is anticipated that some patients will have inflammation that is difficult to control or be intolerant to the drug. These patients may require additional visits that do not fall within the study visit window. It is possible that the circumstances leading to such visits may result in changes to oral or topical corticosteroid dose, or a declaration of treatment failure and a need for rescue treatment.

Guidelines for non-study visits

- Any changes to oral or topical corticosteroid dose will be noted on the appropriate form during the next scheduled study visit.
- If a treatment failure is declared at a non-study visit during follow-up while being treated with...
 - Phase I (initial randomized treatment): Record a treatment failure using Treatment Assessment Form. Perform BL-II visit at this time or within 7 days. Phase II rescue treatment will be administered as soon as BL-II data has been recorded.
 - Phase II: Record a treatment failure using the Treatment Assessment Form. Patient exits study.
 - If treatment failure is declared at a non-study visit, an attempt should be made to collect as much information as possible, including the forms listed in Table 9.

4.2. Study forms completion schedule

Table 9: Forms to be completed throughout patient follow-up

	PHASE I				PHASE II			
	Baseline: Phase I	Follow-up study months 1-5, 9	Treatment Failure*	Follow-up study months 6 and 12	Baseline: Phase II	Follow-up study months 1-5	Treatment Failure*	Follow-up study month 6
Patient Consent Forms	X							
Eligibility Criteria Form	X							
Baseline History Form	X				X			
Clinical Eye Exam Form	X	X	X	X	X	X	X	X
Visual Acuity Forms	X	X	X	X	X	X	X	X
OCT Form	X	X	X	X	X	X	X	X
Fundus Photos	X		X	X	X		X	X
Laboratory Report Form	X	X		X	X	X		X
Adverse Event Forms		(X)	(X)	(X)	(X)	(X)	(X)	(X)
Quality of Life Questionnaires	X		X	X	X		X	X
Treatment Assessment Form		X	X	X	X	X	X	X
Patient Dropout Form (if applicable)		(X)	(X)	(X)	(X)	(X)	(X)	(X)
Protocol deviation form (if applicable)	(X)	(X)	(X)	(X)	(X)	(X)	(X)	(X)

*Note that treatment failure may be declared at a scheduled study visit or at a non-study visit.

4.3. Enrollment and Baseline-I visit

All baseline data must be collected at the Baseline-I visit, with the exception of laboratory measurements which may be collected within 14 days prior to or on the date of randomization.

4.3.1. Consent and eligibility evaluation

Procedures for obtaining consent include explaining the patient's disease, prognosis, and treatment options, discussing the risks and benefits of participation, and addressing the patient's questions and concerns. After explaining the nature of the study and the rights and responsibilities of the patient, the ophthalmologist and/or the study coordinator will obtain written consent from the subject, or written minor assent and parental consent if applicable. The subject is assured that participation in this study is voluntary and he/she can withdraw at any time if he/she feels uncomfortable.

The eligibility evaluation will be performed using the Eligibility Form, which is to be filled out at the Baseline-I visit. For detailed inclusion/exclusion criteria please see Section 2.3.

There is not a mandated separate visit for eligibility screening. If the patient fulfills all eligibility and exclusion criteria on a visit, he/she may sign the consent form and be randomized at the beginning of the official Baseline-I visit. Note that this requires that the patient have laboratory results that are current according to inclusion criteria guidelines.

In some cases, partial eligibility will be confirmed on a screening visit but more information may be needed (such as laboratory confirmation of acceptable values of the CBC, AST, ALT and creatinine). If and when the laboratory results meet eligibility criteria, the patient will then be asked to complete a consent form, followed by randomization and the official Baseline-I visit.

4.3.2. Randomization

Assignment of a randomization number takes place during the Baseline-I visit after eligibility has been determined and the consent forms have been signed by the patient. After obtaining the written consent, the patient is assigned the next identification number from the randomization list. The study coordinator then informs the on-site person who carries the treatment assignment list to find out the treatment assignment that corresponds to the particular study ID.

4.3.3. Procedures for data collection

Required study procedures include the following:

- Medical and treatment history
- Clinical eye exam
- Visual acuity exam
- Optical Coherence Tomography (OCT)
- Fundus photography
- Laboratory measurements

- Health-related quality of life questionnaire
- Vision-related quality of life questionnaire

4.3.4. Specimens

The following specimens will be collected for laboratory measurements:

- Blood for complete blood count (CBC with differential, limited to percentages of neutrophils and lymphocytes)
- Blood for serum chemistry panel (AST, ALT, creatinine)
- Blood or urine pregnancy test (all female patients, excluding those that are post- menopausal)

4.3.5. Forms for data collection

The following forms will be filled out as part of the Baseline-I visit:

- Patient Consent Forms
- Eligibility Form
- Baseline History Form
- Clinical Eye Exam Form
- Right Eye Visual Acuity Form
- Left Eye Visual Acuity Form
- OCT Form
- Fundus Photography Form
- Laboratory Report Form
- Quality of Life Questionnaire Forms

4.4. Follow-up visits

All follow-up visit data must be collected within the study visit window.

4.4.1. Procedures for data collection

Required study procedures include the following:

- Clinical eye exam
- Visual acuity exam
- Optical Coherence Tomography
- Fundus Photography
- Laboratory measurements
- Health-related quality of life questionnaire (if applicable*)
- Vision-related quality of life questionnaire (if applicable*)

*Phase 1: treatment failure or 6 month visit (whichever is first), 12 month visit; Phase 2: treatment failure or 6 month visit.

4.4.2. Specimens

The following specimens will be collected for laboratory measurements:

- Blood for complete blood count (CBC with differential, limited to percentages of neutrophils and lymphocytes)
- Blood for serum chemistry panel (AST, ALT, creatinine)

- Blood or urine pregnancy test (all female patients, excluding those that are post- menopausal)

4.4.3. Forms for data collection

The following forms will be filled out as part of the follow-up visits:

- Baseline History Form Phase II (as needed*)
- Clinical Eye Exam Form
- Right Eye Visual Acuity Form
- Left Eye Visual Acuity Form
- OCT Form
- Fundus Photography Form
- Laboratory Report Form
- Adverse Event Checklist
- Medication Adherence Form
- Treatment Assessment Form
- *Adverse Event Log (update if necessary)*
- *Quality of Life Questionnaire Forms (if applicable**)*
- *Serious Adverse Event Narrative Form (if applicable)*
- *Patient Dropout Form (if applicable)*
- *Protocol Deviation Form (if applicable)*

*This will only be needed if patients switch to Phase II.

*Phase 1: baseline, treatment failure or 6 month visit (whichever is first), 12 month visit;
Phase 2: treatment failure or 6 month visit

4.5. Baseline-II

Note that some Baseline-II visit data may correspond to data collected for the visit at which treatment failure was declared for Phase I.

4.5.1. Eligibility

In Phase I, if failure is due to efficacy or tolerability, the patient will be considered as eligible for Phase II of the study. If there is a serious adverse event in Phase I, the patient will exit the study and not enter Phase II.

The Baseline History Form-II will be completed to obtain updated health related information.

As in Phase I, there is no mandated separate visit for eligibility screening. If the patient fulfills all eligibility criteria at the time of treatment failure, he/she may immediately proceed to the Baseline-II visit.

4.6. Non-study visits

Despite frequent study visits, some patients may need additional visits with their clinician according to standard of care that do not fall within study visit windows. Required data collection during these non-study visits is limited to adverse event reporting and declaration of treatment failure.

4.6.1. Procedures for data collection

Required study procedures include the following:

- Clinical eye exam (if treatment failure is declared)

4.6.2. Specimens

No specimens are required during non-study visits.

4.6.3. Forms for data collection

The following forms will be filled out at non-study visits *only if treatment failure is declared*.

- Clinical Eye Exam Form
- Treatment Assessment Form

The following forms will be filled out at non-study visits *only if a serious or non-serious adverse event has occurred*:

- Adverse Event Checklist
- Adverse Event Log (update)

All Phase II procedures and protocol are the same as Phase I. For Phase I patients who are continuing on the same medication, physicians can see the patients as often as they would like. However, for purposes of this study we will only be recording information at Month 9 and Month 12, or a non-study visit that leads to treatment failure.

5. Study examinations and procedures

5.1. Quality of life questionnaire administration

All patients will be asked to complete standard quality of life questionnaires related to overall health and visual function at baseline visits as well as at 6 months or treatment failure (whichever is first) in order to measure quality of life outcomes. Patients who experience treatment success with Phase I treatment through the maximum follow-up of 12 months will also complete questionnaires at the 12- month visit. The following questionnaires will be administered:

Health-related quality of life

- SF-36 questionnaire (all patients)

Vision-related quality of life

- NEI-VFQ-25 (U.S. patients only)
- IND-VFQ (Indian patients only)

Given data suggesting that SF-36 scores vary by method of administration such that patients overstate quality of life in clinic interviews, questionnaires will be self-administered whenever possible at clinic appointments. It is anticipated that some patients will not have adequate visual function to complete the questionnaire on their own, and some patients may also be illiterate. In such cases, the coordinator will read the questions aloud to the patient and record the patient's answers on the appropriate questionnaire forms (Section A.14). It is very important that the questions are answered in their original form, so

coordinators should never rephrase or interpret questions for the patient.

5.2. Refraction and visual acuity

5.2.1. Refraction procedure

Beginning Approximate Refraction

The beginning approximate refraction should be obtained by performing retinoscopy or auto-refraction. One of these measurements is used as the beginning approximate refraction at each visit.

Subjects who arrive for examination wearing contact lenses are asked to remove the lenses prior to refraction. The subject must wait for 30 minutes after removing the contact lenses before refraction can be performed.

Refraction may be initially performed at distances different than four meters (i.e. using a phoropter in a common refraction lane). However, if this is done, the spherical power refinement step must be repeated with lenses in place after the subject has been positioned at four meters for visual acuity testing.

The examiner will use Chart R (Precision Vision Chart Version 2305b) for manifest refraction. Each eye is refracted at four meters unless the visual acuity measured at this distance on chart R is worse than 20/200 (defined as missing 2 or more letters on the top line, the 20/200 or 6/60 line). This subject must then be moved to a distance of one meter from the study visual acuity chart, and refraction must be performed and recorded at this distance. Use of Visual Acuity Form R is optional but may be helpful in keeping track of patient's acuity level.

Manifest Refraction

In general, instructions are to 'push plus' and to add minus diopter corrections only if there is a demonstrated increase in visual acuity, i.e., the patient is able to read more letters. The steps are as follows:

- Seat the subject 4 meters in front of the refraction chart;
- Place and adjust the trial frame on the subject's face so that the lens cells are parallel to the anterior plane of the orbit;
- Adjust the pupillary distance of the trial frame to make sure that the lenses position in front of the centers of the pupils;
- Adjust the lens cells for the proper distance from the cornea;
- Occlude the eye not being refracted;
- Insert spherical lens correction into the compartment closest to the eye;
- Place cylindrical lens correction in the compartment in the front of the frame;
- Set cylindrical lens to appropriate axis setting

Please refer to the table below to ensure that proper lenses are used for the appropriate visual acuity level:

Vision with Best Correction	Sphere		Cylinder Use correct JCC as below			Sphere Refinement	
	Power	Increment	Axis	Power	Increment	Power	Increment

6/3-6/24	+0.50	+0.50	0.50	0.25	+0.25	+0.37	+0.25
20/10-20/80 (4 meters)	-0.37	-0.25			-0.25	-0.37	-0.25
	+0.50	+0.50				+0.37	+0.25
6/30-6/60	+1.00	+1.00	1.00	1.00	+1.00	+0.50	+0.50
20/100-20/200 (4 meters)	-1.00	-1.00			-1.00	-0.50	-0.50
	+1.00	+1.00				+0.50	+0.50
<6/60	+2.00	+2.00	1.00	1.00	+1.00	+1.00	+1.00
<20/200 (1 meter)	-2.00	-2.00			-1.00	-1.00	-1.00
	+2.00	+2.00				+1.00	+1.00

Examples for each visual acuity level are detailed below.

For Patients with Visual Acuity of 6/3-6/24 (20/10-20/80):

Determine Sphere Power

- Ask patient to identify the orientation of the tumbling “E”s on the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.50 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.50 more plus;
- Continue to check with the +0.50 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +0.50 lens makes the subject’s vision worse, remove the +0.50 lens
- Then hold a -0.37 spherical lens over the eye;
- If this -0.37 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.25 more minus;
- If the -0.37 spherical lens does not allow the patient to read more letters or if it makes the vision worse, move on to cylindrical testing;• Remember, if the patient reports that the -0.37 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -0.25.

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 0.50 diopter cross-cylinder with the positive axis first at 90° and then at 180°, asking if either position makes the letters clearer;
- If the patient prefers either one of these positions, place a +0.50 cylindrical lens in the trial frame aligned with the preferred axis;
- If the patient did not prefer cylinder at axis 90° or 180°, position the cross cylinder with the positive axis first at 45° then 135°;
- Ask if the patient prefers either of these positions;
- If so, place a +0.50 cylinder lens in the trial frame aligned with the preferred axis;
- If the subject prefers none of the four positions, no further cylinder testing is

- required;
- **If cylinder is present** in the beginning approximate refraction **or if you have added +0.50 cylinder power in the above step**, position the +/- 0.50 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves vision (position one or position two?);
 - If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
 - If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see Table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder.

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Switch to +/- 0.25 diopter cross-cylinder;
- Align the ± 0.25 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by +0.25 diopter;
- If a subject indicates a change that would introduce negative cylinder power, remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;
- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +0.25 diopter and retest;
- **Beginning with cylinder powers of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere power by 0.25 diopter of the opposite sign; this is done to maintain the spherical equivalent.**

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.37 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.25 more plus;
- Continue to check with the +0.37 lens to see if the subject will accept more

- plus by repeating the step above;
- When an additional +0.37 lens makes the subject's vision worse, remove the +0.37 lens;
- Then hold a -0.37 spherical lens over the eye;
- If this -0.37 lens improves the subject's vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.25 more minus;
- Continue presenting the -0.37 lens to see if there is any further improvement in vision;
- When an additional -0.37 lens does not improve vision;
- Present the +0.37 lens, again asking "if vision is better, worse or the same?"
- If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
- If patient responds that vision is worse, testing is complete.
- **Remember to always to end the refraction by checking with plus lenses.**

For Patients with Visual Acuity of 6/30-6/60 (20/100-20/200):

Determine Sphere Power

- Ask patient to identify the orientation of the tumbling "E"s on the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +1.00 spherical lens in front of the right eye. Ask the subject, "Is vision better, worse, or no change?"
- If the subject responds that vision is made better or is the same, replace the spherical lens with one that is +1.00 more plus;
- Continue to check with the +1.00 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +1.00 lens makes the subject's vision worse, remove the +1.00 lens
- Then hold a -1.00 spherical lens over the eye;
- If this -1.00 lens improves the subject's vision, even by one letter, replace the spherical lens in the trial frame by one that is -1.00 more minus;
- If the -1.00 spherical lens does not allow the patient to read more letters or if it makes the vision worse, move on to cylindrical testing;
- Remember, if the patient reports that the -1.00 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -1.00.
- **NOTE:** if visual acuity improves significantly during manifest refraction, the examiner may need to change to trial lenses that are specified for the new level of acuity for the remainder of the refraction. Please refer to the Trial Lens Guide above.

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 1.00 diopter cross-cylinder with the positive axis first at 90° and then at 180°, asking if either position makes the letters clearer;
- If the patient prefers either of these positions, place a +1.00 cylindrical lens in

- the trial frame at the preferred axis;
- If the patient did not prefer cylinder at axis 90° or 180°, position the cross cylinder with the positive axis first at 45° then 135°;
 - Ask if the patient prefers either of these positions;
 - If so, place a +1.00 cylinder lens in the trial frame at the preferred axis;
 - If the subject prefers none of the four positions, no further cylinder testing is required;
 - **If cylinder is present** in the beginning approximate refraction **or if you have added +1.00 cylinder power in the above step**, position the +/- 1.00 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves the vision (position one or position two?);
 - If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
 - If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see Table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Align the ± 1.00 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by +1.00 diopter;
- If a subject indicates a change that would introduce negative cylinder power, remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;
- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +1.00 diopter and retest;
- Beginning with cylinders of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere by 0.25 diopter of the opposite sign; this is done to maintain the spherical equivalent.

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.50 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.50 more plus;
- Continue to check with the +0.50 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +0.50 lens makes the subject’s vision worse, remove the +0.50 lens
- Then hold a -0.50 spherical lens over the eye;
- If this -0.50 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.50 more minus;
- Continue presenting the -0.50 lens to see if there is further improvement in vision;
- When an additional -0.50 lens does not improve vision;
- Show the patient the +0.50 lens, again asking “if vision is better, worse or the same?”
- If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
- If patient responds that vision is worse, refraction testing is complete.
- **Remember to always to end the refraction by checking with plus power.**

For Patients with Visual Acuity < 6/60 (<20/200):

Determine Sphere Power

NOTE: If refraction cannot be performed at 4 meters, defined as missing 2 or more letters on the largest line, then the subject should be moved to 1 meter and the above refraction sequence followed. **At 1 meter, a + 0.75 spherical lens is added** to the beginning approximate refraction to adjust for the accommodative difference between 4 and 1 meter.

- Ask patient to identify the orientation of the tumbling “E”s on the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +2.00 spherical lens in front of the right eye. Ask the subject, “Is it better, worse, or no change?”
- If the subject responds that vision is made better or is the same, replace the spherical lens with one that is +2.00 more plus;
- Continue to check with the +2.00 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +2.00 lens makes the subject’s vision worse, remove the +2.00 lens
- Then hold a -2.00 spherical lens over the eye;
- If this -2.00 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -2.00 more minus;
- If the -2.00 spherical lens does not allow the patient to read more letters or if it makes the vision worse, move on to cylindrical testing;
- Remember, if the patient reports that the -2.00 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -2.00.
- **NOTE:** if visual acuity improves significantly during manifest refraction, the examiner may need to change to trial lenses that are specified for the new level of acuity for the remainder of the refraction. Please refer to the Trial Lens Guide

above.

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 1.00 diopter cross-cylinder with the positive axis first at 90° and then at 180°, asking if either position makes the letters clearer;
- If the patient prefers either of these positions, place a +1.00 cylindrical lens in the trial frame at the preferred axis;
- If the patient did not prefer cylinder at axis 90° or 180°, position the cross cylinder with the positive axis first at 45° then 135°;
- Ask if the patient prefers either of these positions;
- If so, place a +1.00 cylinder lens in the trial frame at the preferred axis;
- If the subject prefers none of the four positions, no further cylinder testing is required.
- **If cylinder is present** in the beginning approximate refraction **or if you have added +1.00 cylinder power in the above step**, position the +/- 1.00 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves the vision (position one or position two?);
- If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
- If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Align the ± 1.00 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by 1.00 diopter;

- If a subject indicates a change that would introduce negative cylinder power, remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;
- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +1.00 diopter and retest;
- Beginning with cylinders of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere by 0.25 diopter of the opposite sign, this is done to maintain the spherical equivalent.

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +1.00 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +1.00 more plus;
- Continue to check with the +1.00 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +1.00 lens makes the subject’s vision worse, remove the +1.00 lens
- Then hold a -1.00 spherical lens over the eye;
- If this -1.00 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -1.00 more minus;
- Continue presenting the -1.00 lens to see if there is further improvement in vision;
- When an additional -1.00 lens does not improve vision;
- Present the +1.00 lens, again asking “if vision is better, worse or the same?”
- If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
- If patient responds that vision is worse, testing is complete.
- **Remember to always to end the refraction by checking with plus power.**

Record the lens correction obtained during manifest refraction for the right eye on the appropriate examination forms in the section for visual acuity measurements (Section A.5). Then proceed to refraction of the left eye, following steps as outlined above.

5.2.2. Visual acuity procedure

Visual acuity measurement is necessary for the secondary outcome in this trial. Therefore, we have created a standardized method that aims to minimize any bias from either the refractionist or the patient. This has been adapted from the Visual Acuity protocols from the Age Related Eye Disease Study (AREDS 1999)³², and the Aravind Eye Hospital’s Practical Guide to Refraction³³ and is similar to the method we are currently using at Aravind Eye Hospital and Proctor/UCSF for the NEI funded Steroids for Corneal Ulcers Trial and the Mycotic Ulcer Treatment Trial.

Visual Acuity Charts

The following equipment is used: a set of three charts, which are modified Bailey-Lovie charts, Charts 1, 2 and R (Precision Vision Chart 2305, 2305a and 2305b, respectively). Each chart consists of 14 lines of high-contrast “tumbling E’s”. There is

a geometric progression of letter size (and, thus, an arithmetic progression of the logarithm of minimum angle of resolution) from line to line.

Chart 1 is for measuring aided visual acuity of the right eye and Chart 2 is to be used for measuring aided visual acuity of the left eye at all visits. Chart R will be used for obtaining all manifest subjective refractions.

Visual Acuity Boxes

The dimensions of the light box are 24 and 3/4 inches (62.9 cm) by 25 and 3/4 inches (65.4 cm) by 7 inches (17.8 cm). The box can be mounted on a wall or on a cylindrical stand. The stand is mounted on a five-pronged wheelbase, with each prong about 14 inches (35.6 cm) long; two of the five wheels are lockable. When the box is mounted on the stand, its height can be varied. The light box should be mounted at a height such that the top of the third row of letters (0.8 logMAR, 45 letters, 20/125 Snellen) is 49 +/- 2 inches (124.5 +/-5.1 cm) from the floor. The rear of the box provides storage space for the two charts not being used.

Illumination

The overhead room lights should be turned **off** during the visual acuity test. The box itself provides sufficient illumination for the examiner to record the test results. Additional light can have an adverse effect such as glare. With the box light off, not more than 15 foot-candles of light should fall on the center of the chart. The visual acuity light box is equipped with two **20-watt** fluorescent tubes. Because the illumination of fluorescent tubes diminishes by 5 percent during the first 100 hours and by another 5 percent during the next 2,000 hours, new tubes should be kept "on" for about 4 days (approximately 96 hours, does not have to be continuous) before use. All tubes should be replaced once a year.

Each tube is partially covered by a 14-inch (35.6 cm) fenestrated sleeve, open in the back, which serves as a baffle to reduce illumination. Each sleeve should be centered on the tube such that an equal length of tube (about 4 and 3/16 inches or 10.6 cm) is left uncovered to the right and left of the sleeve.

4- and 1-Meter Visual Acuity Lanes

A distance of 4 meters (13 feet and 1.5 inches, or 157.5 inches) is required between the subject's eyes and the visual acuity chart for the 4-meter test, and a distance of 1 meter (39 and 3/8 inches) is required for the 1-meter test. The room for visual acuity testing must have, in addition to the 4-meter lane, space for the visual acuity box (and possibly a stand) and space for the subject.

- Wall-mounted box: In addition to the 4-meter lane, 7 inches (17.8 cm) must be allowed for the depth of the box plus space for the subject to sit or stand.
- Stand-mounted box: In addition to the 4-meter lane, 13 inches (33 cm) must be allowed for two of the stand's casters to touch the rear wall (or a line marked on the floor when there is no wall) plus space for the subject to sit or stand.

Marking the Distance

4 Meters

- If the chair and visual acuity box are permanently affixed, distance

measurements need to be made only once and no floor marks are needed to ensure the correct distance.

- If the box is mounted on the wall but the subject's chair is not permanently affixed, the 4- meter distance of the subject's eye from the chart must be marked clearly and permanently.
- If the box is mounted on a movable stand, the 4-meter distance must be marked clearly and permanently. The location and orientation of the box must be rechecked each time a new chart is put in place or the box is touched. When the stand touches the rear wall of the room, two of the five casters should touch the wall.

1 Meter

- The 1-meter distance is measured from the eye of the subject, who is seated comfortably in a chair with his or her back firmly placed against the chair's back, to the center of the second (for testing the left eye) or fourth letter (for testing the right eye) of the third line of the chart. A stick, one meter long, should be used to confirm the distance for each subject.

Visual Acuity Procedure

- Visual acuity will be measured at each study visit.
- Visual acuity should be measured for each eye AFTER refraction. Visual acuity should NOT be recorded during the refraction procedure.
- It is very important that the examiner is not aware of the patient's clinical records, in order to minimize bias. Therefore, the visual acuity examiner will not have access to the patient's previous clinical examination or treatment results.
- Visual acuity is tested separately for each eye (one eye at a time). The patient's untested eye will be completely covered with a patch, to block out all light from entering this eye. The examiner must constantly ensure that this eye remains occluded at all times.
- The patient is instructed to read each letter on the chart starting with the largest line, at the 4-meter distance.
- The patient will show the orientation of the tumbling "E" with the hand that they are not using to occlude the untested eye. If the patient cannot identify the orientation of a letter, they are encouraged to guess. **Only one response is allowed per letter.**
- The examiner must ensure that the patient does not squint (creating a pin-hole effect) or lean forward (reducing the distance to the chart).
- Once a patient has given a response for a letter and has moved on to provide a response for the next letter, any corrections of previous response will not be accepted.
- However, if the patient has given a response for a letter and has not yet moved on to provide a response for the next letter, a correction of the previous response is accepted.
- If the subject gives two possible responses for a letter, tell the patient to commit to one answer. **The examiner CANNOT, at anytime, give the patient any indication as to whether a response is correct or incorrect.**
- If 3 or fewer letters are identified correctly on any row from Row 3 or below, STOP testing on that row.
- In the case that the patient reads less than 10 letters at 4 meters, move the patient or the chart so that there is a distance between the two of 1 meter.

- Visual acuity will then be retested at this 1 meter distance.
- Only the first 6 rows of letters need to be read at 1 meter.
- If less than 10 letters are read at 1 meter, then the examiner must proceed to Low Vision Testing, starting with Count Fingers testing. If the patient does not adequately Count Fingers (see below), proceed to Hand Motion. If the patient does not adequately recognize Hand Motion (see below), then proceed to Light Perception.

Testing of Count Fingers Vision

In testing for count fingers vision, the examiner's hand presenting 1, 2, or 5 fingers is held steady at a distance of 1 meter directly in front of the eye being examined. The fellow eye is completely occluded with a patch. Refractive correction should not be used. A light should be shown directly on the hand from behind the subject and room lights should be turned on. The examiner's fingers should be presented in random order and repeated 5 times. Eccentric viewing should be encouraged. If the subject correctly identifies three of the five presentations, then count fingers vision is noted. If not, then the subject must be tested for hand motion vision.

Testing of Hand Motion Vision

The examiner's hand with all fingers spread out should be extended $\frac{1}{2}$ meter directly in front of the eye being examined. The fellow eye should be occluded with a patch. Refractive correction should not be used. A light should be shone directly on the hand from behind the subject and room lights should be turned on. The examiner's hand should be moved in an up-and-down direction (vertically) or in a side-to-side direction (horizontally) at a constant speed of approximately one back and forth presentation per second. The subject is instructed that the examiner's hand will be presented and they will have to respond to the question: "What am I doing with my hand?" This should be repeated five times. Four out of five correct responses indicate that hand motion vision is present. If the subject does not correctly identify four out of five, then you must test for light perception.

Testing for Light Perception

The indirect ophthalmoscope is used as the light source for testing light perception. Room lights should be off. The opposite eye must be completely patched. No correction should be used. From a distance of $\frac{1}{2}$ meter with the light source turned up to maximum intensity, the light from the indirect ophthalmoscope is directed into the subject's eye four times. The subject is asked to respond when the light is "on". Light Perception is recorded if the examiner is convinced the subject sees the light. Otherwise, the vision should be recorded as "No Light Perception".

Scoring Best Corrected Visual Acuity

On the Visual Acuity Forms, the examiner will circle all letters read correctly. Letters read incorrectly or not read at all will be left unmarked. At the end of each row of letters, the examiner will write down the total number of letters read correctly on the line provided. If visual acuity was not tested at 1 meter, the examiner will indicate this on the form.

After each measurement of visual acuity, the biostatistician will calculate the score for the visit. The visual acuity score is defined as follows:

- If 10 or more letters of the first line are read correctly at 4 meters, the 4 meter

visual acuity score is equal to the number of letters read correctly at 4 meters plus 30.

- If 3 or fewer letters of the largest line are read correctly at 4 meters, the visual acuity score is equal to the number of letters read correctly at 1 meter.
- If 3 or fewer letters are read at 1 meter, then low vision testing must be performed. (This result, count fingers, hand motion, light perception, or no light perception, will be used for the analysis by converting into a logMAR score according to Visual Acuity Calculation Table).

The highest attainable 4-meter visual acuity score is 100.

The Snellen equivalent, defined as the Snellen ratio corresponding to the most difficult line for which the subject read at least 4 of 5 letters correctly, will also be entered by the examiner on the 4-meter Visual Acuity Form (Section A.5).

The data entry staff will enter the number correct on each row at 4 meters, and if applicable, 1 meter and low vision testing results (They will not enter which letters the examiner circled, i.e., which letters the patient identified correctly.). The biostatistician will calculate the visual acuity score and double check the data entered by the examiner and data entry staff by reviewing the original forms.

5.2.3. Visual acuity training and certification

The goal of the certification process is to standardize methodology for refraction and visual acuity measurement. All visual function examinations must be performed by study-certified technicians. The principal investigator at each site is responsible for ensuring that the appropriate personnel are identified, trained and certified. A qualified visual function examiner (SL) from the Clinical Coordinating Center (Proctor Foundation) will certify the rooms and technicians at each site.

Technicians are expected to perform the refraction and visual acuity tests on at least one and possibly more non-study subjects according to protocol requirements. The examiner will determine whether or not the candidate executes the study protocol accurately for each procedure. A checklist (Visual Acuity/Refraction Certification Form, Section B.1) containing required procedures will be used to facilitate this process.

Room certification will be performed and recorded (Room Certification Form, section B.2) to ensure that all study rooms meet illumination, equipment, and distance requirements. Logs should be kept to document dates of light box bulb replacement.

Certification is valid for a period 18 months (\pm 2 months) from the date of certification. The process should begin as soon as possible, as technicians must be certified before the first study subject is seen. **A minimum of two certified technicians** are required at each site.

The visual acuity measuring schedule may be found on the Study Forms Completion Schedule.

5.3. Ophthalmic procedures

5.3.1. Grading inflammation

The study ophthalmologist at each site will be required to perform an eye examination at each study visit. This examination should be similar to that performed in the routine care of uveitis patients. Several components will be assessed in detail per study protocol. The grading schemes to be used for these assessments are adapted from the Standardization of Uveitis Nomenclature (SUN) Working Group.²

Anterior Chamber Cells

SUN Working Group Grading Scheme for Anterior Chamber Cells

Grade	Cells in Field*
0	<1
0.5+	1-5
1+	6-15
2+	16-25
3+	26-50
4+	>50

*Field size is a 1mm by 1mm slit lamp beam. Grading should be conducted in a completely dark room.

Anterior Chamber Flare

Anterior Chamber Flare will be assessed by slit lamp exam but will not be part of our study criteria for controlled inflammation.

SUN Working Group Grading Scheme for Anterior Chamber Flare

Grade	Description
0	None
1+	Faint
2+	Moderate (iris and lens details clear)
3+	Marked (iris and lens details hazy)
4+	Intense (fibrin or plastic aqueous)

*Adapted from: Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis: I. Anterior Uveitis. AM J Ophthal 1964;47:155-170; Grading should be conducted in a completely dark room

Vitreous Cells

There is currently no accepted standard for grading vitreous cells, which will not be part of our study criteria for controlled inflammation. However, we will collect this information using the grading scheme below, which is adapted from the MUST trial:

Grade	Cells in Field*
0	No cells
0.5+	0 to 5 cells
1+	6-10 cells
2+	11-20 cells
3+	21-50 cells
4+	>50

*Field size is a 1mm by 0.5mm beam; Grading should be conducted in a completely dark room; These cells are graded by slit lamp exam after dilation.

Vitreous Haze

Vitreous haze will be assessed using an indirect ophthalmoscope set at mid-power and a 20D lens. Fundus examination will be done with the last view being the area around the

optic disc. The examiner should then compare this view to the photograph (Figure 1) and determine the level of vitreous haze. The National Eye Institute System for grading vitreous haze will be used for all primary and secondary outcome measures. Additionally, vitreous haze will be assessed on the 9-point grading scale recently published by Davis et al. An exploratory analysis will correlate measurements from the NEI and Davis scales. Clinical measurements of vitreous haze will also be compared to objective assessments done by grading of fundus photos.

Figure 1: National Eye Institute system for grading vitreous haze


Grade	Description
0	Clear
0.5+	Slight blurring of optic disc margin Normal striations and reflex of nerve fiber layer cannot be visualized
1+	Opacities without obscuration of retinal details
2+	Few opacities resulting in mild blurring of details of optic nerve and retinal vessels
3+	Optic nerve head and retinal vessels significantly blurred but still visible
4+	Dense opacity obscuring optic nerve head

*Grading should be conducted in a completely dark room.



From Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. *Ophthalmology* 1985; 92: 467-471.

Figure 2: Davis et al 9-point system for grading vitreous haze



From Davis JL, Madow B, Cornett J, et al. Scale for photographic grading of vitreous haze in uveitis. *Am J Ophthalmol*;150:637-641 e1.

Slit lamp examination and dilated funduscopic exam are important parts of our study: assessments of anterior chamber cells and vitreous haze will determine the patient's course of treatment. All of our study physicians are fellowship-trained uveitis specialists who have participated in prior uveitis studies.

5.3.2. Inter-observer variation of ocular inflammation

At the 6th month study visit, the 12th month study visit, or at treatment failure (whichever is earlier), inter-observer agreement on slit lamp observations and funduscopic exam will be assessed. Coordinators will arrange for two certified study physicians to measure anterior chamber cells, anterior chamber flare, vitreous cells, and vitreous haze at the Month 6 and 12 visit or at declaration of treatment failure. The inter-observer variation will be reported. The primary study ophthalmologist's measurements will be used for primary analysis

5.4. Optical coherence tomography

We will be using spectral-domain optical coherence tomography (SD-OCT) in this study to monitor the effects of treatment by measuring macular thickness and changes in macular thickness. We will be utilizing the Heidelberg Spectralis SD-OCT unit and the Zeiss Cirrus SD-OCT unit for all study assessments. Each site must choose either Heidelberg Spectralis or Zeiss Cirrus at the time of study initiation and continue to use that same scanner for all patients the duration of the study.

5.4.1. Required patient assessments—Heidelberg Spectralis

For our study, one of each of the following scans is required for each eye:

- **20° x 20° High Speed Volume scan centered on the macula**

- **7 Line Preset scan centered on the macula**

5.4.2. Scan procedures—Heidelberg Spectralis

Creating Patient Files

For Baseline Scans:

To ensure patient confidentiality, patient ID only will be used. Patient name and other identifying information will not be used on the scans. Therefore, when setting up the patient file, please follow the instructions below:

- Click on the red forward facing icon in the toolbar
- In the Last Name field, enter study name: FAST
- In the First Name field, enter patient's unique study ID number
- For Date of Birth, always use 1/1/2000
- Click proper field in gender section
- In Patient ID field enter patient's unique study ID number, example: "1-APR-211"

For Follow-up Scans:

- Click on the side facing icon in the toolbar
- Ensure that a scan from the baseline visit has been set as a reference scan:
 - Identify the scan from the baseline visit that you would like to set as reference
 - Right click on the scan
 - Select "Progression"
 - Select "Set Reference"
 - This setting will be confirmed by a red icon appearing on the bottom left corner of the selected scan

Procedures for Obtaining Scans

General Guidelines

- Scans may be obtained if the patient's pupils are not dilated. However, pupil dilation prior to obtaining scans is encouraged
- Clean chin rest and forehead rests
- Adjust table and chin rest height to ensure patient comfort
- Make sure that patient is aligned straight; slight face turns to the left or right may decrease scan quality

Click on the Preset "**Dense**" scan icon on the screen to obtain the 20° x 20° volume scan. Please make sure that the scan will have the following parameters:

- 20° x 20°
- 49 sections
- 16 frames (ART)
- Pull the camera all the way back
- Move the instrument toward the patient slowly, taking care not to alarm patient and to not touch the patient's eyes or eyelashes with the instrument
- Ask patient to fixate on the blue light on the inside of the machine
- Remind patient not to follow the movement of the red scan lines
- If patient is having trouble focusing on fixation light, you may need to help the patient direct his/her gaze by using external fixation targets
- Focus in on the circular black and white retinal reflex
- Move the camera forward so that the fundus image comes into view and fills the

- screen
- Use the focusing knob to obtain maximum brightness and clarity of the image
 - Ensure that the image is maintained in the **upper third** of the screen
 - Click “Acquire”
 - Repeat for next eye

Click on the “**7 Line**” Preset Scan icon

This scan will have the following parameters:

- 30° x 5°
 - 7 sections
 - 25 frames (ART)
- Focus image as described above
 - Click “Acquire”
 - Repeat for next eye
 - **Please review scans for completeness and quality. A good quality scan should have a score of at least 20. Please repeat any scans that are not complete or of poor quality.**

5.4.3. Obtaining retinal thickness data—Heidelberg Spectralis

- After closing the acquisition window, double click on the volume scan.
- Select “Thickness Map” tab
- Record central subfield thickness on data sheet
- Print out copy of scan for patient file

Be sure to complete analysis of data and record information on data collection form as soon as possible. This will ensure that the treating physician will be able to use the SD-OCT results in real time to determine if macular edema is present or not.

5.4.4. Saving/Exporting data—Heidelberg Spectralis

Saving Data

- All scans should be saved and archived at each study site on the Heidelberg SD-OCT unit.
- After obtaining scans, right click on each scan icon and choose “Export as E2E”
- Save the “E2E” data onto a removable hard drive separate from the main unit: this raw data may be requested from each site at a later date.

Exporting Data

- One image of the central macula from each 20° x 20° scan should be emailed to the Proctor Foundation for review.
- With volume scan displayed, and with the central macular scan highlighted, click on “Image” tab on toolbar
- Select “Export as Picture”
- Export and save image on a desktop folder or onto a USB drive
- Save images as “jpg” files
- Also create a PDF file of the “Thickness Map” described above in section 5.4.3
- Place these images of both eyes in a file

- Label the file with patient's unique study ID, visit number, and date of visit, example: "1-APR-211-BL-10AUG2012"
- Email images for each patient to Proctor Foundation: [REDACTED]
- Repeat above steps for scan number 4 of the 7 Line Preset Scan
- If images cannot be obtained or are of poor quality, please provide comments in email

5.4.5. Required patient assessments—Zeiss Cirrus

For our study, one of each of the following scans is required for each eye:

- **Macular Cube Scan**
- **5 Line Raster scan centered on the macula**

5.4.6. Scan procedures—Zeiss Cirrus

Creating Patient Files

To ensure patient confidentiality, patient ID only will be used. Patient name and other identifying information will not be used on the scans. Therefore, when setting up the patient file, please follow the instructions below:

- In the Last Name field, enter study name: FAST
- In the First Name field, enter patient's unique study number
- For Date of Birth, always use 1/1/2000
- Click proper field in gender section
- In Patient ID field enter patient's unique study ID number, example: "1-APR-211"

Procedures for Obtaining Scans

General Guidelines

- Scans may be obtained if the patient's pupils are not dilated. However, pupil dilation prior to obtaining scans is encouraged
- Clean chin rest and forehead rests
- Adjust table and chin rest height to ensure patient comfort
- Make sure that patient is aligned straight; slight face turns to the left or right may decrease scan quality
- Ensure that the camera is pulled all the way back
- Move the instrument toward the patient slowly, taking care not to alarm patient and to not touch the patient's eyes or eyelashes with the instrument

Select "**Scan Macular Cube 512x218**" default in the upper panel of the Acquire screen

- In the Iris Viewport, center the scan beam through the pupil by clicking on the pupil center or using the X-Y controls
- Focus the iris image using the chinrest arrows
- Center the fundus image in the Fundus Viewport
- Click on "Auto Focus"
- Use small arrows to focus manually
- Click "Optimize"
- Ask patient to blink right before image capture
- Click "Capture"
- Review scan; if acceptable, click "Save"
- If not acceptable, click "Try Again"

Repeat above steps to acquire "**5 Line Raster**" default Scan

- If patient is having trouble focusing on fixation light, you may need to help the patient direct his/her gaze by using external fixation targets
- Ensure that the scan image is maintained in the **upper half** of the screen
- Please review scans for completeness and quality. Signal strength should be at least 5 or higher. Please repeat any scans that are not complete or of poor quality.

5.4.7. Obtaining retinal thickness data—Zeiss Cirrus

- Obtain Macular Thickness analysis
- Obtain 5 Line Raster analysis
- Record central subfield thickness on data sheet

Be sure to complete analysis of data and record information on data collection form as soon as possible. This will ensure that the treating physician will be able to use the SD-OCT results in real time to determine if macular edema is present or not.

5.4.8. Saving/Exporting data—Zeiss Cirrus

- All scans should be saved and archived at each study site on the Zeiss Cirrus SD-OCT unit. This raw data should also be saved onto a separate removable hard drive so that it is available for export and review at a later date.
- The following images should be emailed to the Proctor Foundation for review.
 - One image/screen shot of macular cube printout for each eye
 - One image/screen shot of 5 line raster printout for each eye
 - Images can be sent as “jpg”, “tiff” or “pdf” files
 - Images should be sent to: [REDACTED]
 - If images cannot be obtained or are of poor quality, please provide comments in email

5.4.9. OCT operator qualifications

Prior to the study start date, at least 2 personnel who will be responsible for obtaining SD-OCT scans at each site should be identified. These individuals should have prior experience with operation of either the Heidelberg SD-OCT or Zeiss Cirrus SD-OCT instrument for routine clinic purposes. Dr. Salena Lee will go to each site before that start of the trial to meet with these technicians to review all required OCT procedures specified in our protocol. OCT operators must be able to demonstrate ability to obtain scans as well as knowledge of the study protocol.

5.5 Fundus Photography

Color fundus photography will be performed at baseline, 6 months, 12 months or treatment failure. Photos will include fundus reflex images and non-stereoscopic fundus images. Vitreous haze will be graded according to the NEI and Davis scales by masked graders. Photographers will need to be certified by the Uveitis Photograph Reading Center prior to obtaining photos for our study. Please see UPRC manual (Appendix C) for instructions on certification and obtaining study photos.

5.6. Laboratory measurements

Hematology and serum chemistry will be monitored in all patients prior to enrollment and throughout participation in the study. Each of the participating sites has an accredited onsite laboratory where all blood draws and laboratory measurements will be performed. The following will be measured and recorded on the Laboratory Report Form (Section A.7) for each:

Hematology

- Hemoglobin and/or hematocrit
- Platelet count
- White blood cell count (WBC)
 - % neutrophils; % lymphocytes

Serum Chemistry

- SGOT (AST)
- SGPT (ALT)
- Creatinine
- Serum or urine for pregnancy test

Laboratory measurements used for baseline visits should be collected within 14 days of the official visit date. Those used for follow-up visits may be collected at any time within the study visit window.

All abnormal values will be reported on the Adverse Event Checklist (Section A.9) and monitored for resolution on the Adverse Event Log. Abnormalities which result in a non-serious adverse event (i.e. AST or ALT increasing to twice the upper limit of normal) will result in immediate stopping of study medications. As these abnormalities are often reversible, patients will be allowed one month to regain eligibility. If the lab results have returned to normal within one month, patients may be re-administered the study drug according to protocol. Labs can be checked prior to one month, and if normal, treatment can resume. Otherwise, treatment failure will be declared and patients will exit the study and be treated according to the best medical judgment of their physician. Note that treatment failure may be declared due to lack of efficacy if a patient's inflammation becomes uncontrolled during this one month period if it occurs at the 6 month visit.

Abnormalities which meet the designated threshold of a severe adverse event (SAE) will result in immediate stopping of study medications, and should be reported on the Serious Adverse Event Narrative form (Section A.11). Patients will then exit the study and be treated according to the best medical judgment of their physician.

6. Adverse events

6.1. Non-serious adverse event (AE)

Non-serious adverse events may include any unfavorable medical occurrences in patients who have ever received study medication, regardless of any causal relationship with treatment. Examples* may include:

- Increased intraocular pressure (>24 mm Hg)
- Abnormal lab findings (> 2 times but < 5 times the upper limit of normal AST or

ALT, rise in creatinine to ≥ 1.5 to < 2 mg/dL, reduction of white blood cell count to below 2.5)

- Concurrent accident or illness
- Increase in the frequency and severity of symptoms of a pre-existing condition
- Side effects such as gastrointestinal upset, nausea, vomiting, fatigue

*For additional details, please see the adverse event checklist (Section A.9)

6.2. Serious adverse event (SAE)

Serious adverse events include any medical occurrence that results in the following outcomes, or any other adverse event classified as severe*:

- ≥ 5 times the upper limit of normal AST or ALT
- Death
- Non-elective surgery or hospitalization for any reason
- Myocardial infarction or stroke
- Life-threatening adverse drug experience
- Persistent or significant disability or incapacity

*For additional details, please see the adverse event checklist (Section A.9)

6.3. Adverse event reporting

Non-serious and serious adverse events will be recorded at each study visit on the appropriate form (Adverse Event Checklist and Log, Sections A.9-A.10). An adverse event log will be maintained for each patient to record the onset and resolution of any adverse events.

In case of a Serious Adverse Event (SAE), the Serious Adverse Event Narrative Form (Section A.11) will be completed by the Investigator and submitted to the Medical Monitor, Dr. Todd Margolis () within 24 hours of the SAE. Information recorded on this form will include the nature of the event, date of onset, date of resolution, date of notification to Medical Monitor, and action taken. The form will be reviewed, signed and forwarded to the DSMC by the Medical Monitor. Any significant study drug-related adverse events will be reported by the coordinating center to the FDA and CHR office as appropriate.

6.4. Patient death

Any patient death that occurs during the study will be reported by the study center's Study Coordinator to the Medical Monitor within 24 hours. The study arm of any deceased patient will be made available to the DSMC by the DCC if appropriate.

7. Data collection and management

This section discusses how the data will be collected from the different Study Centers, entered into the computer database and stored, and transferred to the Data Analysis Committee under the supervision of the Data Coordinating Center (DCC). The data management plan described

below is similar to what we are already using for our NEI-funded SCUT and MUTT clinical trials, which enroll patients at Proctor/UCSF, Dartmouth, and at Aravind Eye Hospital in India. Proctor/UCSF is the clinical and data coordinating center for these trials.

7.1. Data collection forms

The data collection forms are derived from the Steroids for Corneal Ulcers Trial, the Mycotic Ulcer Treatment Trial pilot and main trial, and the FAST pilot trial initiated as a precursor to this proposed study. These forms have been extensively field-tested by UCSF and Aravind investigators.

Study personnel at each site will be given specific training for each form for which they will be responsible. Paper forms for each patient will be completed by study personnel (study physicians, refractionists, etc.) within 48 hours following the study visit at each study site. Questions which arise during the use of the forms will be communicated with the Data Coordinating Center at Proctor, and the results and answers will be communicated to all sites. Teleconferences and site visits will be held periodically for all users of the forms to review procedures and address questions.

7.2. Data review

Before data entry, the forms will be reviewed and cross-checked for consistency and completeness by the study coordinator within **24 hours** of completing the form. If the forms are not filled out completely, the study coordinator will contact the person responsible for completing the form to provide the missing data, or clarify any inconsistent data. The study coordinator or investigators who filled out the form are the only people who are authorized to add missing data or make any changes to the study forms. All changes should be made with a red ink pen, and then signed and dated. The computer data entry forms contain two fields at the end, in which the data entry personnel will indicate whether or not there was any “red ink” (corrections to the paper form), and which fields contained corrections; this will be used in quality assurance monitoring. Further investigation may be conducted if certain fields or personnel are associated with a higher rate of paper form errors.

7.3. Data entry

Once the completed study forms have been reviewed and approved by the study coordinator, the study coordinator will enter the first round of data entry, before giving the forms to the data entry operators at each site, for them to complete the second entry. All data will be entered into the official electronic research data capture service at UCSF; REDCap.

Our goal is for both data entries to occur within **two working days** of form review and approval by the study coordinator (and **within 3 working days** of form completion) in order to prevent the accumulation of un-entered forms. The database program contains an entry module for each form, prompting the user to enter the data in the same order as the form and clearly indicating each question. All data will be double-entered at each site, by the study coordinators and independent data entry operators to ensure accuracy.

7.3.1. Data entry errors

At each site, a data analyst will compare double-entered study data using the automated

feature in REDCap (with a goal of completing within **2 days of data entry completion**). Wherever there is a mismatch, an error file will be generated with relevant data such as the form, field name, visit name, and data for which discrepancy is found. The data analyst will then contact the data entry operators to verify the forms and re-enter the data. Discrepancies and missing values will be assessed by the data analyst, and resolved by queries sent to the study coordinator and appropriate observers (clinician, refractionist, etc). A logfile will preserve the date and time of any changes, together with who entered the changes.

7.3.2. Data consistency and validity

A database data quality assessment program will be created in R programming software to help prevent inconsistencies or invalid data. The database program will check for the following errors: (1) improper entry of the patient ID based on the checksum, (2) data fields that are out of range, (3) inconsistent or illogical entries, (4) incompleteness, and (5) numerical values that are far outside the range of those previously entered. The software will create an error file with relevant data such as the form identification, field names and the data. Automated checks will be made to ensure consistency and that each variable in the analysis set has in-range values (protecting against negative ages, spelling errors in categorical factors, and similar errors). The DCC will conduct regular checks of the data at each site and will contact the study coordinator about any errors in order to resolve the inconsistencies and have the data entry operators enter the correct data.

7.3.3. Data preparation and cleaning

Data sets for analysis will be produced in Microsoft Excel® worksheets (downloaded from the REDCap system) containing a single header line whose variable names match the REDCap database. Each analysis set will be in the form of a rectangular table in which each column corresponds to a single variable and each row to an observation. All missing values will be coded explicitly using the string "NA" (as used in the R software). Codes for categorical variables (such as 1 for male, and 2 for female) will be avoided in favor of self-documenting character strings (such as Male, Female) whenever possible.

A detailed codebook will be prepared, containing for each variable, (a) the form from which the variable derived, (b) the text of the question, (c) all possible values for the variable, and (d) summary statistics for the variable. Note that all codes and character strings that represent categorical factors will be clearly defined in the codebook. Units for each continuous variable (e.g. logMAR) will be unambiguously indicated for each variable. Each release of the analysis set will be accompanied by the corresponding version of the codebook. Version numbering with dates will be strictly observed.

7.3.4. Monitoring

We will maintain a record of (1) changes to the initial entries on database forms, and (2) changes made to all entered data. Database errors include (a) missing information, (b) erroneous information that was initially entered, and (c) errors arising from difficulties with the forms themselves. Weekly quality assurance reports will summarize the number of each of these. Most importantly, we will closely monitor the waiting time between the collection of the initial form and the entry of the data to ensure that this time is **less than 48 hours**. If entry times exceed 48 hours, then this will trigger a response, which may include investigation, retraining, and even reassignment.

7.4. Data analysis

Following data checks by the data analyst, the Data Analysis Committee will be responsible for analyzing the data. It will merge the unmasked data with the randomization list, perform statistical analyses and prepare reports.

Standard report-generation software included with the R statistical and data analysis package will be used to ensure consistency of the codebook and analysis set at all times.

Data monitoring reports will be prepared based on analysis data sets. These will be prepared using report-generation software. Monitoring reports will include (a) recruitment reports for each center, (b) compliance reports, (c) retention reports, and (d) data quality reports. These will be reviewed by the DCC on a monthly basis, and communicated to the study sites on a monthly basis.

7.5. Data storage and security

Paper forms will be maintained in locked file cabinets in locked rooms only accessible to research staff at each study site.

All electronic storage, both at the Aravind sites and at Proctor and Casey, will be subject to standard security procedures in compliance with established enterprise information security standards. Each computer will be hardware-firewalled and will not be accessible outside the Local Area Network. Hard-disk encryption will be used for each machine, and the machine will not be accessible without a network account and password. Only one individual at each site will have password access to the machine; new accounts may be provided by the local network administrator only with the approval of the DCC. Accounts will be immediately deactivated for data entry or other personnel who leave the study. The computer used for data entry and storage will be kept in a physically locked room, and only authorized study personnel will be able to access this machine. All individuals who access the server room will be logged as to time and date. At each center, the complete database (including all data tables as well as change logs) will be backed up weekly on the server and weekly on a CD/DVD, which will be kept at a safe, locked cabinet. Temperature logs will be maintained for the server room and reported.

The database at the DCC will be stored on a SQL server located at 95 Kirkham Street, San Francisco, CA and three sets of backup copies on CD/DVD will be kept. The server is hardware-firewalled and also uses hard-disk encryption; it is inaccessible outside the Proctor network and cannot be physically accessed by anyone other than the network administrator. Other visitors must be accompanied by an information security professional and the visit will be logged. All data will be protected with passwords and the computer/server on which the data is stored and the backup copies on CD/DVD will be located in a lock-secured facility. Each back-up file will be archived offsite. In the event of disruption due to unforeseen circumstances, all materials needed to continue will be available from the offsite archive.

8. Quality control

With the help of the Data Coordinating Center and the Data Analysis Committee, the Clinical Coordinating Center will evaluate the quality of study activities (clinical examination, treatment compliance, refraction, etc.).

8.1. Medication storage and expiry

Study medications will be stored at room temperature. The expiration dates of the treatment kits will be regularly monitored and all expired study medicine will be discarded appropriately.

8.2. Periodic reports

The Study Coordinators will send weekly reports on the number of eligible patients screened, the number of patients enrolled, reasons for ineligibility, and the number of patients who have come back for follow-up visits to the Clinical Coordinating Center. This will be used to monitor the enrollment/follow-up progress and any protocol violation in enrollment. The CCC will send bi-weekly reports to all investigators with a summary of overall enrollment and breakdown of enrollment at each site.

When a site visit or training/certification is conducted at a study site, a report will be prepared and sent to the Executive Committee.

The minutes of the DSMC meeting will be circulated electronically among the investigators and the members of the DSMC after each meeting.

8.3. Data management, security and quality assurance

See Section 7.

8.4. Monitoring compliance

Patients will be asked to record missed doses in individual treatment diaries and to bring them with their medication to each follow-up visit. The study coordinator will collect details of the number of doses missed by the patient and recorded these in the medication adherence log. In addition study coordinators will conduct pill counts at each visit.

8.5. Certification

For training and certification process, see Sections 5.2.3.

8.6. Data audits

Samples of data forms will be audited at each site to ensure consistency between the source documents and data entry. Patient charts will also be reviewed two times a year to confirm adherence to the protocol.

9. Duties and responsibilities of staff

9.1. Ophthalmologist

- Responsible for enrolling study subjects
- Provide information for completing the clinical examination forms
- Obtain written consent from the subjects with the help of study coordinator
- Initiate study medication as per the randomization
- Responsible for the care of the patient throughout the course of the study
- Manage adverse events

9.2. Clinical Trial Manager

- Ensure the execution of the study as per the protocol
- Arrange training of the ophthalmic assistants, and refractionists
- Coordinate with the collaborating centers
- Prepare weekly reports regarding recruitment and follow-up progress
- Handle correspondence between centers
- Maintain IRB approval and renewals
- Communicate with central pharmacy regarding drug orders and distribution to sites

9.3. Study Coordinator

- Make sure that appropriate patients are screened and enrolled in to the study (including obtaining appropriate assent/consent)
- Prepare weekly reports regarding recruitment and follow-up progress
- Send reminders to study subjects for follow-up visits
- Meeting with the patient at each study visit, prior to the study ophthalmologist to help maintain masking
- Assist ophthalmologist, ophthalmic assistants, and refractionists for conformity to study procedures
- Verify data forms for completion and collect missing information
- Transfer study forms for prompt data entry
- Maintain stock of and dispense study medications

9.4. Data Analyst

- Develop data entry programs specific to the study forms under the supervision of DCC
- Monitor the flow of forms from the coordinator
- Supervise data entry operators for any errors or omissions
- Develop consistency checks
- Communicate with study coordinators and data entry operators to correct any mistakes in study forms and data entry
- Transfer data as and when requested by the DCC
- Back up all data appropriately

9.5. Data Entry Operator

- Enter all data from study forms when submitted by the study coordinator
- Verify inconsistencies in the forms and send them for correction to the study coordinator
- Perform double entry to ensure accurate recording

9.6. Biostatistician (Proctor)

- Review data for quality control purposes
- Prepare reports for DSMC
- Lock database at completion of study after database is cleaned
- Conduct analyses at the conclusion of the study
- Prepare randomization list and distribute the list to a pharmacist and non-masked, senior physicians at the study sites in case of emergency.

9.7. Ophthalmic Assistants

- Obtain patient information
- Measure preliminary vision
- Assist ophthalmologist in the clinical examination/enrollment of the subject
- Counsel and motivate patients to return for scheduled follow-up visits

9.8. Refractionists

- Perform manifest refraction as specified by protocol of both eyes at each visit
- Measure and record best spectacle-corrected visual acuity at each visit
- Enter visual acuity (number of letters read and Snellen equivalent) on the study form

9.9. OCT Operators

- Perform OCT photography as specified by protocol of both eyes at all visits

9.10. Fundus Photographers

- Perform fundus photography as specified by protocol of both eyes at the baseline, 6 months, 12 months or treatment failure visits.

9.11. Fundus Graders

- Complete grading of vitreous haze from images of fundus photography.

10. Study Organization

10.1. Executive Committee

The Executive Committee will be chaired by Dr. Acharya at the Proctor Foundation and will include Dr. Lietman and Dr. Porco. This committee will act as the administrative and executive arm of the clinical trial and will meet once a month to provide overall oversight for the study and make decisions on day-to-day operational issues. The role of the Executive Committee includes but is not limited to monitoring study progress and data collection process, supervising the Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC) for overall quality control, evaluating and adopting changes in study procedures as necessary, communicating with and implementing recommendations from the Data and Safety Monitoring Committee, making executive decisions on the allocation of resources, establishing policies on publications and authorship, and approving and overseeing ancillary studies.

10.2 Clinical Coordinating Center (CCC)

Dr. Acharya will also be responsible for directing the CCC, located at the Proctor Foundation/UCSF. The responsibility of the CCC includes oversight and coordination of the clinical implementation of the trial at Aravind, Oregon Health Sciences and at Proctor/UCSF. Specifically, this includes roles such as maintaining an up-to-date manual of operations, obtaining human research approvals from Institutional Review Boards, conducting training and certification of all personnel including physicians and refractionists, supervising

preparation and dispensing of study medication, ensuring proper masking, and monitoring protocol adherence and recruitment. The CCC will monitor the recruitment progress with weekly reports from each of the study sites. It will also organize twice yearly site visits to conduct chart reviews, training and certification of study personnel and monthly phone calls with study investigators to review enrollment, retention and any other study-related issues. Under the direction of the CCC, Dr. Salena Lee, the senior optometrist at the Proctor Foundation, will be responsible for training/certifying study refractionists and managing the refraction protocol. She will also be responsible for monitoring overall quality of the OCT imaging. Dr. Todd Margolis, co-investigator, will serve as medical monitor of the trial. He will receive all reports of serious adverse events from all study sites, ascertain whether further information is needed, and convey that information to the DSMC. As with our current NEI-funded studies, the study coordinator at Proctor/UCSF (Natalie Nardone) will assist with many of the clinical coordination activities listed above and also check in weekly by email with the study coordinators at each site to discuss any study-related issues.

10.3 Data Coordinating Center (DCC)

The DCC including, Dr. Lietman, Dr. Porco and Dr. Enanoria, is responsible for supervising data collection, data management, data quality control, data analysis, event adjudication, and training and certification of study site staff in the data management systems. The DCC will also be responsible for coordinating and supporting the activities of the Data Safety Monitoring Committee, including preparing interim and final data reports and organizing meetings with the Data Analysis Committee. The DCC will also be responsible for the dissemination of datasets for use by the Data Analysis Committee and other investigators. The DCC will meet weekly to monitor the progress and quality of data entry/management and address any issues. The DCC will be in close contact with the data analysts and data entry operators to ensure quality assurance of data entry. See MOP for further information on data management (Section 7).

10.4 Data Analysis Center (DAC)

Dr. Porco will direct the Data Analysis Committee with assistance from Dr. Enanoria. The primary functions of the DAC include designing a statistical analysis plan, preparing and distributing randomization lists, performing data analysis, and coordinating publications and presentations. The Committee is responsible for obtaining data from the Data Coordinating Center, performing unmasked data analyses and for preparing reports for the Data and Safety Monitoring Committee, and at the conclusion of the study, for the Principal Investigator. The DAC will also be responsible for conducting the prespecified interim analysis (when 1/3 of patients complete the study) and also for providing data to the DSMC to evaluate the stopping guidelines.

10.5 Data Safety and Monitoring Committee (DSMC)

The Data Safety and Monitoring Committee (DSMC) will be independent and NEI-appointed, with experts from diverse fields including ethics, biostatistics, epidemiology, ophthalmology, and international health care, and include at least one member of the NEI staff as an ex officio member. The committee will meet for the first time before the study begins. Only after the DSMC reviews and approves the protocol will patients be enrolled. We anticipate the group will meet regularly throughout the study and review information on data quality, enrollment, patient retention, and study outcomes, etc. Committee members will be instructed to be vigilant for any trend in severe or unexpected adverse events that may threaten the safety of the patients. They will be authorized to implement a conservative,

early stopping rule.

10.6 Editorial Committee

The Editorial Committee is composed of the principal investigator Dr. Acharya and co-investigators Dr. Rathinam and Dr. Suhler. This committee has the responsibility to assist in the preparation of the primary study results and to review secondary manuscripts produced by the study investigators. They have the responsibility to ensure the completion of the primary manuscript (Specific Aim 1) in a timely manner and direct its submission for publication.

10.7 Study Sites

Under the supervision of the CCC, Dr. Rathinam will direct the Aravind clinical centers, Dr. Suhler will direct the Casey Eye Institute clinical center, and Dr. Acharya will be in charge of the Proctor Foundation clinical center.

10.8 Pharmacy

Leiter's Pharmacy (San Jose, CA) is one of the country's largest ophthalmic compounding pharmacies and is well known among ophthalmologists for their quality and reproducibility. They have participated in a number of clinical trials with experience in preparing and masking medications identified only by study ID, including the SCUT, MUTT and FAST pilot trials. We have worked with Chuck Leiter to discuss drug preparation for this study and cost estimates, and have experience with the medication distribution process from our pilot trial. Leiter's Pharmacy will prepare all of the study medications for the trial.

10.9 Study Communications

The study coordinator at the Proctor Foundation (Natalie Nardone) will be responsible for ensuring that communication between all facilities and committees is conducted seamlessly. Communication between study personnel at the Proctor Foundation and investigators at other sites will be performed by extensive use of secure email. Much of the communication will be through email, but we have found that regular, international, conference calls are valuable, and that regular, face-to-face meetings are mandatory. Members of the CCC and the DCC at the Proctor Foundation will visit Oregon and Aravind every 4-6 months through the duration of the study to discuss details of the study and monitor quality control.

11. Bibliography

1. Nussenblatt RB. The natural history of uveitis. *Int Ophthalmol* 1990;14:303-8.
2. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. *Br J Ophthalmol* 1996;80:332-6.
3. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. *Ophthalmology* 2004;111:491-500; discussion 500.
4. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. *Br J Ophthalmol* 1996;80:844-8.
5. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. *Ophthalmologica* 2004;218:223-36.
6. Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. *Br J Ophthalmol* 1992;76:137-41.
7. Smit RL, Baarsma GS, de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. *Int Ophthalmol* 1993;17:71-6.
8. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. *Am J Ophthalmol* 1996;121:35-46.
9. Mercanti A, Parolini B, Bonora A, Lequaglie Q, Tomazzoli L. Epidemiology of endogenous uveitis in north-eastern Italy. Analysis of 655 new cases. *Acta Ophthalmol Scand* 2001;79:64-8.
10. Das D, Bhattacharjee H, Bhattacharyya PK, et al. Pattern of uveitis in North East India: a tertiary eye care center study. *Indian J Ophthalmol* 2009;57:144-6.
11. Rathinam SR, Namperumalsamy P. Global variation and pattern changes in epidemiology of uveitis. *Indian J Ophthalmol* 2007;55:173-83.
12. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. *Am J Ophthalmol* 2000;130:492-513.
13. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. *Ophthalmology* 2008;115:1826-32.
14. Siepmann K, Huber M, Stubiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. *Graefes Arch Clin Exp Ophthalmol* 2006;244:788-94.
15. Teoh SC, Hogan AC, Dick AD, Lee RW. Mycophenolate mofetil for the treatment of uveitis. *Am J Ophthalmol* 2008;146:752-60, 760 e1-3.
16. Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. *Ophthalmology* 2005;112:1472-7.
17. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. *Ophthalmology* 1999;106:370-4.
18. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. *Lancet* 1998;352:35-6.
19. Baltatzis S, Tufail F, Yu EN, Vredevelde CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. *Ophthalmology* 2003;110:1061-5.
20. Choudhary A, Harding SP, Bucknall RC, Pearce IA. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. *J Ocul Pharmacol Ther* 2006;22:168-75.
21. Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. *Ocul Immunol Inflamm* 2001;9:35-40.
22. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. *Ophthalmology* 1999;106:111-8.
23. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. *J Rheumatol* 2005;32:362-5.

24. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for Ocular Inflammatory Diseases. *Ophthalmology* 2009.
25. Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, Volcker HE. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. *Ger J Ophthalmol* 1992;1:142-4.
26. Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low-dose methotrexate therapy for ocular inflammatory disease. *Ophthalmology* 1992;99:1419-23.
27. Taylor SR, Habet-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. *Ophthalmology* 2009;116:797-801.
28. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate Mofetil for Ocular Inflammation. *Am J Ophthalmol* 2009.
29. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. *Ophthalmology* 2008;115:1416-21, 1421 e1.
30. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol* 2005; 140: 509-16.
31. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. *Ophthalmology* 1985;92:467-71.
32. Manual of Operations: Age Related Eye Disease Study, 2000.
33. Sherring AK. A Practical Guide on Refraction, 1999.

NEI U10 EY021125-01

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

Manual of Operations & Procedures (MOP)

January 06, 2017
Version 4.5

TABLE OF CONTENTS

INVESTIGATORS, PERSONNEL AND STUDY SITES	4
DATA SAFETY AND MONITORING COMMITTEE (DSMC) MEMBERS.....	6
NATIONAL EYE INSTITUTE (NEI) PROGRAM OFFICER.....	6
BACKGROUND	7
1. INTRODUCTION TO TRIAL	8
1.1. RESEARCH QUESTION.....	8
1.2. SPECIFIC AIMS.....	8
2. TRIAL DESIGN	9
2.1. DESIGN SUMMARY	9
2.2. STUDY TIMELINE.....	10
2.3. ELIGIBILITY.....	11
2.3.1. <i>Anatomical location of inflammation</i>	11
2.3.2. <i>Inclusion Criteria</i>	12
2.3.3. <i>Exclusion criteria</i>	13
2.3.3.a. <i>Screening for Active Tuberculosis</i>	13
2.4. RANDOMIZATION AND MASKING.....	14
2.5. DEFINITIONS FOR PRIMARY ENDPOINT.....	16
2.5.1. <i>Determination of Treatment Success/Failure</i>	16
2.5.2. <i>Treatment failure</i>	16
2.5.3. <i>Dropouts, Non-Compliant Patients and Follow-up</i>	18
2.5.4 <i>Primary Endpoint Flowchart</i>	19
3. TREATMENT PLAN.....	20
3.1. STUDY DRUGS	20
3.1.1. <i>Methotrexate</i>	21
3.1.2. <i>Mycophenolate Mofetil</i>	22
3.1.3. <i>Folic acid</i>	23
3.1.4. <i>Packaging and distribution of study medications</i>	23
3.1.5. <i>Adherence to the treatment plan</i>	24
3.2. CORTICOSTEROID THERAPY	24
3.2.1. <i>Oral prednisone</i>	24
3.2.2. <i>Supplements</i>	27
3.2.3. <i>Topical corticosteroid</i>	27
3.2.4. <i>Periocular and Intravitreal Injections</i>	27
3.2.5 <i>Other adjunctive treatments/procedures</i>	28
3.3. STUDY PROCEDURES.....	28
4. STUDY VISITS	29
4.1. VISIT SCHEDULES	29
4.1.1. <i>Phase I: First-line treatment</i>	29
4.1.2. <i>Phase II: Rescue treatment</i>	30
4.1.3. <i>Non-study visits</i>	31
4.2. STUDY FORMS COMPLETION SCHEDULE.....	32
4.3. PHASE I ENROLLMENT/BASELINE VISIT.....	33
4.3.1. <i>Consent and eligibility evaluation</i>	33
4.3.2. <i>Randomization</i>	34
4.3.3. <i>Procedures for data collection</i>	34
4.3.4. <i>Specimens</i>	34
4.3.5. <i>Forms for data collection</i>	35
4.4. FOLLOW-UP VISITS.....	35
4.4.1. <i>Procedures for data collection</i>	35
4.4.2. <i>Specimens</i>	35

4.4.3. Forms for data collection	36
4.5. BASELINE PHASE II	36
4.5.1. Eligibility	36
4.6. NON-STUDY VISITS	37
4.6.1. Study Procedures	37
4.6.2. Specimens	37
4.6.3. Forms for data collection	37
5. STUDY EXAMINATIONS AND PROCEDURES	38
5.1. QUALITY OF LIFE QUESTIONNAIRE ADMINISTRATION	38
5.2.A REFRACTION AND VISUAL ACUITY (PROTOCOL – FOR LETTER VISION CHARTS)	38
5.2.1.A Refraction procedure	38
5.2.2.A Visual acuity procedure	46
5.2.3.A Visual acuity training and certification	49
5.2.B REFRACTION AND VISUAL ACUITY (PROTOCOL – FOR TUMBLING E CHART)	50
5.2.1.B Refraction procedure	50
5.2.2.B Visual acuity procedure	57
5.2.3.B Visual acuity training and certification	61
5.3. OPHTHALMIC PROCEDURES	61
5.3.1. Grading Cataracts	61
5.3.2. Grading inflammation	62
5.3.3. Inter-observer variation of ocular inflammation	65
5.3.4. Training and certification of ophthalmologists and study coordinators	65
5.4. OPTICAL COHERENCE TOMOGRAPHY	66
5.4.1. Required patient assessments—Heidelberg Spectralis	66
5.4.2. Scan procedures—Heidelberg Spectralis	66
5.4.3. Obtaining retinal thickness data—Heidelberg Spectralis	67
5.4.4. Saving/Exporting data—Heidelberg Spectralis	67
5.4.5. Required patient assessments—Zeiss Cirrus	69
5.4.6. Scan procedures—Zeiss Cirrus	69
5.4.7. Obtaining retinal thickness data—Zeiss Cirrus	70
5.4.8. Saving/Exporting data—Zeiss Cirrus	70
5.4.9. OCT operator qualifications	70
5.5. FUNDUS PHOTOGRAPHY	71
5.6. LABORATORY MEASUREMENTS	71
6. ADVERSE EVENTS	72
6.1. NON-SERIOUS ADVERSE EVENT (AE)	72
6.2. SERIOUS ADVERSE EVENT (SAE)	72
6.3. ADVERSE EVENT REPORTING	72
6.4. PATIENT DEATH	73
7. DATA COLLECTION AND MANAGEMENT	73
7.1. DATA COLLECTION FORMS	73
7.2. DATA REVIEW	74
7.3. DATA ENTRY	74
7.3.1. Data entry errors	74
7.3.2. Data consistency and validity	74
7.3.3. Data preparation and cleaning	75
7.3.4. Monitoring	75
7.4. DATA ANALYSIS	75
7.5. DATA STORAGE AND SECURITY	75
8. QUALITY CONTROL	76
8.1. MEDICATION STORAGE AND EXPIRY	76
8.2. PERIODIC REPORTS	76
8.3. DATA MANAGEMENT, SECURITY AND QUALITY ASSURANCE	77
8.4. MONITORING COMPLIANCE	77
8.5. CERTIFICATION	77

8.6. DATA AUDITS	77
9. DUTIES AND RESPONSIBILITIES OF STAFF	77
9.1. OPHTHALMOLOGIST	77
9.2. CLINICAL TRIAL MANAGER	77
9.3. STUDY COORDINATOR	77
9.4. DATA ANALYST	78
9.5. DATA ENTRY OPERATOR	78
9.6. BIostatistician (PROCTOR)	78
9.7. OPHTHALMIC ASSISTANTS	78
9.8. REFRACTIONISTS	78
9.9. OCT OPERATORS	78
9.10. FUNDUS PHOTOGRAPHERS	79
9.11. THE READING CENTER	79
10. STUDY ORGANIZATION.....	79
10.1. EXECUTIVE COMMITTEE	79
10.2. CLINICAL COORDINATING CENTER (CCC).....	79
10.3. UVEITIS PHOTOGRAPH READING CENTER (UPRC)	79
10.4. DATA COORDINATING CENTER (DCC)	80
10.5. DATA ANALYSIS CENTER (DAC).....	80
10.6. DATA SAFETY AND MONITORING COMMITTEE (DSMC).....	80
10.7. EDITORIAL COMMITTEE	80
10.8. STUDY SITES.....	81
10.9. PHARMACY.....	81
10.10 STUDY COMMUNICATIONS.....	81
11. BIBLIOGRAPHY	82

APPENDIX A: STUDY FORMS

APPENDIX B: CERTIFICATION FORMS

APPENDIX C: QUALITY OF LIFE QUESTIONNAIRES

APPENDIX D: PATIENT CALENDARS

APPENDIX E: UPRC MANUAL

APPENDIX F: TABLE FOR ASSESSING UVEITIS ACTIVITY

Investigators, Personnel and Study Sites

Nisha Acharya, MD, MS	Principal Investigator Site Director San Francisco Study Ophthalmologist San Francisco [REDACTED]
John Gonzales, MD	Study Ophthalmologist San Francisco
Thuy Doan, MD	Study Ophthalmologist, San Francisco
SR Rathinam, MD, PhD	Site Director Aravind Eye Hospital Madurai Study Ophthalmologist Madurai
T Radhika, MD	Study Ophthalmologist Madurai
Vedhanayaki, MD	Study Ophthalmologist Madurai
VK Anuradha, MD	Site Director Aravind Eye Hospital Coimbatore Study Ophthalmologist Coimbatore
VR Saravanan, DO, DNB, FRCS	Study Ophthalmologist Coimbatore
Upendra Babu, MD	Study Ophthalmologist Coimbatore
S. Bala Murugan, MD	Site Director Aravind Eye Hospital Pondicherry Study Ophthalmologist Pondicherry
Prabu Baskaran, MD	Study Ophthalmologist Pondicherry
Lourdes Arellanes-Garcia, MD	Site Director Mexico City Study Ophthalmologist Mexico City
Luz Elena Concha del Rio, MD	Co-investigator Mexico City Study Ophthalmologist Mexico City
Hassan Al Dhibi, MD	Site Director Riyadh Study Ophthalmologist Riyadh
Donald Stone, MD	Study Ophthalmologist Riyadh
Mohammed Al Shamrani, MD	Study Ophthalmologist Riyadh
Abdulelah Al Abdullah, MD	Study Ophthalmologist Riyadh
Lyndell Lim, MD	Site Director Melbourne Study Ophthalmologist Melbourne
Debra Goldstein, MD	Site Director Chicago Study Ophthalmologist Chicago
Eric Suhler, MD, MPH	Site Director Portland Study Ophthalmologist Portland

Investigators, Personnel and Study Sites, continued.

Jeremy Keenan, MD, MPH	Medical Monitor [REDACTED]
Thomas Lietman, MD	Data Coordinating Center [REDACTED]
Travis Porco, MPH, PhD	Data Coordinating Center, Principal statistician [REDACTED]
Maya Rao, MPH	Coordinating Center Manager Study Coordinator San Francisco [REDACTED]
Erica Browne, MS	Data Manager/ Study Coordinator San Francisco [REDACTED]
Mr. AL. Sivaram	Study Coordinator Madurai
Mrs. G. Jeyakohila	Study Coordinator Madurai
Ms. V. Gracy Evangelin	Study Coordinator Madurai
Ms. R. Srija	Study Coordinator Coimbatore
Ms. R. Thilagavathi	Study Coordinator Pondicherry
Tracy Giles	Study Coordinator Oregon
Yoko Burgoa	Study Coordinator Mexico City
Hilda Hernández	Study Coordinator Mexico City
Julie Morrison	Study Coordinator Melbourne
Tanya Pejnovic	Study Coordinator Melbourne
Julie A. Johnson	Study Coordinator Chicago
Sara Al Nuwaysir	Study Coordinator Riyadh
Abdulrahman Al Hommadi	Study Coordinator Riyadh

Data Safety and Monitoring Committee (DSMC) Members

Maureen Maguire, PhD

Chair of DSMC
Biostatistics
Carolyn F. Jones Professor of Ophthalmology
University of Pennsylvania
[REDACTED]

William Barlow, PhD

Biostatistics
Research Professor, Biostatistics
University of Washington
[REDACTED]

Jackie Glover, PhD

Ethics
Professor of Pediatrics
University of Colorado
[REDACTED]

Steven Yeh, MD

Uveitis
Associate Professor of Ophthalmology
Emory University
[REDACTED]

Narsing Rao, MD

Uveitis
Professor of Ophthalmology and Pathology
Doheny Eye Institute
[REDACTED]

Albert Vitale, MD

Uveitis
Professor of Ophthalmology & Visual Sciences
University of Utah School of Medicine
[REDACTED]

National Eye Institute (NEI) Program Officer

Donald Everett, MA

Program Officer
National Eye Institute
National Institutes of Health
[REDACTED]

Background

In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, we propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uveitis. Uveitis, a set of conditions defined by intraocular inflammation, is a significant cause of vision loss and morbidity in the United States and the world.^{1, 2} The incidence was recently estimated to be more than 50 cases per 100,000 person-years, with a prevalence of approximately 115 per 100,000 persons.³ Additionally, uveitis is believed to be the cause of up to 10% of cases of legal blindness in the United States, or approximately 30,000 new cases of blindness per year.^{1, 3, 4} In contrast to common age-related eye disorders, uveitis may have a stronger socio-economic impact because it disproportionately affects younger working-age patients.⁵ Although the etiology of uveitis is varied, most cases are presumed to be immune-mediated and lack a known infectious cause.⁶⁻⁹ Even in developing countries such as India that have a larger burden of infection, the vast majority of cases are non-infectious.^{10, 11}

The current mainstay of treatment for non-infectious uveitis is corticosteroids (topical, systemic, locally injected, or corticosteroid-eluting implants). Due to the well documented local and systemic side effects associated with corticosteroid therapy, other immunosuppressive therapies are frequently used as corticosteroid-sparing agents in patients who need long-term therapy. These include antimetabolites, calcineurin inhibitors, alkylating agents, and biologic drugs.¹² Cost and morbidity associated with uncontrolled inflammation make the selection of an effective initial steroid-sparing agent extremely important.

When corticosteroid-sparing therapy is required, the two most commonly used first-line immunosuppressive agents are methotrexate and mycophenolate mofetil.¹³ Because of cost and potentially dangerous long-term side effects, other classes of drugs such as biologics are typically reserved for refractory cases in which other treatments have failed.¹² It is common practice for patients requiring a steroid-sparing agent to be treated first with the less expensive methotrexate and then switched to mycophenolate mofetil in the event of treatment failure. However, results from non-comparative retrospective case series indicate that uveitis patients may be much more likely to achieve controlled inflammation and tolerate treatment with mycophenolate mofetil.¹³⁻²⁸ Furthermore, approximately half of the patients who fail treatment with methotrexate go on to successful treatment with mycophenolate mofetil.²⁹ Unlike in rheumatology, where clinical trials have demonstrated differential efficacy of antimetabolites for systemic inflammatory diseases, there have been no prospective randomized, controlled trials in uveitis to systematically determine which antimetabolite is more clinically efficacious as initial corticosteroid-sparing therapy. This makes it difficult for clinicians to make informed, evidence-based decisions about first-line immunosuppressive treatment. In addition, if patients fail one antimetabolite, there is no evidence basis for deciding whether to switch to another antimetabolite, or to move on to another class of immunosuppressives, including biologics.

1. Introduction to trial

The proposed study is a randomized comparative effectiveness trial to determine which treatment, methotrexate or mycophenolate mofetil, is more effective as first-line corticosteroid-sparing treatment for patients with non-infectious intermediate, posterior and panuveitis requiring corticosteroid-sparing therapy.

Two hundred sixteen patients with non-infectious uveitis in need of corticosteroid-sparing therapy will be randomized to receive either oral methotrexate or oral mycophenolate mofetil at Aravind Eye Hospitals (Madurai, Coimbatore, and Pondicherry, South India), Casey Eye Institute (Oregon Health and Science University, Portland), "Dr. Luis Sánchez Bulnes" Hospital, Asociación Para Evitar la Ceguera (Mexico City), Center for Eye Research Australia at the Royal Victorian Eye & Ear Hospital (University of Melbourne), Northwestern University Feinberg School of Medicine (Chicago, IL), King Khaled Eye Specialist Hospital (Riyadh, Saudi Arabia), and the F.I Proctor Foundation (University of California, San Francisco). They will be followed monthly for 6 months after enrollment or until treatment failure. Patients who achieve success at 6 months will continue for another 6 months on the same medication. Patients who fail at 6 months will switch treatments and be followed for an additional 6 months or until failure of the second treatment.

1.1. Research question

Which treatment—methotrexate or mycophenolate mofetil—is more effective as a first-line immunosuppressive treatment for patients with non-infectious intermediate, posterior and panuveitis requiring corticosteroid-sparing therapy?

1.2. Specific aims

Aim 1: Establish which immunosuppressive treatment, methotrexate or mycophenolate mofetil, results in a higher proportion of patients achieving corticosteroid-sparing control of inflammation. As a primary outcome, proportion of successful corticosteroid-sparing control of inflammation will be compared at 6 months after enrollment. We will also evaluate differences in secondary outcomes, such as visual acuity, macular thickness, time to control of inflammation, efficacy within various anatomic locations of uveitis, tolerability, quality of life, and adverse events.

Aim 2: Evaluate the clinical efficacy of switching agents after initial treatment failure. Patients who are recorded as a treatment failure on the initial randomized drug will be switched to the other treatment. These patients will be followed an additional 6 months from the date of treatment failure, following the same protocol with the same primary and secondary outcomes as in Aim 1.

2. Trial design

2.1. Design summary

Study type

- Randomized, observer-masked comparative effectiveness trial
- Block randomization by site: Aravind Eye Hospitals, Casey Eye Institute, Asociación Para Evitar la Ceguera, Center for Eye Research Australia at the Royal Victorian Eye & Ear Hospital, Northwestern University Feinberg School of Medicine, King Khaled Eye Specialist Hospital, and F.I. Proctor Foundation
- Sample size: 216 patients, 108 patients per arm (Table 1)

Treatment arms

- Oral methotrexate
- Oral mycophenolate mofetil

Treatment timeline

- Phase I
 - Initial treatment from 0-6 months. If treatment success (i.e. achieving corticosteroid-sparing control of inflammation at 6 months), treatment extended to 12 months.
- Phase II
 - Second therapy initiated after failure to achieve corticosteroid-sparing control of inflammation in Phase I (0-6 months).

Outcomes

- **Primary outcome (Specific Aim 1):**
 - Proportion of overall treatment success at 6 months, where treatment success is defined as controlled ocular inflammation (Table 2) with 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate
- **Secondary outcomes**
 - Proportion of corticosteroid-sparing treatment success at 6 months after switching treatments in patients who are a treatment failure in the first 6 months where treatment success is defined as in Aim 1 (**Specific Aim 2**)
 - Time to control of inflammation
 - Time to treatment success
 - Proportion achieving treatment success at 5 months and sustaining, for at least 28 days, to 6 months
 - Proportion achieving treatment success at 12 months in Phase I
 - Phase I treatment success (6-12 months) with complete discontinuation of corticosteroid
 - Proportion achieving treatment success at 6 months in Phase II
 - Change in best spectacle-corrected visual acuity (BSCVA)
 - Presence of macular edema
 - Change in macular thickness
 - Change in vitreous haze as assessed clinically by the Miami (formerly Davis) scale
 - Change in vitreous haze as assessed by fundus photography grading by NEI and Miami (formerly Davis) scales
 - Efficacy for intermediate, posterior and panuveitis subgroups
 - Efficacy for retinal vasculitis
 - Proportion discontinuing due to intolerability
 - Rate of adverse events
 - Proportion discontinuing due to serious adverse events
 - Quality of life (Health related and vision related)

- Dose reduction
- Efficacy of treatment in patients with Vogt-Koyanagi-Harada (VKH) disease
- Proportion of patients beginning with at least 2+ inflammation in anterior chamber cells who experience a 2-step reduction (i.e. decreasing from 2+ to 0.5+; 3+ to 1+; 4+ to 2+).
- Proportion of patients beginning with at least 2+ inflammation in vitreous haze who experience a 2-step reduction (i.e. decreasing from 2+ to 0.5+; 3+ to 1+; 4+ to 2+).
- Proportion of patients who started with at least 1+ inflammation levels in anterior chamber cells who achieve a decrease to 0 level of inflammation in anterior chamber cells.
- Proportion of patients who started with at least 1+ inflammation levels in vitreous haze who achieve a decrease to 0 level of inflammation in vitreous haze.
- Proportion of patients achieving controlled inflammation defined by 0 level of inflammation in vitreous haze and 0 level of inflammation in anterior chamber cells
- Proportion of patients requiring injections for severe inflammation during the trial
- Proportion of patients requiring injections for macular edema during the trial

2.2. Study timeline

Table 1: Timeline for study completion

Date	Planned Activity
December 2011 through September 2012	Pre-study activities: refine/finalize MOP, IRB, IND, Indian Council of Medical Research approval
September 2012 through	1st meeting of DSMC, conduct final certification of sites and study personnel, earliest project start date
August 2013* through April 2017	Enrollment and follow-up
Through November 2017	Finish 6 month follow-up (Phase I) + 1 month visit window
Through May 2018	Finish follow-up (Maximum of 12 months + 1 month visit window period)
Through November 2018	Lock database, analyze, publish, and disseminate results

* San Francisco started enrollment in August 2013. Other sites on boarded at differing times after Aug 2013.

2.3. Eligibility

2.3.1. Anatomical location of inflammation

All patients must have met the criteria for intermediate, anterior and intermediate, posterior or panuveitis, as defined by the Standardization of Uveitis Nomenclature (SUN) Working Group, at any time since their diagnosis of uveitis.

The Standardization of Uveitis Nomenclature

Type	Primary Site of Inflammation	Includes
Anterior Uveitis	Anterior Chamber	Iritis Iridocyclitis Anterior cyclitis
Intermediate Uveitis	Vitreous	Pars planitis Posterior cyclitis Hyalitis
Posterior Uveitis	Retina or Choroid	Focal, multifocal, or Diffuse choroiditis Chorioretinitis Retinochoroiditis Retinitis Neuroretinitis
Panuveitis	Anterior Chamber Vitreous Retina or Choroid	

*Adapted from the SUN Working Group Anatomic Classification of Uveitis

According to SUN criteria:

“There was consensus that the term intermediate uveitis should be used for that subset of uveitis where the vitreous is the major site of inflammation, and that the presence of peripheral vascular sheathing and macular edema should not change the classification. The diagnostic term *pars planitis* should be used only for that subset of intermediate uveitis where there is snowbank or snowball formation occurring in the absence of an associated infection or systemic disease (that is “idiopathic”). The term *panuveitis* should be reserved for those situations in which there is no predominant site of inflammation, but inflammation is observed in the anterior chamber, vitreous, and retina and/or choroid (this is, retinitis, choroiditis, or retinal vasculitis). For the definition of panuveitis, structural complications such as macular edema or neovascularization should not be considered in classifying the anatomic location of uveitis. Inflammation in the anterior chamber and vitreous (this is, more vitritis than in an iridocyclitis and more anterior chamber inflammation than in intermediate uveitis) should be referred to as anterior and intermediate uveitis and not panuveitis.”³⁰ If vasculitis is present in the setting of intermediate uveitis, it should be called intermediate uveitis with vasculitis, not posterior uveitis.

2.3.2. Inclusion Criteria

All the following criteria must be met at enrollment:

- History of non-infectious intermediate, anterior and intermediate, posterior or panuveitis in at least one eye
- Active inflammation within the last 180 days, defined by the presence of **any of the following** (in at least one eye) according to SUN criteria and the NEI vitreous haze grading scale:
 - ≥ 2+ anterior chamber cells and/or
 - ≥ 2+ vitreous haze and/or
 - active retinal or choroidal inflammation
- Active inflammation in at least one eye at enrollment, defined by **any of the following**:
 - ≥ 1+ anterior chamber cells and/or
 - ≥ 1+ vitreous haze and/or
 - active retinal/choroidal inflammation (bullous serous retinal detachment qualifies if choroidal thickening)
- **At least one** of the following criteria must be met before or at enrollment:
 - 1.) Active inflammation after 4 weeks of high-dose (1mg/kg prednisone equivalent) oral corticosteroid treatment
 - 2.) Treatment with oral corticosteroids resulting in a reduction of inflammation, followed by an increase in inflammation (of at least 1 grade in anterior chamber cells or vitreous haze or a change of non-active to active retinal/choroidal lesions) when corticosteroid is tapered, in the 180 days prior to enrollment
 - 3.) Treatment with ≥10mg/day oral prednisone or equivalent over at least the past 90 days prior to enrollment
 - 4.) Active inflammation after long-acting corticosteroid injection 4 weeks to 180 days prior to enrollment
 - 5.) One of the following uveitic conditions necessitating corticosteroid-sparing immunosuppressive treatment¹²:
 - Behcet's disease with posterior segment involvement
 - Multifocal choroiditis with panuveitis
 - Serpiginous choroidopathy
 - Birdshot retinochoroidopathy
 - Diffuse retinal vasculitis
 - Severe Vogt-Koyanagi-Harada syndrome (VKH) (for example: acute VKH that has been active for at least 4 weeks, or VKH with bullous serous retinal detachments and/or choroidal detachments with other signs of ocular inflammation)
 - Sympathetic ophthalmia
 - 6.) If the patient does not fit any of these categories, but the physician believes corticosteroid-sparing immunosuppressive therapy is indicated, eligibility may be assessed on a case-by-case basis after discussion with the coordinating center. Please contact Dr. Acharya at 415-624-7710 or by email.
- Willingness to start corticosteroid treatment at 1mg/kg or 60mg a day of prednisone, whichever is less (starting at a lower dose is acceptable if patient has known tolerability issues)
- Willingness to limit alcohol consumption (American College of Rheumatology recommendation is 2 drinks per month or less)
- Willingness to use an acceptable method of contraception during the study period (i.e. pharmacologics, devices, barrier methods) or abstinence.

2.3.3. Exclusion criteria

Any one excludes patient:

- Any infectious cause of uveitis
- Prior immunosuppressive therapy other than corticosteroids in the past 12 months
- Prior intolerance or safety issues with methotrexate or mycophenolate mofetil
- Prior failure to control ocular or other inflammation using methotrexate or mycophenolate mofetil
- Prior biologic therapy at any time
- < 16 years of age at enrollment
- Media opacity (such as cataract and/or corneal scar) and/or extensive posterior synechiae such that examination of the posterior segment is not possible in both eyes
- Chronic hypotony (IOP < 5 mm Hg for > 3 months) in both eyes
- Periocular or intravitreal corticosteroid injection in the past 4 weeks
- Fluocinolone acetonide implant in either eye in < 3 years
- Intraocular surgery in < 30 days, or planned surgery within the next 180 days
- Best spectacle-corrected visual acuity of hand motion or worse in better eye
- Planning to conceive during the study period, pregnant or breast-feeding (blood or urine pregnancy test for all females, excluding those who are post-menopausal is mandatory within 4 weeks prior to enrollment)
- History of cancer (If a patient has a history of non-melanoma skin cancer they can still be considered for inclusion in this study, provided it is not currently active).
- Systemic autoimmune disease or ocular condition (besides uveitis) anticipated to dictate treatment course
- Abnormal CBC (\leq 2,500 white blood cells and/or \leq 75,000 platelets and/or \leq 9 hemoglobin) within 4 weeks prior to enrollment*
- Abnormal alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \geq 2 times the upper limit of normal for the lab and/or creatinine \geq 1.5 within 4 weeks prior to enrollment
- Evidence of active tuberculosis, HIV infection, syphilis, or hepatitis B or C (patients must have a tuberculin skin test, or interferon-gamma release assay, a chest radiograph, RPR/VDRL, FTA-ABS, or other treponemal tests, Hepatitis B surface antigen and Hepatitis C antibody tests within 90 days prior to enrollment)

Beyond the tests listed above, the remainder of the work-up is at the discretion of the investigator and should be tailored to the clinical situation. Distinguishing between infectious and non-infectious uveitis is part of standard of care and should be dictated by the patient's clinical exam, but at minimum, all patients must have testing for tuberculosis, syphilis and hepatitis within 90 days prior to enrollment. If there is any clinical suspicion of infection, other tests should be considered at the investigator's discretion (i.e. leptospirosis in India). Testing is available for this at Aravind Eye Hospitals if indicated.

2.3.3.a. Screening for Active Tuberculosis

Given that treatment with antimetabolites is not thought to increase the risk of tuberculosis, patients with latent (but not active) tuberculosis will be eligible for this study. It is at the study doctor's discretion to determine if the patient has active or latent tuberculosis, based on the testing required. There is no specific cut off for the tuberculin skin test for inclusion in the trial. Treatment for latent TB should be handled according to the standard of care in the

country in which the patient is enrolled. For example, patients with latent TB may be treated with INH in the U.S. However, this is not standard practice in India. Particular consideration to TB as an etiology should be given to patients with serpiginous chorioretinopathy, and an evaluation by an internist should be done if needed.

2.4. Randomization and masking

Block randomization of the patients will ensure that an equal number of patients are randomized to each study arm at each site. Randomization lists will be created by the biostatistician (Travis Porco) and accessed online via REDCap database. The following people will be able to access to the list of patients who have been randomized through the REDCap database:

Emergency Contact Personnel*

- Dr. Lalitha Prajna, Chief Microbiologist, Aravind Eye Hospital Madurai
- Dr. R. Revathi, Chief, Cornea Services, Aravind Eye Hospital Coimbatore
- Dr. R. Venkatesh, Chief Medical Officer, Aravind Eye Hospital Pondicherry
- Dr. Maggie Ryan, Research Pharmacist, Casey Eye Institute, Oregon
- Dr. Stephen McLeod, Chairman Department of Ophthalmology, University of California San Francisco
- Dr. Ma. del Carmen Preciado, Ophthalmologist, APEC, Mexico
- Dr. Sukhpal Sandhu, Retinal ophthalmologist, CERA, Melbourne
- Dr. Andrea Birnbaum, Ophthalmologist, Northwestern University, Chicago
- Dr. Marco Mura, Chief of Vitreoretinal Services, KKESH, Riyadh

*Emergency contacts will log into REDCap to consult the list of randomized patients in case of an emergency in which unmasking is necessary for patient safety and Dr. Thomas Lietman of the DCC cannot be reached.

Data Coordinating Center (DCC) Personnel

- Dr. Thomas Lietman, Professor of Ophthalmology and Epidemiology, University of California San Francisco, Proctor Foundation
- Dr. Travis Porco, Principal statistician, Proctor Foundation
- Ms. Erica Browne, Research analyst, Data Manager, Proctor Foundation
- Ms. Maya Rao, Study Coordinator, Coordinating Center Manager, Proctor Foundation

The study coordinators (listed below) will be aware of patient treatment assignment and will have a copy of the patient ID list for their site; however, they will not know future treatment assignments prior to randomizing patients. After consenting patients for enrollment and confirming all eligibility requirements have been met, study coordinators will log into REDCap and perform the randomization. Study coordinators will then give patients their assigned treatment.

The following study coordinators will have access to REDCap to perform randomizations but will not know the treatment assignments prior to randomizing patients:

- Ms. Maya Rao*, Study Coordinator, University of California, San Francisco
- Ms. Erica Browne, Study Coordinator, University of California, San Francisco
- Mr. Sivaram, Study Coordinator, Aravind Eye Hospital Madurai, India
- Ms. V. Gracy Evangelin, Study Coordinator, Aravind Eye Hospital Madurai, India
- Ms. R. Srija, Study Coordinator, Aravind Eye Hospital Coimbatore, India
- Ms. R. Thilagavathi, Study Coordinator, Aravind Eye Hospital Pondicherry, India
- Ms. Tracy Giles, Study Coordinator, Casey Eye Institute, Oregon
- Ms. Yoko Burgoa, Study Coordinator, APEC, Mexico

- Ms. Hilda Hernández, Study Coordinator, APEC, Mexico
- Ms. Julie Morrison, Study Coordinator, CERA, Melbourne
- Ms. Tanya Pejnovic, Study Coordinator, CERA, Melbourne
- Ms. Julie A. Johnson, Study Coordinator, Northwestern University, Chicago
- Ms. Sara Al Nuwaysir, Study Coordinator, KKESH, Riyadh
- Mr. Abdulrahman Al Hommadi, Study Coordinator, KKESH, Riyadh

*Ms. Rao will act as study coordinator to Proctor Foundation patients, as well as Coordinating Center Manager overseeing all other sites. She will have access to the randomization lists for other sites, in order to check patient treatment assignment as a quality assessment and manage distribution of medications to all sites.

All patients and study coordinators will be unmasked to treatment assignment after enrollment, as the two study drugs are different in appearance and must be administered on different weekly schedules. Study ophthalmologists performing the clinical eye exams, as well as visual acuity examiners, OCT operators, fundus photographers and fundus graders will be masked to treatment assignment to prevent bias in study outcomes. The UCSF Pharmacy's investigational drugs department will purchase and supply mycophenolate mofetil and methotrexate.

The UCSF pharmacy will be responsible for purchasing and distributing bottles of the medications labeled with NDC/lot number and expiration dates to Proctor Foundation, who will add dosing instructions and distribute medication to the Mexico City, India, and Chicago sites, and to Casey Eye Institute's and CERA's pharmacies where they will distribute the medication.

Dose reduction instructions and study ID labels will be provided to each site on separate label sheets. Each site will place the study ID label on the bottle after randomization, before dispensing the drug to the patient. The format of the study ID numbers are as follows: the first character will be a number: "1" for Melbourne, "2" for Proctor Foundation, "3" for Chicago, "4" for Casey Eye Institute, "5" for Mexico City, "6" for KKESH, "7" for Madurai, "8" for Coimbatore, and "9" for Pondicherry. The next character is a checksum character, which will be a single letter. The last three characters will be sequential digits beginning at 001. An example identifier is 4J101; all identifiers have exactly five characters, and no other study at the sites uses this format.

After enrollment and randomization, the patient ID labels will be placed on the medication bottles by the study coordinator or pharmacist, depending on site-specific requirements. If a dose reduction is used, the study coordinator will place the reduction labels on the medication bottles. At no time will the study doctor handle labeling or distribution of the study medication. Study coordinators will record the study ID, drug, date dispensed, bottle number, lot number, and expiration date of each bottle dispensed during the trial in the drug accountability log.

To maintain masking throughout the trial, steps will be taken to avoid the study doctors discovering patient assignment. Not only will the study doctors have no part in handling the medication bottles, all patients will be given dark bags to place and keep their bottles in throughout the trial. They will be instructed to bring their medication to their visits enclosed in the bags, and an extra bag will be kept at the front desk of the clinics in case they forget. This will minimize the chances of the study doctor seeing the medications. Additionally, patients will meet with the study coordinator first, before seeing their study doctor. The study coordinator will review the patients' medication calendars with them and keep the calendars and study bottles in his/her office for the entire patient visit. Before bringing patients to the study doctor, the study coordinator will remind them to not discuss their dosing and

medication name with their study doctor.

Clinical examiners, refractionists, OCT operators, fundus photographers and fundus graders will not be given any information on medication assignment. If personnel are unmasked at any time, a protocol deviation form must be completed, scanned and emailed to both the Medical Monitor [REDACTED], Principal Investigator [REDACTED] and Coordinating Center Manager [REDACTED]. Note that these patients should still continue in the trial.

2.5. Definitions for primary endpoint

2.5.1. Determination of Treatment Success/Failure

Treatment success is defined as controlled ocular inflammation (see Table 2) in both eyes with 7.5 mg/day of prednisone, no periocular or intravitreal corticosteroid injections after the first 90 days of follow up, and ≤ 2 drops/day of topical 1% prednisolone acetate at the 6 month visit without treatment failure any point due to safety, tolerability or futility. Patients can stop medication at any time, but that in and of itself does not count as a treatment failure.

Table 2: Criteria for controlled inflammation

Parameter	Definition of control
Anterior chamber cells*	$\leq 0.5+$
Vitreous haze**	$\leq 0.5+$
Choroid & retina***	No active inflammation or retinal vasculitis posterior to the equator

*SUN criteria³⁰; ** NEI vitreous haze grading scale³¹ *** Cystoid macular edema is not sufficient to be called active inflammation

2.5.2. Treatment failure

- Failure due to efficacy:** Patients can be declared a treatment failure due to futility and be declared a treatment failure and enter Phase II **at any time during follow-up** if the following occurs: The treating physician determines that it is futile to continue the current study medication due to persistent, uncontrolled inflammation that appears to be non-responsive to treatment. This option of declaring futility should only be declared if treatment with study medication seems completely unlikely to be able to control inflammation. Since the medications take up to a few months to fully take effect, increase in inflammation early on in the trial is not an indication of treatment failure. Corticosteroids may be increased in the case of increased inflammation.

Efficacy will be judged at the primary endpoint of 6 months. Specifically, at 6 months, if there is a lack of efficacy, patients will be declared a treatment failure and enter Phase II if the following occurs: The patient does not have controlled inflammation (see Table 2) with a prednisone dose of 7.5 mg/day and less than or equal to 2 prednisolone acetate 1% drops per day by 6 months.

- Failure due to intolerance:** Patients who experience severe symptoms thought to be related to the drug should try a dose reduction if they are willing. If this is not successful and the patient is unable to continue their

medication due to symptoms and is also not willing to continue, treatment failure can be declared. Please refer to Table 5 for dose reduction guidelines. Trial of a dose reduction is strongly encouraged, however it **is not required** for a patient to be determined a treatment failure due to intolerability.

- Failure due to safety:** Patients who experience abnormal lab results meeting the designated threshold of a *non-serious adverse event* (e.g. AST or ALT increasing to twice the upper limit of normal) will immediately stop taking their medication. As these abnormalities are often reversible, patients whose abnormalities are classified as non-serious adverse events (see Table 3) will be *allowed 28 days to regain eligibility*. It is recommended that these patients repeat lab tests within 1-2 weeks of the initial abnormal result to see if the results return below the designated threshold (e.g. AST or ALT less than twice the upper limit of normal). If the lab results return below the designated threshold of a *non-serious adverse event* within 28 days, patients may be re-administered the study drug per protocol or at one of the designated dose reduction levels, at the investigator's discretion.

If lab results remain at or above the threshold of a *non-serious adverse event* for 28 days, this is classified as a serious adverse event and treatment failure will immediately be declared. At this point, patients will be treated according to the best medical judgment of their clinician and not switch to Phase II (if currently in Phase I). However, month 6 visit data and imaging should still be collected (Phase I and Phase II), if the serious adverse event occurs before the six month visit. For other non-serious adverse events (such as an opportunistic infection) the study drug may be stopped temporarily as per the discretion of the investigator. If an infection does not resolve within 28 days, it is considered a serious adverse event.

Table 3: Thresholds for classifying non-serious and serious lab abnormalities

	Non-Serious Adverse Event*	Serious Adverse Event
Leukocytes	>1,000 to <2,500/ μ L	\leq 1,000/ μ L
Platelets	20,000 to 75,000/ μ L	< 20,000/ μ L
Hemoglobin	\geq 6.5 to < 9 g/dL	< 6.5 g/dL
SGOT (AST) or SGPT (ALT)	2 to <5 times the upper limit of normal of the reference range	\geq 5 times the upper limit of normal of the reference range
Creatinine	\geq 1.5 to < 2 mg/dL	\geq 2 mg/dL

*NOTE: If any non-serious lab abnormality does not resolve within 28 days, then it must be classified as a serious adverse event, and treatment failure due to safety will be declared.

For all non-laboratory SAEs, treatment failure cannot be declared until the Medical Monitor judges that the SAE is related to the study drug. This will require the investigator notifying the Medical Monitor about the event, and the Medical Monitor contacting the investigator regarding his determination. The Medical Monitor will determine two things: 1, whether this is a true treatment failure because the SAE is likely to be related to the study drug, and 2, whether it is safe to switch the patient to Phase II. If it is not safe to switch, the patient will be treated according to best medical judgment, and still be followed up at their 6 month visit (Phase I and Phase II).

If the investigator thinks the SAE is related to the study drug, he/she can stop the study medication anytime (including prior to determination of treatment failure by the Medical Monitor). If the investigator thinks treatment failure is likely (prior to hearing from the Medical Monitor) they should obtain all study assessments which would be collected at a treatment failure visit. However, the investigator will wait to complete the Treatment Assessment Form and officially declare treatment failure until they are instructed to do so by the Medical Monitor.

2.5.3. Dropouts, Non-Compliant Patients and Follow-up

- **Dropout from study:** Patients will be considered to have dropped out from the study only if they **declare they are no longer interested in further participation and not willing to return for any study visits, or are deceased**. If patients are not willing to return for any study visits, no further information will be collected on those patients. We anticipate that a few patients may drop out due to unwillingness to continue or death. In case of patient dropout, the patient dropout form should be filled out.


If death is considered to be related to the study drug, the patient will be counted as a treatment failure. If death is not related to the study drug, the patient will be counted as a dropout. This would be at the discretion of the Medical Monitor.

- **Non-compliant Patients:** Patients who stop the study treatment for reasons other than efficacy, tolerability and/or safety (i.e. fear of potential side effects) but are willing to return for study visits, are not considered dropouts. Also, if patients miss study visits, and do not respond to contact, they are not considered dropouts. These patients will be considered **non-compliant patients**, and will be encouraged to return for subsequent study visits regardless of whether or not they are taking study medication, especially the 6 month visit (Phase I and Phase II).

It should be noted that missing a visit does not mean that a patient has dropped out of the study. These patients are considered to be non-compliant. For example, if they missed the 1 month visit, every attempt will be made to bring them back as soon as possible and to continue with subsequent visits. Also, a non-serious adverse event or discontinuation of study medication does not mean that the patient has dropped out and they should continue to be followed according to the protocol, as they may be able to resume treatment. Even if the patient is not willing to resume treatment, but is willing to return for study visits they are not considered dropouts.

- **Following Patients who fail prior to Phase I & Phase II (6 months):** If patients are declared a treatment failure prior to Phase I or Phase II 6 Months, every effort should be made to bring the patient back for the 6 month visit. Note, that patients who are declared treatment failure, and are switching from Phase I to Phase II will already be followed.

2.5.4 Primary Endpoint Flowchart



*Criteria for controlled inflammation: Anterior chamber cells ≤0.5 +; Vitreous haze ≤ 0.5 +; No active choroid and retina lesions

** 2 drops/day refers to topical 1% prednisolone acetate or equivalent

3. Treatment plan

3.1. Study drugs

Patients will be randomized to receive either methotrexate or mycophenolate mofetil. In addition, folic acid supplements will be given to all patients who have been randomized to methotrexate. **All study ophthalmologists, refractionists, OCT operators, fundus photographers and fundus graders will be masked to treatment assignment.** For dosing schedules, see Tables 4 and 5.

To maintain masking, study coordinators will review patient side effects with the patient at each visit, prior to meeting with the physician. At this time, the study coordinator will remind the patient **not to speak to their study doctor regarding the name of the medication or dosing instructions.** If the patient is experiencing intolerable side effects, the study coordinator and patient will speak with the study doctor about the possibility of a dose reduction, without revealing the name of the medication or the dosing instructions. The study doctor will then decide if the dose reduction should be tried and communicate this with the patient and study coordinator. The study coordinator will then provide the patient with new dosing instructions, away from the vicinity of the study physician (see Table 5).

Table 4: Weekly Dosing Schedule

	Drug	Day						
		1	2	3	4	5	6	7
Introductory Dose	Methotrexate	7.5 mg BID						
	Mycophenolate Mofetil	500 mg BID	500 mg BID	500 mg BID	500 mg BID	500 mg BID	500 mg BID	500 mg BID
Weeks 1&2	Folic Acid (methotrexate only)	1 mg daily	1 mg daily	1 mg daily	1 mg daily	1 mg daily	1 mg daily	1 mg daily
	Methotrexate	12.5 mg BID						
Maintenance Dose	Mycophenolate Mofetil	1.5 g BID	1.5 g BID	1.5 g BID	1.5 g BID	1.5 g BID	1.5 g BID	1.5 g BID
	Folic Acid (methotrexate only)	1 mg daily	1 mg daily	1 mg daily	1 mg daily	1 mg daily	1 mg daily	1 mg daily
Post week 2								

Table 5: Dose Reduction Guidelines*

	Drug	Day						
		1	2	3	4	5	6	7
Reduction Level I	Methotrexate	10mg BID						
	Mycophenolate mofetil	1g BID	1g BID	1g BID	1g BID	1g BID	1g BID	1g BID
Reduction Level II	Methotrexate	7.5mg BID						
	Mycophenolate mofetil	500 mg BID	500 mg BID	500 mg BID	500 mg BID	500 mg BID	500 mg BID	500 mg BID

*Doses should only be reduced in response to intolerable side effects and safety concerns. If there are no tolerability/safety issues, the patient should stay on the maintenance dose for the duration of follow-up. Note: Even if a dose reduction is used for methotrexate, folic acid should remain at 1 mg daily. 20

All individuals handling methotrexate and mycophenolate, including study participants and/or family members/others caring for and assisting study participants with their medications outside of the hospital/clinic, will be educated on the Safe Handling of Hazardous Medications guidelines outlined in the National Institute for Occupational Safety and Health manual, Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings.

The National Institute for Occupational Safety and Health manual can be found at:
<http://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf>

3.1.1. Methotrexate

All methotrexate doses **will be taken once per week in a divided dose**, one dose taken in the morning and one in the evening. Patients on methotrexate will be instructed to take their medication with food. For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally will be administered to assess tolerability. This means taking 3 pills in the morning and 3 pills in the evening once a week. Patients should be instructed at the Enrollment/Baseline visit to begin methotrexate on a day that is convenient for them, within 6 days of enrollment. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID) This means taking 5 pills in the morning and 5 pills in the evening once a week, until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy.

If there are tolerability issues in the first two weeks such that the patient is not able to increase the dose, and unwilling to continue the current dose, treatment failure due to intolerability should be declared. The patient would then be eligible to switch treatment in Phase II. If this occurs in Phase II, treatment failure would be declared and patient will be treated according to best medical judgment. If the dose is increased per protocol at two weeks, the study ophthalmologist can decide to reduce the maintenance dose if the patient experiences severe side effects.

3.1.1.a. Dose Reduction MTX

If the patient is experiencing intolerable side effects, the study coordinator and patient will speak to the doctor about the possibility of a dose reduction, without revealing the name of the medication or the dosing instructions. The study doctor will then decide if the dose reduction should be done and inform the study coordinator and patient. The study coordinator will then provide the patient with new dosing instructions, away from sight of study physician. A dose reduction is not mandatory but is encouraged in the setting of intolerability.

For the first dose reduction, methotrexate will be reduced to 20 mg/week (10mg BID, once a week). This means taking 4 pills in the morning and 4 pills in the evening once a week. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15mg/week (7.5mg BID, once a week). This means taking 3 pills in the morning and 3 pills in the evening, once a week. After the second dose reduction, treatment can be stopped if intolerability persists and the patient can switch to Phase II.

Although dose reductions are strongly encouraged, they **are not mandatory to attempt before determining treatment failure**. Treatment failure due to intolerability can be declared without trial of a dose reduction.

If a dose reduction has been utilized, and the investigator feels that the tolerability/safety issues have been resolved, it is at their discretion to return the patient to the maintenance dose level of the medication.

3.1.2. Mycophenolate Mofetil

Mycophenolate mofetil **will be taken twice daily**. Patients on mycophenolate mofetil will be instructed to take their medication on an empty stomach with no food one hour before or after taking each dose. For the first two weeks, an introductory dose of 500 mg BID orally will be administered to assess tolerability. This means taking one pill in the morning and one pill in the evening. After two weeks, the dose will be increased to 1.5 g BID. This means taking 3 pills in the morning and 3 pills in the evening until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy.

If there are tolerability issues in the first two weeks such that the patient is not able to increase the dose, and also is unwilling to continue, treatment failure due to intolerability should be declared. The patient would then be eligible to switch treatment in Phase II. If this occurs in Phase II, treatment failure would be declared. If the dose is increased per protocol at two weeks, the study ophthalmologist can decide to reduce the maintenance dose if the patient experiences severe side effects.

At any point if treatment failure is declared due to tolerability, the patient should be treated according to best medical judgment and still be followed up to their 6th month assessment (Phase I and Phase II).

3.1.2.a. Dose Reduction Mycophenolate Mofetil

If the patient is experiencing intolerable side effects, the study coordinator and patient will speak to the doctor about the possibility of a dose reduction, without revealing the name of the medication or the dosing instructions. The study doctor will then decide if the dose reduction should be done and inform the study coordinator and patient. The study coordinator will then provide the patient with new dosing instructions, away from sight of study physician. A dose reduction is not mandatory but is encouraged in the setting of intolerability.

For the first dose reduction, mycophenolate will be reduced to 1g BID. This means taking 2 pills in the morning and 2 pills in the evening. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg BID. This means taking 1 pill in the morning and 1 pill in the evening. After the second dose reduction, treatment can be stopped if intolerability persists and the patient can switch to Phase II.

Although dose reductions are strongly encouraged, they **are not mandatory to attempt before determining treatment failure**. Treatment failure due to intolerability can be declared without trial of a dose reduction.

If a dose reduction has been utilized, and the investigator feels that the tolerability/safety issues have been resolved, it is at their discretion to return the patient to the maintenance dose level of the medication.

3.1.2.b. Proton Pump Inhibitors and Mycophenolate Mofetil

Upon entering the trial some patients may be taking proton pump inhibitors (e.g. omeprazole). Due to a potential interaction with mycophenolate mofetil, H2 blockers are preferred over proton pump inhibitors. However, proton pump inhibitors are acceptable if the physician and/or patient does not want to change. This should be noted on the Baseline History Form under current systemic medications.

3.1.3. Folic acid

It is standard of care to prescribe folic acid supplements to reduce the severity of side effects in patients treated with methotrexate. All patients randomized to methotrexate will be prescribed 1mg per day of folic acid. It is fine to take folic acid the day methotrexate is taken.

3.1.4. Packaging and distribution of study medications

Patient medications will be purchased and packaged by UCSF's pharmacy, printed with the medication name, lot number, and expiration date. Proctor Foundation will be responsible for distributing medications and labels with dosage instructions to all other sites.

Initial dose bottles will contain 14 days of medication at the lower initial dose. The initial two-week supply of methotrexate is 12 pills, and the initial two-week supply for mycophenolate mofetil is 28 pills. Maintenance dose bottles will contain 30 days' worth of medication, plus additional pills as a buffer for visit scheduling. Methotrexate maintenance dose bottles will contain 50 pills each. Mycophenolate mofetil maintenance doses will be provided in bottles of 100 pills each.

At the patient's first visit (i.e. Baseline for Phase I) they will be given the 14 day introductory dose and either one maintenance dose bottle of mycophenolate (100 pills) or one maintenance dose bottle of methotrexate (50 pills). At every monthly visit following, patients will be given an additional 30 days' worth of medication (50 pills of methotrexate, or 200 pills of mycophenolate) until 5 months. If a patient needs to schedule their appointment beyond the visit window allowed by the medication supply, additional bottles may be dispensed to ensure sufficient supply of medicine, although this scheduling should be discouraged.

If patients enter Phase II after treatment failure in Phase I, patients' medication will be dispensed following the same schedule as in Phase I. If patients enter Phase I (6-12 months) after treatment success in Phase I (0-6 months), they will be given 120 days' worth of medication at their 6 month visit. Lost bottles will be replaced.

Study medications, labeled with the appropriate dosing instructions, will be distributed to the study coordinator prior to each study visit. After randomization, before the drug is dispensed, the study coordinator will place the Study ID label on the bottles. If a dose reduction is used, the study coordinator will put a label on the bottle with the new instructions.

Study coordinators will also place number labels, provided by the coordinating center, on all bottles in order to track which individual bottles were dispensed to patients. Study coordinators will indicate on the Medication Log, what type of bottle they have dispensed (i.e. initial or maintenance), how many bottles, what type of bottle has been returned, and the numbers of the bottles.

If at any time the patient fails to bring in their used maintenance bottles, the study coordinator should refer to the clinic staff member responsible for maintaining the randomization list to verify patient assignment. This will ensure that the patient is given the correct maintenance bottle corresponding to their assignment.

3.1.5. Adherence to the treatment plan

Patients will be given a treatment diary in the form of a monthly calendar on which they will be asked to record the medications they are taking as well as reasons for missed doses. They will be asked to bring the calendars with them to each visit. Adherence will be monitored by the study coordinator through review of the calendars, and will be recorded on the Medication Log in each patient file. Pill counting of pills in bottles remaining from the previous study period will also be done for a more objective measure of adherence. If a patient has just started on a new bottle shortly before the visit, do not count these pills. For instance, if a patient returns for their two week visit two weeks plus two days after the baseline visit, the study coordinator will not count the pills remaining in the maintenance dose bottle they have just started on. If the patient fails to bring in their calendar, the study coordinator should ask the patient to estimate the number of doses they have missed.

3.1.5.a. Missed Doses

The following instructions will be given to the patients if they miss scheduled doses of their medication:

Methotrexate: If a patient misses their scheduled dose, they may take it the next day. If it is not taken the next day, they should wait until the following week. If patients make-up their dose on the next day, they should continue their medication weekly from the original day.

Mycophenolate Mofetil: If the patient misses a dose, they should continue with the regular dosing schedule.

3.2. Corticosteroid therapy

3.2.1. Oral prednisone

Prednisone vs. alternative oral corticosteroid

Unless contraindicated, oral prednisone should be used. An equivalent dose of an alternative oral corticosteroid may be used only if a specific contraindication to oral prednisone is present. All references to oral corticosteroid and specific dosing schedules presented in this Manual of Procedures are given for oral prednisone.

Initial dose

All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Treatment success is dependent upon successfully tapering concomitant prednisone to 7.5 mg/day. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered.¹ Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study. Further reduction of corticosteroids will be allowed in Phase I after six months. If patients switch treatments and enter Phase II due to a failure of efficacy in Phase I, they will follow the same protocol as the initial Phase I corticosteroid

treatment and begin at 1 mg/kg or 60 mg, whichever is less. In patients failing for efficacy, investigators may start at a lower prednisone dose if they feel it is medically indicated. However, following the corticosteroid tapering guidelines is strongly encouraged. If patients switch treatments and enter Phase II due to a failure of intolerability in Phase I, then it is at the study doctor's discretion at what dose of corticosteroid to start the patient.

Tapering schedule

For all patients, oral prednisone will be tapered gradually according to Standardization of Uveitis Nomenclature (SUN) guidelines (see Table 6). As it takes 6-8 weeks for the study medications to take full effect, it is expected that inflammation may become uncontrolled with a corticosteroid taper in some patients during the first 3 months of the study. This does not necessarily mean that the randomized treatment has failed, since more time may be needed to ensure the drug has reached its full effect. If the study ophthalmologist believes that continued treatment is futile prior to the primary endpoint, treatment failure may be declared and the patient should enter Phase II. If this occurs in Phase II, treatment failure will be declared and the patient should be treated according to best medical judgment. However, all patients should be followed up to their 6th month assessment in Phase II.

At any point in Phase I or Phase II, investigators have the option of reducing the prednisone dose, and following a faster taper, if the patient is experiencing severe side effects. However, it is strongly encouraged that investigators follow the corticosteroid tapering guidelines. If **absolutely medically necessary**, the investigator may digress from the protocol and reduce steroids below 7.5 mg/day in the first six months, but this is strongly discouraged.

The corticosteroid tapering schedule for Phase I (6-12 months) is optional, and physicians may taper patients as they deem medically acceptable. It is not mandatory for patients to reduce down to 0mg of prednisone by 12 months. In general, a rapid taper in Phase I months 6-12 is not recommended due to issues of adrenal insufficiency.

Table 6: Tapering schedule for oral prednisone: Phase I or if starting new medication in Phase II*

Dose (mg/day)	Duration (weeks)	Decrement (mg/day)
60	2 – 4 ¹	10
50	1	10
40	1	5
35	1	5
30	1	5
25	1	5
20	1	2.5
17.5	1	2.5
15	1	2.5
12.5	1	2.5
10	1	2.5
7.5	hold*	

NOTE: Begin patients at 1mg/kg or 60 mg/day, whichever is less. For Phase I hold patients at 7.5 mg/day, up to the end of 6 months.

*If starting Phase II and failed Phase I due to efficacy.

If uveitis does not improve at the end of the first 4 weeks, use best medical judgment regarding supplemental treatment (e.g. pulse dose treatment, corticosteroid injections, additional immunosuppressives).

Table 7: Optional tapering schedule Phase I (6-12 months)

Dose (mg/day)	Duration (weeks)	Decrement (mg/day)
7.5	1*	2.5
< 7.5 & ≥ 5	2 – 4	1 - 2.5
< 5 & ≥ 2.5	2 - 4	1.5 - 2.5
< 2.5 & ≥ 1	2 – 4	1
0		

NOTE: When beginning Phase I (6-12 months), hold patient at 7.5 mg/day, for at least one week.

Directions for Rescue Taper

Reactivations can be mild or severe. Mild reactivations are considered an increase in inflammation up to the 1+ level in anterior chamber cell or vitreous haze. Severe reactivations are considered an increase in inflammation up to the 2+ level or higher in anterior chamber cell or vitreous haze. Retinal/choroidal lesions may be considered mild or severe at the discretion of the study physician.

If uveitis reactivates:

- Increase oral prednisone up to a dose of 1 mg/kg for severe reactivations, or for mild reactivations, up to double the dose at which the flare occurred, until uveitis is controlled. Then re-taper according to the guidelines.

Uveitis is considered non-responsive if inflammation does not increase but does not further improve after the first 4 weeks of treatment on 1mg/kg oral prednisone.

If uveitis is non-responsive:

- Hold the current dose of prednisone for an additional week. If still no improvement, treatment failure due to futility may be declared, and patients may proceed to Phase II. Alternatively, other therapies may be added, but these should be noted as a protocol deviation.
- If treatment failure is declared due to futility in Phase I, before the primary endpoint of 6 months, patients may switch to Phase II. Patients who refuse to switch to Phase II should be encouraged to return for a 6-month visit. Patients who switch to Phase II will already be followed.
- If treatment failure is declared due to futility in Phase II, before the primary endpoint of 6 months, patients will be treated according to best medical judgment. If treatment failure is declared prior to 6 months, Phase I and Phase II, every attempt must be made to bring patients back for their 6 month assessment.

After suppression of uveitis is once again achieved (either in the case of reactivation or non-response) follow the taper guidelines for Phase I. Patients who have failed the treatment to which they are randomized will then switch treatments, begin Phase II, and follow the same taper guidelines as Phase I (0-6 months). If patients flare during Phase II, they can follow directions for the rescue taper listed above. Patients who fail the second treatment at the 6 month endpoint will be treated as per the investigators discretion.

3.2.2. Supplements

All patients will be given recommendations for supplemental treatment. This treatment is important for patients receiving oral corticosteroids, in order to minimize the incidence of osteoporosis. Recommendations will include:

- Calcium supplement, 500 mg 3 times daily (unless contraindicated)
- Vitamin D, 400-800 IU daily.

3.2.3. Topical corticosteroid

In addition to oral prednisone, patients may enter the study on varying doses of topical corticosteroid drops. Topical corticosteroids should be tapered according to the suggested guidelines (Table 8). Various types of topical corticosteroids are acceptable. The chronic use of two times a day prednisolone acetate 1% was considered to be medically acceptable in a survey we conducted of the American Uveitis Society members. Thus, a dose of ≤ 2 drops a day prednisolone acetate 1% or equivalent corticosteroid will be considered sufficient in order to declare treatment success. If possible, the goal will be to completely taper off topical corticosteroids. In order to determine treatment success or failure, the equivalent amount of prednisolone acetate 1% would have to be determined, and if greater than 2 times a day treatment failure will be declared.

Table 8: Suggested tapering schedule for topical corticosteroid drops

Dose	Duration (weeks)
1 drop, 8-10 times a day	1-2
1 drop, 6 times a day	1
1 drop, 4 times a day	1
1 drop, 3 times a day	1
1 drop, 2 times a day	1
1 drop, 1 time a day	1
None	

3.2.4. Periocular and Intravitreal Injections

The use of periocular and intravitreal injections during the trial is strongly discouraged, as it hinders the ability to assess the study drugs' effectiveness for controlling inflammation. One injection, either periocular triamcinolone 40mg or intravitreal triamcinolone 4mg, may be administered to treat persistent macular edema during the first 90 days of follow-up if the investigator thinks this is medically necessary. One injection for persistent macular edema is permitted in the first 90 days of follow-up of Phase I, and similarly, one injection treating persistent macular edema is permitted in the first 90 days of follow-up of Phase II. If an injection is given at any time solely for the purpose of treating inflammation, a Protocol Deviation Form should be completed and sent to the Medical Monitor

[REDACTED], Principal Investigator [REDACTED] and Coordinating Center Manager [REDACTED]. If an injection is given for any reason after the first 90 days of follow-up of either Phase I or Phase II, a Protocol Deviation Form should be completed and sent to the Medical Monitor, Principal Investigator, and

Coordinating Center Manager.

3.2.5 Other adjunctive treatments/procedures

The protocol dictates use of oral prednisone, corticosteroid drops and study medication (methotrexate or mycophenolate). The investigator may use other topical adjunctive medications such as IOP lowering medications and cycloplegic agents. These should be recorded on the Treatment Assessment form at each visit. The protocol does not allow for intravenous therapy, additional immunosuppressives or surgery during the study period. If such therapies are deemed necessary, the Protocol Deviation form should be completed and sent to the Medical Monitor, Principal Investigator, and Coordinating Center Manager.

3.3. Study procedures

Enrollment/Baseline visit

Study coordinators should adhere to the following protocol for study procedures taking place at the enrollment visit.

- The patient's eligibility for participating in the study will be determined by the study ophthalmologist, aided by the study coordinator.
- If eligible, the patient will review the consent form with the study coordinator and the study physician, and give their consent.
- After consent, the study coordinator will assign the patient a unique Patient ID (derived from the list provided to study coordinator by the principal statistician).
- The study coordinator will then contact the designated person on site, holding the randomization list, to obtain the patient's drug assignment. This will be done away from sight of the study physician.
- The study coordinator will then label the medication with the assigned Patient ID. They should also place the appropriate number for the bottles (i.e. if it is the first bottle dispensed, it should have the #1 on the bottle).

Study visits

Study coordinators should adhere to the following protocol for study procedures taking place, after the patient is consented, enrolled and randomized. All study procedures should follow the schedule listed below:

- The patient comes for a study visit and meets with the study coordinator before their study doctor.
- The patient's medication bottle and folic acid bottle (*if applicable*) is immediately placed in a secure, opaque bag and left at the study coordinators desk for the remainder of the visit. Patient medication calendars should also be placed in the opaque bag.
- The study coordinator will check-in with the patient and complete the following in any order:
 - Review of patient medication diaries
 - Review of adverse events since last visit*
 - Dispense new medication bottle (*if applicable*)
 - Completion of SF-36 questionnaire (All patients) (*if applicable*)

- Completion of NEI-VFQ-25 (all patients) and IND-VFQ (Indian patients only)
- Remind the patient that they should not speak to their study doctor about their dosing schedule, or the name of the medication that they are currently taking.

*If the patient is experiencing intolerable side effects, the study coordinator and patient will speak to the doctor about the possibility of a dose reduction, without revealing the name of the medication or the dosing instructions. The study doctor will then decide if the dose reduction should be done and inform the study coordinator and patient. The study coordinator will then provide the patient with new dosing instructions, away from sight of study physician. A dose reduction is not mandatory but is encouraged in the setting of intolerability.

- The patient will then complete the study assessments, in the following order:
 - Visual Acuity Assessment
 - Slit lamp front of the eye exam and intra-ocular pressure
- The patient's eyes will then be dilated and the following assessments will be completed, in any order**:
 - Posterior segment exam
 - OCT imaging
 - Fundus photography
 - Fluorescein angiogram (not a study assessment, but if performed results should be recorded)
 - Laboratory measurements
- After completion of the study visit, the patient will meet with the coordinator, review scheduling for the next study visit, and retrieve their medication.

**It is essential that visual acuity measurements, front of the eye exams and intra-ocular pressure are completed *before* dilation of the eyes.

Data handling and data entry

After completion of each study visit, study coordinators at all sites will scan data collection forms and send them electronically in PDF format to the study email address [REDACTED]. Hard copies of the forms should be kept in a secure location at each site. Study staff at Madurai will perform double data entry of the PDF forms into a web-based REDCap database from which data can be electronically extracted for analysis. See section 7 for further details on the data entry process.

4. Study visits

4.1. Visit schedules

4.1.1. Phase I: First-line treatment

After eligibility has been evaluated and informed consent given for participation in the trial, patients will be randomized to receive oral methotrexate or mycophenolate mofetil. Patients will continue with this course of treatment unless treatment failure occurs due to safety, intolerability or lack of efficacy. If a failure is recorded within the first 6 months, the treatment assignment will be switched to the drug not initially randomized to, and the patient will follow a new visit schedule.

Patients who are treatment failures in Phase I due to safety (i.e. a serious adverse event deemed to be related to the study drug by the Medical Monitor) may or may not proceed to

Phase II depending on the Medical Monitor’s determination. In most cases of an SAE, the patient will likely not be allowed to switch to Phase II, but in some cases, such as an SAE due to intolerability, it may be deemed safe to switch to Phase II. Even if the patient does not switch to Phase II, outcome data at 6 months should be collected if the patient is willing.

Treatment success, according to the primary endpoint, will be assessed at 6 months. If treatment has been deemed successful for a patient at 6 months, they will be provided study medication for an additional 6 months and return for additional study visits as shown below. As long as the patient stays on the first randomized medication, Visit Schedule I will be followed.

Guidelines for Visit Schedule I

- Day 1 corresponds to the Baseline-I visit, which is also the first day the patient receives treatment.
- Visit windows are determined based on the date of randomization.
- The baseline eye exam and other baseline assessments may be collected at a separate visit up to 14 days before the patient is enrolled and randomized. Laboratory measurements may be collected within either 4 weeks or 90 days prior to the date of randomization, depending on the laboratory test.
- There should be a minimum of 2 weeks between each study visit.
- Data for the baseline and follow-up visits may be collected anytime within the visit window.

Table 9: Visit Schedule Phase I (0-6 months) or Phase II

Visit	Window Days/Weeks
Baseline*	
Week 2	±3 days
Month 1*	±15 days
Month 2	±15 days
Month 3	±15 days
Month 4	±15 days
Month 5	±15 days
Month 6	-15 to +30

*Every monthly visit scheduled will be calculated from the baseline visit date (Phase 1), using the average amount of days per month. If a patient does not come in within the visit window, every attempt should be made to get them in for a clinic visit as soon as possible.

Table 10: Visit Schedule Phase I (6-12 months)

Visit	Window (Weeks)
Month 9*	±15 days
Month 12*	-15 to +30

* Since baseline/treatment administration (Phase 1)

4.1.2. Phase II: Rescue treatment

In case of the first randomized treatment failure due to intolerability or lack of efficacy within the first six months of treatment, the treatment assignment will be switched to the alternate treatment. At this point, the patient will receive the antimetabolite not originally randomized to and will be followed an additional 6 months or until failure of the second treatment.

Patients will be given 2 weeks to enter into Phase II after treatment failure in Phase I. If patients do not enter within the 2-week window, they should be treated according to best medical judgment of their physician. If the physician believes a patient would benefit from treatment in Phase II, but there is an exceptional circumstance preventing the patient from entering Phase II within the 2-week window, contact the Coordinating Center for assistance.

Guidelines for Visit Schedule II

- Day 1 corresponds to the Baseline-II visit, which is also the first day the patient receives rescue treatment with the medication not initially received. Day 1 may be its own visit date (i.e. if within 2 weeks of the end of Phase I). Alternatively Day 1 may be the same day as the last day of Phase I. All study forms should indicate what visit it is for Phase I and what visit it is for Phase II, if applicable. See the following example below.

Phase	<input checked="" type="checkbox"/> 1	<input checked="" type="checkbox"/> 2								
Visit	<input checked="" type="checkbox"/> Baseline	<input type="checkbox"/> Two weeks	<input type="checkbox"/> Non-study visit (treatment failure only)							
Month:	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4	<input type="checkbox"/> 5	<input checked="" type="checkbox"/> 6	<input type="checkbox"/> 9	<input type="checkbox"/> 12		

- Visit dates are determined based on the date of the Baseline-II visit (which may be the same date as Phase I treatment failure), and may not be changed.
- The Baseline-II visit form should be completed to gather information on any changes in health status or medications.
- There should be a minimum of 2 weeks between each study visit.
- Data for the follow-up visits may be collected anytime within the visit window.

4.1.3. Non-study visits

Despite the regular follow-up outlined in the visit schedules above, it is anticipated that some patients will have inflammation that is difficult to control or be intolerant to the drug, leading to additional visits. These additional visits may not fall within the study visit window. It is possible that the circumstances leading to such visits may result in changes to oral or topical corticosteroid dose, or a declaration of treatment failure and a need for rescue treatment. If treatment failure is declared at a non-study visit, all of the forms required at the time treatment failure is declared should be completed.

Guidelines for non-study visits

- Any changes to oral or topical corticosteroid dose will be noted on the appropriate form during the next scheduled study visit.
- If a treatment failure is declared at a non-study visit during follow-up while being treated during...
 - Phase I (initial randomized treatment): Record a treatment failure using Treatment Assessment Form. Perform Baseline II visit at this time or within 14 days. Phase II rescue treatment can start immediately.
 - Phase II: Record a treatment failure using the Treatment Assessment Form. Patient should continue to be followed until 6 months and 6th month data collected.
 - If treatment failure is declared at a non-study visit, an attempt should be made to collect as much information as possible, including the forms listed in Section 4.2.

4.2. Study form completion schedule

Forms	PHASE I					PHASE II				
	Baseline : Phase I	Week 2	Follow up months 1-5, 9	Treatment Failure anytime*	Follow up months 6 & 12	Baseline: Phase II**	Week 2	Follow up months 1-5	Treatment Failure anytime*	Follow up month 6
Eligibility/ Screening Form	X									
Consent Form	X									
Baseline History Form	X									
Clinical Eye Exam Form	X		X	X	X			X	X	X
Secondary Clinical Eye Exam Form	X			X	X				X	X
Visual Acuity Form	X		X	(x)	X			X	(x)	X
OCT Form	X		X	(x)	X			X	(x)	X
Fundus Form	X			(x)	X				(x)	X
Laboratory Report Form	X	X	X	(x)	X		X	X	(x)	X
Adverse Event Checklist		X	X	X	X	X	X	X	X	X
Vision Related Quality of Life	X			X	X				X	X
Health Related Quality of Life	X			X	X				X	X
Treatment Assessment Form	X	X	X	X	X	X	X	X	X	X
Patient Calendar***		X	X	X	X		X	X	X	X
Medication Log	X	X	X	X	X	X	X	X	X	X
Patient Dropout	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)
Protocol Deviation Form	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)
Adverse Event Narrative	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)
Adverse Event Log	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)	(x)

***Note that treatment failure may be declared at a scheduled study visit or at a non-study visit;**

All (x) are only to be filled out if applicable.

****If not switching on the same day as Phase I treatment failure**

*****Patients will complete this form and bring to the study coordinator for review**

4.3. Phase I Enrollment/Baseline visit

The Phase I Enrollment/Baseline visit should occur after the patient has been screened and determined to be eligible for the study. Screening is a process that should occur before or on the date of the patient's Enrollment/Baseline visit. The baseline eye exam and other baseline assessments may be collected at a separate visit up to 14 days before the patient is enrolled and randomized, with the exception of laboratory measurements which may be collected within 4 weeks or 90 days prior to or on the date of randomization (depending on the test).

Many patients will still have active enough inflammation at the time of enrollment to meet criteria ($\geq 1+$ AC cells, $\geq 1+$ vitreous haze by NEI scale, or active retinal/choroidal inflammation). However, some patients may have had active inflammation when screened (within 14 days prior to enrollment) but at the time of enrollment, the inflammation is improved because of steroid treatment. As long as the inflammation met inclusion criteria within this 14 day period, those values can be used for the baseline exam (enrollment exam). If there is a patient whom you think is very likely to be enrolled in the next 14 days but you are still waiting for some screening labs, it is fine to go ahead and consent and obtain the baseline study assessments (eye exam with secondary grader using both NEI and Miami scales for vitreous haze, fundus photos, OCT, questionnaires, etc.), as long as you do not randomize. Randomization can only occur once all eligibility criteria have been verified. The inflammation recorded on the baseline Clinical Eye Exam form needs to meet inflammation eligibility criteria.

4.3.1. Consent and eligibility evaluation

Procedures for obtaining consent include explaining the patient's disease, prognosis, and treatment options, discussing the risks and benefits of participation, and addressing the patient's questions and concerns. After explaining the nature of the study and the rights and responsibilities of the patient, the ophthalmologist and/or the study coordinator will obtain written consent from the subject, or written minor assent and parental consent if applicable. The subject is assured that participation in this study is voluntary and he/she can withdraw at any time if he/she feels uncomfortable.

The eligibility evaluation will be performed using the Eligibility Form, which is to be filled out at the Baseline-I visit. For detailed inclusion/exclusion criteria please see Section 2.3.

There is not a mandated separate visit for eligibility screening. If the patient fulfills all eligibility and exclusion criteria on a visit, he/she may sign the consent form and be randomized at the beginning of the official Baseline-I visit. Note that this requires that the patient have laboratory results that are current according to inclusion criteria guidelines.

In some cases, partial eligibility will be confirmed on a screening visit but more information may be needed (such as laboratory confirmation of acceptable values of the CBC, AST, ALT and creatinine). If and when the laboratory results meet eligibility criteria, the patient will then be asked to complete a consent form, followed by randomization and the official Baseline-I visit. All other criteria must be met at the time the consent form is signed and randomization occurs (except the active inflammation criteria which must be met within 14 days prior to randomization).

4.3.2. Randomization

Randomization treatment assignment takes place during the Baseline-I visit after eligibility has been determined and the consent forms have been signed by the patient. In some cases randomization can occur on the same day that patient is screened for enrollment, if the patient signs the consent form on that day. If the patient wishes to come back at a later time to sign the consent forms, randomization will occur on the date they return. If a patient returns to sign the consent and enroll on a different date to his or her screening visit, he or she must have had the relevant laboratory tests within 4 weeks prior to enrollment for trial eligibility.

After obtaining the written consent, the study coordinator will assign the next identification number from the patient ID list. The coordinator will then log into the REDCap database to perform the randomization for the corresponding patient ID. The coordinator will take note of the treatment assigned by REDCap, dispense the assigned treatment to the patient, and review dosing instructions with the patient.

4.3.3. Procedures for data collection

Required study procedures include the following:

- Medical and Treatment History
- Clinical eye exam
- Visual acuity exam
- Optical Coherence Tomography (OCT)
- Fundus photography
- Laboratory measurements
- Health-related quality of life questionnaire
- Vision-related quality of life questionnaire(s)

4.3.4. Specimens

The following specimens will be collected for laboratory measurements *within 4 weeks prior to enrollment*:

- Blood for complete blood count (CBC with differential, limited to percentages of neutrophils and lymphocytes)
- Blood for CD4 at AEH, KKESH, and UCSF sites only
- Blood for serum chemistry panel (AST, ALT, creatinine)
- Blood or urine pregnancy test (all female patients, excluding those that are post-menopausal)

The following specimens will be collected for laboratory measurements *within 90 days prior to enrollment*:

- Hepatitis B surface antigen (HBsAg)
- Hepatitis C antibody
- Tuberculin skin test
- Interferon gamma release assay
- Chest radiograph
- Syphilis (RPR/VDRL/other non-specific)
- Syphilis (FTA-ABS/MHATP/other specific)

4.3.5. Forms for data collection

The following forms will be filled out as part of the Baseline-I visit:

- Patient Consent Forms
- Eligibility/Screening Form
- Baseline History Form
- Clinical Eye Exam Form
- Secondary Clinical Eye Exam Form
- Right Eye Visual Acuity Form
- Left Eye Visual Acuity Form
- OCT Form
- Fundus Photography Form
- Laboratory Report Form
- Quality of Life Questionnaire Forms
- Treatment Assessment Form
- Protocol Deviation Form (if applicable)

4.4. Follow-up visits

It is strongly encouraged for all follow up data to be collected within the study visit window, but should be collected regardless.

All Phase II procedures and protocol are the same as Phase I. For Phase I patients who are continuing on the same medication, physicians can see the patients as often as they would like. However, for purposes of this study we will only be recording information at Month 9 and Month 12, or a non-study visit that leads to treatment failure.

Laboratory test results will be collected monthly.

4.4.1. Procedures for data collection

Required study procedures include the following:

- Clinical eye exam
- Secondary Clinical eye exam*
- Visual acuity exam
- Optical Coherence Tomography
- Fundus Photography*
- Laboratory measurements
- Quality of Life Questionnaire Forms*

*Phase 1: treatment failure and 6 month visit (whichever is first), 12 month visit; Phase 2: treatment failure and 6 month visit.

4.4.2. Specimens

The following specimens will be collected for laboratory measurements:

- Blood for complete blood count (CBC with differential, limited to percentages of neutrophils and lymphocytes)
- Blood for CD4 at AEH, KKESH, and UCSF sites only at Baseline, Month 3, 6, & 12
- Blood for serum chemistry panel (AST, ALT, creatinine)
- Blood or urine pregnancy test (all female patients, excluding those that are post- menopausal)

4.4.3. Forms for data collection

The following forms will be filled out as part of the follow-up visits:

- Clinical Eye Exam Form
- Secondary Clinical Eye Exam Form*
- Right Eye Visual Acuity Form
- Left Eye Visual Acuity Form
- OCT Form
- Fundus Photography Form*
- Laboratory Report Form
- Adverse Event Checklist
- Medication Log
- Patient Medication Calendar (to be completed by the patient)
- Treatment Assessment Form
- *Adverse Event Log (update if necessary)*
- *Quality of Life Questionnaire Forms **
- *Serious Adverse Event Narrative Form (if applicable)*
- *Patient Dropout Form (if applicable)*
- *Protocol Deviation Form (if applicable)*

*Phase 1: baseline, treatment failure and 6 month visit, 12 month visit; Phase 2: treatment failure and 6 month visit; Treatment failure anytime (study or non-study visit)

For follow-up visits, all the above procedures and forms should be completed for all patients, regardless of if they are taking the medication or compliant with study visits.

4.5. Baseline Phase II

This visit may occur on the same day as treatment failure in Phase I, if the patient proceeds directly to Phase II. If both visits occur on the same day, study coordinators will mark the Phase I visit and Phase II visit at the same time on the case report forms. However, patients have up to two weeks to come back to clinic and begin Phase II after treatment failure in Phase I. In this case, complete the Baseline Phase II form packet on the date Baseline II starts.

4.5.1. Eligibility

In Phase I, if failure is due to efficacy or tolerability or for selected cases for safety (if deemed safe by the Medical Monitor), the patient will be considered as eligible for Phase II of the study. If there is a serious adverse event in Phase I, deemed to be related to the study drug by the Medical Monitor, the patient will be declared a treatment failure. The Medical Monitor will determine if it is safe for the patient to enter Phase II. If not, the patient should still be followed for 6 months.

As in Phase I, there is no mandated separate visit for eligibility screening in Phase II. If the patient is declared a treatment failure in Phase I for any reason other than an SAE deemed to be related to the study drug (by the Medical Monitor), he/she may immediately proceed to Phase II. Any reason for eligibility failure for Phase II will be captured in the adverse event log of the last Phase I visit, thus there is no need to have a separate eligibility screening form.

4.6. Non-study visits

Despite frequent study visits, some patients may need additional visits with their ophthalmologist according to standard of care that do not fall within study visit windows. Required data collection during these non-study visits is limited to adverse event reporting and declaration of treatment failure if it occurs. It is preferable that treatment failure is declared at a regularly scheduled study visit rather than a non-study visit, however if it is necessary the physician can decide to do so.

4.6.1. Study Procedures

Every attempt should be made to obtain all study procedures at a non-study visit if treatment failure is being declared. However, if this is not possible the required study procedures include the following:

- Clinical eye exam (if treatment failure is declared)

4.6.2. Specimens

No specimens are required during non-study visits.

4.6.3. Forms for data collection

The following forms will be filled out at non-study visits *only if treatment failure is declared*. Every attempt should be made to acquire information for all other forms. However, if this is not possible, at the minimum the following must be completed:

- Clinical Eye Exam Form
- Treatment Assessment Form
- Quality of Life
- Medication Log
- Adverse Event Checklist
- *Adverse Event Log (update if necessary)*
- *Serious Adverse Event Narrative Form (if applicable)*

5. Study examinations and procedures

5.1. Quality of life questionnaire administration

All patients will be asked to complete standard quality of life questionnaires related to overall health and visual function at baseline visits as well as at 6 months or treatment failure (whichever is first) in order to measure quality of life outcomes. Patients who experience treatment success with Phase I treatment and continue into Phase I (6-12 months) also complete questionnaires at the 12-month visit, or earlier if treatment failure is declared. The following questionnaires will be administered:

If treatment failure occurs prior to 6 months (Phase I and Phase II) questionnaires should also be collected at the time of treatment failure as well as 6 months.

Health-related quality of life

- SF-36 questionnaire (all patients)

Vision-related quality of life

- NEI-VFQ-25 (all patients)
- IND-VFQ (Indian patients only)

Given data suggesting that SF-36 scores vary by method of administration such that patients overstate their quality of life in clinic interviews, questionnaires will be self-administered whenever possible at clinic appointments. Additionally the NEI-VFQ should be self-administered whenever possible. It is anticipated that some patients will not have adequate visual function to complete the questionnaires on their own, and some patients may also be illiterate. In such cases, the coordinator will read the questions aloud to the patient and record the patient's answers on the appropriate questionnaire forms (Section A.13). It is very important that the questions are answered in their original form, so coordinators should never rephrase or interpret questions for the patient.

5.2.A Refraction and visual acuity (PRIMARY – FOR LETTER VISION CHARTS)

5.2.1.A Refraction procedure

Beginning Approximate Refraction

The beginning approximate refraction should be obtained by performing retinoscopy or auto-refraction. One of these measurements is used as the beginning approximate refraction at each visit.

Subjects who arrive for examination wearing contact lenses are asked to remove the lenses prior to refraction. The subject must wait for 30 minutes after removing the contact lenses before refraction can be performed.

Refraction may be initially performed at distances different than four meters (i.e. using a phoropter in a common refraction lane). However, if this is done, the spherical power refinement step must be repeated with lenses in place after the subject has been positioned at four meters for visual acuity testing.

The examiner will use Chart R (Precision Vision Chart Version 2110) for manifest refraction. Each eye is refracted at four meters unless the visual acuity measured at this distance on chart R is worse than 20/200 (defined as missing 2 or more letters on the top line, the 20/200 or 6/60 line). This subject must then be moved to a distance of one meter from the study visual acuity chart, and refraction must be performed and recorded at this distance.

Manifest Refraction

In general, instructions are to ‘push plus’ and to add minus diopter corrections only if there is a demonstrated increase in visual acuity, i.e., the patient is able to read more letters. The steps are as follows:

- Seat the subject 4 meters in front of the refraction chart;
- Place and adjust the trial frame on the subject’s face so that the lens cells are parallel to the anterior plane of the orbit;
- Adjust the pupillary distance of the trial frame to make sure that the lenses position in front of the centers of the pupils;
- Adjust the lens cells for the proper distance from the cornea;
- Occlude the eye not being refracted;
- Insert spherical lens correction into the compartment closest to the eye;
- Place cylindrical lens correction in the compartment in the front of the frame;
- Set cylindrical lens to appropriate axis setting

Please refer to the table below to ensure that proper lenses are used for the appropriate visual acuity level:

Vision with Best Correction	Sphere		Cylinder Use correct Jackson Cross Cylinder as below			Sphere Refinement	
	Power	Increment	Axis	Power	Increment	Power	Increment
20/10-20/80 6/3-6/24 (4 meters)	+0.50 - 0.37 +0.50	+0.50 - 0.25 +0.50	0.50	0.25 -0.25	+0.25 -0.25	+0.37 -0.37 +0.37	+0.25 -0.25 +0.25
20/100-20/200 6/30-6/60 (4 meters)	+1.00 -1.00 +1.00	+1.00 -1.00 +1.00	1.00	1.00	+1.00 -1.00	+0.50 -0.50 +0.50	+0.50 -0.50 +0.50
<20/200 <6/60 (1 meter)	+2.00 -2.00 +2.00	+2.00 -2.00 +2.00	1.00	1.00	+1.00 -1.00	+1.00 -1.00 +1.00	+1.00 -1.00 +1.00

Examples for each visual acuity level are detailed below.

For Patients with Visual Acuity of 20/10-20/80 (6/3-6/24):

Determine Sphere Power

- Ask patient to identify the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.50 spherical lens in front of the eye being tested. Ask the subject, “Is

- vision better, worse, or the same?"
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.50 more plus;
 - Continue to check with the +0.50 lens to see if the subject will accept more plus by repeating the step above;
 - When an additional +0.50 lens makes the subject's vision worse, remove the +0.50 lens
 - Then hold a -0.37 spherical lens over the eye;
 - If this -0.37 lens improves the subject's vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.25 more minus;
 - Remember, if the patient reports that the -0.37 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -0.25.
 - If the -0.37 spherical lens does not allow the patient to read more letters or if it makes the vision worse, recheck using the +0.50 lens
 - If the +0.50 lens makes vision better or the same, repeat above sequence
 - If the +0.50 lens makes vision worse, move on to cylindrical testing

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 0.50 diopter cross-cylinder with the positive axis first at 90° and then at 180°, asking if either position makes the letter clearer;
- If the patient prefers either one of these positions, place a +0.50 cylindrical lens in the trial frame aligned with the preferred axis;
- If the patient did not prefer cylinder at axis 90° or 180°, position the cross cylinder with the positive axis first at 45° then 135°;
- Ask if the patient prefers either of these positions;
- If so, place a +0.50 cylinder lens in the trial frame aligned with the preferred axis;
- If the subject prefers none of the four positions, no further cylinder testing is required;
- **If cylinder is present** in the beginning approximate refraction **or if you have added +0.50 cylinder power in the above step**, position the +/- 0.50 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves vision (position one or position two?);
- If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
- If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see Table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder.

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Switch to +/- 0.25 diopter cross-cylinder;
- Align the \pm 0.25 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by +0.25 diopter;
- If a subject indicates a change that would introduce negative cylinder power, remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;
- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +0.25 diopter and retest;
- **Beginning with cylinder powers of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere power by 0.25 diopter of the opposite sign; this is done to maintain the spherical equivalent.**

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.37 spherical lens in front of the eye being tested. Ask the subject, "Is vision better, worse, or the same?"
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.25 more plus;
- Continue to check with the +0.37 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +0.37 lens makes the subject's vision worse, remove the +0.37 lens;
- Then hold a -0.37 spherical lens over the eye;
- If this -0.37 lens improves the subject's vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.25 more minus;
- Continue presenting the -0.37 lens to see if there is any further improvement in vision;
- When an additional -0.37 lens does not improve vision;
- Present the +0.37 lens, again asking "if vision is better, worse or the same?"
- If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
- If patient responds that vision is worse, testing is complete.
- **Remember to always end the refraction by checking with plus lenses.**

For Patients with Visual Acuity of 20/100-20/200 (6/30-6/60):

Determine Sphere Power

- Ask patient to identify the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +1.00 spherical lens in front of the right eye. Ask the subject, "Is vision better, worse, or no change?"
- If the subject responds that vision is made better or is the same, replace the spherical lens with one that is +1.00 more plus;
- Continue to check with the +1.00 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +1.00 lens makes the subject's vision worse, remove the +1.00 lens
- Then hold a -1.00 spherical lens over the eye;
- If this -1.00 lens improves the subject's vision, even by one letter, replace the spherical lens in the trial frame by one that is -1.00 more minus;
- Remember, if the patient reports that the -1.00 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -1.00.
- If the -1.00 spherical lens does not allow the patient to read more letters or if it makes the vision worse, recheck using the +1.00 lens; recheck using +1.00 lens
- If the +1.00 lens makes vision better or the same, repeat above sequence
- If the +1.00 lens makes vision worse, move on to cylindrical testing;
- **NOTE:** if visual acuity improves significantly during manifest refraction, the examiner may need to change to trial lenses that are specified for the new level of acuity for the remainder of the refraction. Please refer to the Trial Lens Guide above.

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 1.00 diopter cross-cylinder with the positive axis first at 90° and then at 180°, asking if either position makes the letter clearer;
- If the patient prefers either of these positions, place a +1.00 cylindrical lens in the trial frame at the preferred axis;
- If the patient did not prefer cylinder at axis 90° or 180°, position the cross cylinder with the positive axis first at 45° then 135°;
- Ask if the patient prefers either of these positions;
- If so, place a +1.00 cylinder lens in the trial frame at the preferred axis;
- If the subject prefers none of the four positions, no further cylinder testing is required;
- **If cylinder is present** in the beginning approximate refraction **or if you have added +1.00 cylinder power in the above step**, position the +/- 1.00 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves the vision (position one or position two?);

- If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
- If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see Table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Align the ± 1.00 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by +1.00 diopter;
- If a subject indicates a change that would introduce negative cylinder power, remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;
- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +1.00 diopter and retest;
- Beginning with cylinders of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere by 0.25 diopter of the opposite sign; this is done to maintain the spherical equivalent.

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.50 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.50 more plus;
- Continue to check with the +0.50 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +0.50 lens makes the subject’s vision worse, remove the +0.50 lens
- Then hold a -0.50 spherical lens over the eye;
- If this -0.50 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.50 more minus;
- Continue presenting the -0.50 lens to see if there is further improvement in vision;
- When an additional -0.50 lens does not improve vision;
- Show the patient the +0.50 lens, again asking “if vision is better, worse or the

- same?”
- If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
 - If patient responds that vision is worse, refraction testing is complete.
 - **Remember to always to end the refraction by checking with plus power.**

For Patients with Visual Acuity <20/200 (<6/60):

Determine Sphere Power

NOTE: **If refraction cannot be performed at 4 meters**, defined as missing 2 or more letters on the largest line, then the subject should be moved to 1 meter and the above refraction sequence followed. **At 1 meter, a + 0.75 spherical lens is added** to the beginning approximate refraction to adjust for the accommodative difference between 4 and 1 meter.

- Ask patient to identify the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +2.00 spherical lens in front of the right eye. Ask the subject, “Is it better, worse, or no change?”
- If the subject responds that vision is made better or is the same, replace the spherical lens with one that is +2.00 more plus;
- Continue to check with the +2.00 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +2.00 lens makes the subject’s vision worse, remove the +2.00 lens
- Then hold a -2.00 spherical lens over the eye;
- If this -2.00 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -2.00 more minus;
- Remember, if the patient reports that the -2.00 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -2.00.
- If the -2.00 spherical lens does not allow the patient to read more letters or if it makes the vision worse, retest using +2.00 lens; If the +2.00 lens makes vision better or the same, repeat above sequence;
- If the +2.00 lens makes vision worse, move onto cylindrical testing;
- **NOTE:** if visual acuity improves significantly during manifest refraction, the examiner may need to change to trial lenses that are specified for the new level of acuity for the remainder of the refraction. Please refer to the Trial Lens Guide above.

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 1.00 diopter cross-cylinder with the positive axis first at 90° and then at 180°, asking if either position makes the letters clearer;
- If the patient prefers either of these positions, place a +1.00 cylindrical lens in the trial frame at the preferred axis;
- If the patient did not prefer cylinder at axis 90° or 180°, position the cross

- cylinder with the positive axis first at 45° then 135°;
- Ask if the patient prefers either of these positions;
 - If so, place a +1.00 cylinder lens in the trial frame at the preferred axis;
 - If the subject prefers none of the four positions, no further cylinder testing is required.
 - **If cylinder is present** in the beginning approximate refraction **or if you have added +1.00 cylinder power in the above step**, position the +/- 1.00 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves the vision (position one or position two?);
 - If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
 - If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Align the ± 1.00 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by 1.00 diopter;
- If a subject indicates a change that would introduce negative cylinder power, remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;
- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +1.00 diopter and retest;
- Beginning with cylinders of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere by 0.25 diopter of the opposite sign, this is done to maintain the spherical equivalent.

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +1.00 spherical lens in front of the eye being tested. Ask the subject, "Is

- vision better, worse, or the same?"
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +1.00 more plus;
 - Continue to check with the +1.00 lens to see if the subject will accept more plus by repeating the step above;
 - When an additional +1.00 lens makes the subject's vision worse, remove the +1.00 lens
 - Then hold a -1.00 spherical lens over the eye;
 - If this -1.00 lens improves the subject's vision, even by one letter, replace the spherical lens in the trial frame by one that is -1.00 more minus;
 - Continue presenting the -1.00 lens to see if there is further improvement in vision;
 - When an additional -1.00 lens does not improve vision;
 - Present the +1.00 lens, again asking "if vision is better, worse or the same?"
 - If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
 - If patient responds that vision is worse, testing is complete.
 - **Remember to always to end the refraction by checking with plus power.**

Record the lens correction obtained during manifest refraction for the right eye on the appropriate examination forms in the section for visual acuity measurements (Section A.5). Then proceed to refraction of the left eye, following steps as outlined above.

5.2.2.A Visual acuity procedure

Visual acuity measurement is necessary for a secondary outcome in this trial. Therefore, we have created a standardized method that aims to minimize any bias from either the examiner or the patient. This has been adapted from the Visual Acuity protocols from the Age Related Eye Disease Study (AREDS 1999)³², and the Aravind Eye Hospital's Practical Guide to Refraction³³ and is similar to the method we are currently using at Aravind Eye Hospital and Proctor/UCSF for the NEI funded Steroids for Corneal Ulcers Trial and the Mycotic Ulcer Treatment Trials.

Visual Acuity Charts

The following equipment is used: a set of three charts, which are modified Bailey-Lovie charts, Charts 1, 2 and R (Precision Vision Chart 2110, 2111 and 2112, respectively). Each chart consists of 14 lines of high-contrast letters. There is a geometric progression of letter size (and, thus, an arithmetic progression of the logarithm of minimum angle of resolution) from line to line.

Chart 1 is for measuring aided visual acuity of the right eye and Chart 2 is to be used for measuring aided visual acuity of the left eye at all visits. Chart R will be used for obtaining all manifest subjective refractions.

Visual Acuity Boxes

The dimensions of the light box are 24 and 3/4 inches (62.9 cm) by 25 and 3/4 inches (65.4 cm) by 7 inches (17.8 cm). The box can be mounted on a wall or on a cylindrical stand. The stand is mounted on a five-pronged wheelbase, with each prong about 14 inches (35.6 cm) long; two of the five wheels are lockable. When the box is mounted on the stand, its height can be varied. The light box should be mounted at a height such that the top of the third row of letters (0.8 logMAR, 45 letters, 20/125 Snellen) is 49 +/- 2 inches (124.5 +/- 5.1 cm) from the floor. The rear of the box provides storage space for the two charts not being used.

Illumination

The overhead room lights should be turned **off** during the visual acuity test. The box itself provides sufficient illumination for the examiner to record the test results. Additional light can have an adverse effect such as glare. With the box light off, not more than 15 foot-candles of light should fall on the center of the chart. The visual acuity light box is equipped with two **20-watt** fluorescent tubes. Because the illumination of fluorescent tubes diminishes by 5 percent during the first 100 hours and by another 5 percent during the next 2,000 hours, new tubes should be kept "on" for about 4 days (approximately 96 hours, does not have to be continuous) before use. All tubes should be replaced once a year.

Each tube is partially covered by a 14-inch (35.6 cm) fenestrated sleeve, open in the back, which serves as a baffle to reduce illumination. Each sleeve should be centered on the tube such that an equal length of tube (about 4 and 3/16 inches or 10.6 cm) is left uncovered to the right and left of the sleeve.

4- and 1-Meter Visual Acuity Lanes

A distance of 4 meters (13 feet and 1.5 inches, or 157.5 inches) is required between the subject's eyes and the visual acuity chart for the 4-meter test, and a distance of 1 meter (39 and 3/8 inches) is required for the 1-meter test. The room for visual acuity testing must have, in addition to the 4-meter lane, space for the visual acuity box (and possibly a stand) and space for the subject.

- Wall-mounted box: In addition to the 4-meter lane, 7 inches (17.8 cm) must be allowed for the depth of the box plus space for the subject to sit or stand.
- Stand-mounted box: In addition to the 4-meter lane, 13 inches (33 cm) must be allowed for two of the stand's casters to touch the rear wall (or a line marked on the floor when there is no wall) plus space for the subject to sit or stand.

Marking the Distance

4 Meters

- If the chair and visual acuity box are permanently affixed, distance measurements need to be made only once and no floor marks are needed to ensure the correct distance.
- If the box is mounted on the wall but the subject's chair is not permanently affixed, the 4-meter distance of the subject's eye from the chart must be marked clearly and permanently.
- If the box is mounted on a movable stand, the 4-meter distance must be marked clearly and permanently. The location and orientation of the box must be rechecked each time a new chart is put in place or the box is touched. When the stand touches the rear wall of the room, two of the five casters should touch the wall.

1 Meter

- The 1-meter distance is measured from the eye of the subject, who is seated comfortably in a chair with his or her back firmly placed against the chair's back, to the center of the second (for testing the left eye) or fourth letter (for testing the right eye) of the third line of the chart. A stick, one meter long, should be used to confirm the distance for each subject.

Visual Acuity Procedure

- Visual acuity will be measured at each study visit.
- Visual acuity should be measured for each eye AFTER refraction. Visual acuity should NOT be recorded during the refraction procedure.
- It is very important that the examiner is not aware of the patient's clinical records, in order to minimize bias. Therefore, the visual acuity examiner will not have access to the patient's previous clinical examination or treatment results.
- Visual acuity is tested separately for each eye (one eye at a time). The patient's untested eye will be completely covered with a patch, to block out all light from entering this eye. The examiner must constantly ensure that this eye remains occluded at all times.
- The patient is instructed to read each letter on the chart starting with the largest line, at the 4-meter distance, and is encouraged to read as many letters as possible.
- If the patient cannot identify a letter, they are encouraged to guess. **Only one response is allowed per letter.**
- The examiner must ensure that the patient does not squint (creating a pin-hole effect) or lean forward (reducing the distance to the chart).
- Once a patient has given a response for a letter and has moved on to provide a response for the next letter, any corrections of previous response will not be accepted.
- However, if the patient has given a response for a letter and has not yet moved on to provide a response for the next letter, a correction of the previous response is accepted.
- If the subject gives two possible responses for a letter, tell the patient to commit to one answer. **The examiner CANNOT, at any time, give the patient any indication as to whether a response is correct or incorrect.**
- In the case that the patient reads less than 20 letters at 4 meters, move the patient or the chart so that there is a distance between the two of 1 meter.
- Visual acuity will then be retested at this 1 meter distance.
- Only the first 6 rows of letters need to be read at 1 meter.
- If no letters are read at 1 meter, then the examiner must proceed to Low Vision Testing (see below), starting with Count Fingers testing. If the patient does not adequately Count Fingers, proceed to Hand Motion. If the patient does not adequately recognize Hand Motion, then proceed to Light Perception.

Testing of Count Fingers Vision

In testing for count fingers vision, the examiner's hand presenting 1, 2, or 5 fingers is held steady at a distance of 1 meter directly in front of the eye being examined. The fellow eye is completely occluded with a patch. Refractive correction should not be used. A light should be shown directly on the hand from behind the subject and room lights should be turned on. The examiner's fingers should be presented in random order and repeated 5 times. Eccentric viewing should be encouraged. If the subject correctly identifies three of the five presentations, then count fingers vision is noted. If not, then the subject must be tested for hand motion vision.

Testing of Hand Motion Vision

The examiner's hand with all fingers spread out should be extended ½ meter directly in front of the eye being examined. The fellow eye should be occluded with a patch.

Refractive correction should not be used. A light should be shone directly on the hand from behind the subject and room lights should be turned on. The examiner's hand should be moved in an up-and-down direction (vertically) or in a side-to-side direction (horizontally) at a constant speed of approximately one back and forth presentation per second. The subject is instructed that the examiner's hand will be presented and they will have to respond to the question: "What am I doing with my hand?" This should be repeated five times. Four out of five correct responses indicate that hand motions vision is present. If the subject does not correctly identify four out of five, then you must test for light perception.

Testing for Light Perception

The indirect ophthalmoscope is used as the light source for testing light perception. Room lights should be off. The opposite eye must be completely patched. No correction should be used. From a distance of ½ meter with the light source turned up to maximum intensity, the light from the indirect ophthalmoscope is directed into the subject's eye four times. The subject is asked to respond when the light is "on". Light Perception is recorded if the examiner is convinced the subject sees the light. Otherwise, the vision should be recorded as "No Light Perception".

Scoring Best Corrected Visual Acuity

On the Visual Acuity Forms, the examiner will circle all letters read correctly. Letters read incorrectly or not read at all will be left unmarked. At the end of each row of letters, the examiner will write down the total number of letters read correctly on the line provided. If visual acuity was not tested at 1 meter, the examiner will indicate this on the form.

After each measurement of visual acuity, the biostatistician will calculate the score for the visit.

The Snellen equivalent, defined as the Snellen ratio corresponding to the most difficult line for which the subject read at least 4 of 5 letters correctly, will also be entered by the examiner on the 4-meter Visual Acuity Form (Section A.5).

The data entry staff will enter the number correct on each row at 4 meters, and if applicable, 1 meter and low vision testing results (They will not enter which letters the examiner circled, i.e., which letters the patient identified correctly.). Coordinating center personnel will double check the data entered by the examiner and data entry staff.

5.2.3.A Visual acuity training and certification

The goal of the certification process is to standardize methodology for refraction and visual acuity measurement. All visual function examinations must be performed by study-certified technicians. The principal investigator at each site is responsible for ensuring that the appropriate personnel are identified, trained and certified. A qualified visual function examiner (SL) from the Clinical Coordinating Center (Proctor Foundation) will certify the rooms and technicians at each site.

Technicians are expected to perform the refraction and visual acuity tests on at least one and possibly more non-study subjects according to protocol requirements. The examiner will determine whether or not the candidate executes the study protocol accurately for each procedure. A checklist (Visual Acuity/Refraction Certification Form, Section B.1) containing required procedures will be used to facilitate this process.

Room certification will be performed and recorded (Room Certification Form, section B.2) to ensure that all study rooms meet illumination, equipment, and distance requirements. Logs should be kept to document dates of light box bulb replacement.

Certification is valid for a period 18 months (\pm 2 months) from the date of certification. The process should begin as soon as possible, as technicians must be certified before the first study subject is seen. **A minimum of two certified technicians** are required at each site. The visual acuity measurement schedule may be found on the Study Forms Completion Schedule.

5.2.B Refraction and visual acuity (PROTOCOL FOR TUMBLING E CHART)

5.2.1.B Refraction procedure

Beginning Approximate Refraction

The beginning approximate refraction should be obtained by performing retinoscopy or auto-refraction. One of these measurements is used as the beginning approximate refraction at each visit.

Subjects who arrive for examination wearing contact lenses are asked to remove the lenses prior to refraction. The subject must wait for 30 minutes after removing the contact lenses before refraction can be performed.

Refraction may be initially performed at distances different than four meters (i.e. using a phoropter in a common refraction lane). However, if this is done, the spherical power refinement step must be repeated with lenses in place after the subject has been positioned at four meters for visual acuity testing.

The examiner will use Chart R (Precision Vision Chart Version 2305b) for manifest refraction. Each eye is refracted at four meters unless the visual acuity measured at this distance on chart R is worse than 20/200 (defined as missing 2 or more letters on the top line, the 20/200 or 6/60 line). This subject must then be moved to a distance of one meter from the study visual acuity chart, and refraction must be performed and recorded at this distance. Use of Visual Acuity Form R is optional but may be helpful in keeping track of patient's acuity level.

Manifest Refraction

In general, instructions are to 'push plus' and to add minus diopter corrections only if there is a demonstrated increase in visual acuity, i.e., the patient is able to read more letters. The steps are as follows:

- Seat the subject 4 meters in front of the refraction chart;
- Place and adjust the trial frame on the subject's face so that the lens cells are parallel to the anterior plane of the orbit;
- Adjust the pupillary distance of the trial frame to make sure that the lenses position in front of the centers of the pupils;
- Adjust the lens cells for the proper distance from the cornea;
- Occlude the eye not being refracted;
- Insert spherical lens correction into the compartment closest to the eye;
- Place cylindrical lens correction in the compartment in the front of the frame;
- Set cylindrical lens to appropriate axis setting

Please refer to the table below to ensure that proper lenses are used for the appropriate visual acuity level:

Vision with Best Correction	Sphere		Cylinder Use correct Jackson Cross Cylinder as below			Sphere Refinement	
	Power	Increment	Axis	Power	Increment	Power	Increment
6/3-6/24	+0.50	+0.50	0.50	0.25	+0.25	+0.37	+0.25
20/10-20/80 (4 meters)	-0.37	-0.25			-0.25	-0.37	-0.25
	+0.50	+0.50				+0.37	+0.25
6/30-6/60	+1.00	+1.00	1.00	1.00	+1.00	+0.50	+0.50
20/100-20/200 (4 meters)	-1.00	-1.00			-1.00	-0.50	-0.50
	+1.00	+1.00				+0.50	+0.50
<6/60	+2.00	+2.00	1.00	1.00	+1.00	+1.00	+1.00
<20/200 (1 meter)	-2.00	-2.00			-1.00	-1.00	-1.00
	+2.00	+2.00				+1.00	+1.00

Examples for each visual acuity level are detailed below.

For Patients with Visual Acuity of 6/3-6/24 (20/10-20/80):

Determine Sphere Power

- Ask patient to identify the orientation of the tumbling “E”s on the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.50 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.50 more plus;
- Continue to check with the +0.50 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +0.50 lens makes the subject’s vision worse, remove the +0.50 lens
- Then hold a -0.37 spherical lens over the eye;
- If this -0.37 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.25 more minus;
- Remember, if the patient reports that the -0.37 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -0.25.
- If the -0.37 spherical lens does not allow the patient to read more letters or if it makes the vision worse, retest using the +0.50 lens;
- If the +0.50 lens makes vision better or the same, repeat above sequence
- If the +0.50 lens makes vision worse, move on to cylindrical testing

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 0.50 diopter cross-cylinder with the positive axis first at 90° and then at 180°,

- asking if either position makes the letters clearer;
- If the patient prefers either one of these positions, place a +0.50 cylindrical lens in the trial frame aligned with the preferred axis;
 - If the patient did not prefer cylinder at axis 90° or 180°, position the cross cylinder with the positive axis first at 45° then 135°;
 - Ask if the patient prefers either of these positions;
 - If so, place a +0.50 cylinder lens in the trial frame aligned with the preferred axis;
 - If the subject prefers none of the four positions, no further cylinder testing is required;
 - **If cylinder is present in the beginning approximate refraction or if you have added +0.50 cylinder power in the above step**, position the +/- 0.50 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves vision (position one or position two?);
 - If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
 - If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see Table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder.

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Switch to +/- 0.25 diopter cross-cylinder;
- Align the ± 0.25 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by +0.25 diopter;
- If a subject indicates a change that would introduce negative cylinder power, remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;
- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +0.25 diopter and retest;
- **Beginning with cylinder powers of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere power by 0.25 diopter of the opposite sign; this is done to maintain the spherical equivalent.**

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.37 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.25 more plus;
- Continue to check with the +0.37 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +0.37 lens makes the subject’s vision worse, remove the +0.37 lens;
- Then hold a -0.37 spherical lens over the eye;
- If this -0.37 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.25 more minus;
- Continue presenting the -0.37 lens to see if there is any further improvement in vision;
- When an additional -0.37 lens does not improve vision;
- Present the +0.37 lens, again asking “if vision is better, worse or the same?”
- If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
- If patient responds that vision is worse, testing is complete.
- **Remember to always to end the refraction by checking with plus lenses.**

For Patients with Visual Acuity of 6/30-6/60 (20/100-20/200):

Determine Sphere Power

- Ask patient to identify the orientation of the tumbling “E”s on the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +1.00 spherical lens in front of the right eye. Ask the subject, “Is vision better, worse, or no change?”
- If the subject responds that vision is made better or is the same, replace the spherical lens with one that is +1.00 more plus;
- Continue to check with the +1.00 lens to see if the subject will accept more plus by repeating the step above;
- If an additional +1.00 lens makes the subject’s vision worse, remove the +1.00 lens
- Then hold a -1.00 spherical lens over the eye;
- If this -1.00 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -1.00 more minus;
- Remember, if the patient reports that the -1.00 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -1.00.
- If the -1.00 spherical lens does not allow the patient to read more letters or if it makes the vision worse, retest using the +0.50 lens;
- If the +1.00 lens makes vision better or the same, repeat above sequence;
- If the +1.00 lens makes vision worse, move on to cylindrical testing;
- **NOTE:** if visual acuity improves significantly during manifest refraction, the examiner may need to change to trial lenses that are specified for the new level of acuity for the remainder of the refraction. Please refer to the Trial Lens Guide above.

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger

- than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 1.00 diopter cross-cylinder with the positive axis first at 90° and then at 180°, asking if either position makes the letters clearer;
 - If the patient prefers either of these positions, place a +1.00 cylindrical lens in the trial frame at the preferred axis;
 - If the patient did not prefer cylinder at axis 90° or 180°, position the cross cylinder with the positive axis first at 45° then 135°;
 - Ask if the patient prefers either of these positions;
 - If so, place a +1.00 cylinder lens in the trial frame at the preferred axis;
 - If the subject prefers none of the four positions, no further cylinder testing is required;
 - **If cylinder is present** in the beginning approximate refraction **or if you have added +1.00 cylinder power in the above step**, position the +/- 1.00 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves the vision (position one or position two?);
 - If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
 - If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see Table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Align the ± 1.00 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by +1.00 diopter;
- If a subject indicates a change that would introduce negative cylinder power, remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;
- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +1.00 diopter and retest;
- Beginning with cylinders of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere by 0.25 diopter of the opposite sign; this is done to maintain the spherical equivalent.

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +0.50 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +0.50 more plus;
- Continue to check with the +0.50 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +0.50 lens makes the subject’s vision worse, remove the +0.50 lens
- Then hold a -0.50 spherical lens over the eye;
- If this -0.50 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -0.50 more minus;
- Continue presenting the -0.50 lens to see if there is further improvement in vision;
- When an additional -0.50 lens does not improve vision;
- Show the patient the +0.50 lens, again asking “if vision is better, worse or the same?”
- If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
- If patient responds that vision is worse, refraction testing is complete.
- **Remember to always to end the refraction by checking with plus power.**

For Patients with Visual Acuity < 6/60 (<20/200):

Determine Sphere Power

NOTE: If refraction cannot be performed at 4 meters, defined as missing 2 or more letters on the largest line, then the subject should be moved to 1 meter and the above refraction sequence followed. **At 1 meter, a + 0.75 spherical lens is added** to the beginning approximate refraction to adjust for the accommodative difference between 4 and 1 meter.

- Ask patient to identify the orientation of the tumbling “E”s on the smallest possible line that he/she can see on the Chart R;
- With the subject looking at the smallest line legible on the visual acuity chart, place a +2.00 spherical lens in front of the right eye. Ask the subject, “Is it better, worse, or no change?”
- If the subject responds that vision is made better or is the same, replace the spherical lens with one that is +2.00 more plus;
- Continue to check with the +2.00 lens to see if the subject will accept more plus by repeating the step above;
- If an additional +2.00 lens makes the subject’s vision worse, remove the +2.00 lens
- Then hold a -2.00 spherical lens over the eye;
- If this -2.00 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -2.00 more minus;
- Remember, if the patient reports that the -2.00 lens makes the vision better but if s/he is unable to read more letters, do not change spherical lens by -2.00.
- If the -2.00 spherical lens does not allow the patient to read more letters or if it makes the vision worse, retest using the +2.00 lens;
- If the +2.00 lens makes vision better or the same, repeat above sequence;
- If the +2.00 lens makes vision worse, move on to cylindrical testing;

- **NOTE:** if visual acuity improves significantly during manifest refraction, the examiner may need to change to trial lenses that are specified for the new level of acuity for the remainder of the refraction. Please refer to the Trial Lens Guide above.

Determine and refine cylinder axis

The following descriptions are for plus cylinders. Adjust accordingly for minus cylinder refraction.

- Ask the subject to look at a letter on a line of Chart R which is one line larger than the smallest line he/she could read (one above threshold);
- **If no cylinder** is present in the beginning approximate refraction, place the +/- 1.00 diopter cross-cylinder with the positive axis first at 90° and then at 180°, asking if either position makes the letters clearer;
- If the patient prefers either of these positions, place a +1.00 cylindrical lens in the trial frame at the preferred axis;
- If the patient did not prefer cylinder at axis 90° or 180°, position the cross cylinder with the positive axis first at 45° then 135°;
- Ask if the patient prefers either of these positions;
- If so, place a +1.00 cylinder lens in the trial frame at the preferred axis;
- If the subject prefers none of the four positions, no further cylinder testing is required.
- **If cylinder is present** in the beginning approximate refraction **or if you have added +1.00 cylinder power in the above step**, position the +/- 1.00 diopter cross-cylinder first with the positive axis 45° to the right of the cylinder axis (position one), and secondly with the positive axis at 45° to the left of the cylinder axis (position two). Ask the subject which position improves the vision (position one or position two?);
- If the subject responds that neither position is better and if this was the first test of axis position, move the axis of the cylinder in the trial frame 15° to the right or left and repeat;
- If the subject prefers one position to the other, rotate the cylinder toward the preferred positive axis of the cross-cylinder in the step sizes recommended (see table below) and repeat. (If the subject states that one position of the cross-cylinder is no better than the other position, proceed to refining cylinder power).

Table: Axis step sizes for refinement of cylinder

Cylinder Power	Axis Step Sizes
< 1.00 D	10°
1.00 to < 2.00 D	5°
2.00 to < 3.00 D	3°
3.00 to < 5.00 D	2°
5.00 to < 8.00 D	1°

Refine cylinder power

- Ask the subject to look at the lowest line on the visual acuity chart which can be read;
- Align the ± 1.00 diopter cross-cylinder first with the positive axis and then with the negative axis coincident with the cylinder axis. Ask the subject which is better;
- If the subject prefers the negative axis coincident with the cylinder axis, decrease the power of the cylinder in the trial frame by 1.00 diopter;
- If a subject indicates a change that would introduce negative cylinder power,

remove all cylinder power and continue testing for positive cylinder power at an axis 90° away from the previous axis;

- If the subject prefers the positive axis coincident with the cylinder axis, increase the power of the trial frame by +1.00 diopter and retest;
- Beginning with cylinders of 1.00 diopter or more, for each 0.5 diopter change in cylinder power, adjust the sphere by 0.25 diopter of the opposite sign, this is done to maintain the spherical equivalent.

Spherical refinement

End the refraction by performing the spherical refinement step.

- With the subject looking at the smallest line legible on the visual acuity chart, place a +1.00 spherical lens in front of the eye being tested. Ask the subject, “Is vision better, worse, or the same?”
- If the subject responds that vision is made better or if there is no change, replace the spherical lens with one that is +1.00 more plus;
- Continue to check with the +1.00 lens to see if the subject will accept more plus by repeating the step above;
- When an additional +1.00 lens makes the subject’s vision worse, remove the +1.00 lens
- Then hold a -1.00 spherical lens over the eye;
- If this -1.00 lens improves the subject’s vision, even by one letter, replace the spherical lens in the trial frame by one that is -1.00 more minus;
- Continue presenting the -1.00 lens to see if there is further improvement in vision;
- When an additional -1.00 lens does not improve vision;
- Present the +1.00 lens, again asking “if vision is better, worse or the same?”
- If patient responds that vision is better or the same, repeat spherical refinement testing as detailed above;
- If patient responds that vision is worse, testing is complete.
- **Remember to always to end the refraction by checking with plus power.**

Record the lens correction obtained during manifest refraction for the right eye on the appropriate examination forms in the section for visual acuity measurements (Section A.5). Then proceed to refraction of the left eye, following steps as outlined above.

5.2.2.B Visual acuity procedure

Visual acuity measurement is necessary for a secondary outcome in this trial. Therefore, we have created a standardized method that aims to minimize any bias from either the refractionist or the patient. This has been adapted from the Visual Acuity protocols from the Age Related Eye Disease Study (AREDS 1999)³², and the Aravind Eye Hospital’s Practical Guide to Refraction³³ and is similar to the method we are currently using at Aravind Eye Hospital and Proctor/UCSF for the NEI funded Steroids for Corneal Ulcers Trial and the Mycotic Ulcer Treatment Trials.

Visual Acuity Charts

The following equipment is used: a set of three charts, which are modified Bailey-Lovie charts, Charts 1, 2 and R (Precision Vision Chart 2305, 2305a and 2305b, respectively). Each chart consists of 14 lines of high-contrast “tumbling E’s”. There is a geometric progression of letter size (and, thus, an arithmetic progression of the logarithm of minimum angle of resolution) from line to line.

Chart 1 is for measuring aided visual acuity of the right eye and Chart 2 is to be used for

measuring aided visual acuity of the left eye at all visits. Chart R will be used for obtaining all manifest subjective refractions.

Visual Acuity Boxes

The dimensions of the light box are 24 and 3/4 inches (62.9 cm) by 25 and 3/4 inches (65.4 cm) by 7 inches (17.8 cm). The box can be mounted on a wall or on a cylindrical stand. The stand is mounted on a five-pronged wheelbase, with each prong about 14 inches (35.6 cm) long; two of the five wheels are lockable. When the box is mounted on the stand, its height can be varied. The light box should be mounted at a height such that the top of the third row of letters (0.8 logMAR, 45 letters, 20/125 Snellen) is 49 +/- 2 inches (124.5 +/-5.1 cm) from the floor. The rear of the box provides storage space for the two charts not being used.

Illumination

The overhead room lights should be turned **off** during the visual acuity test. The box itself provides sufficient illumination for the examiner to record the test results. Additional light can have an adverse effect such as glare. With the box light off, not more than 15 foot-candles of light should fall on the center of the chart. The visual acuity light box is equipped with two **20-watt** fluorescent tubes. Because the illumination of fluorescent tubes diminishes by 5 percent during the first 100 hours and by another 5 percent during the next 2,000 hours, new tubes should be kept "on" for about 4 days (approximately 96 hours, does not have to be continuous) before use. All tubes should be replaced once a year.

Each tube is partially covered by a 14-inch (35.6 cm) fenestrated sleeve, open in the back, which serves as a baffle to reduce illumination. Each sleeve should be centered on the tube such that an equal length of tube (about 4 and 3/16 inches or 10.6 cm) is left uncovered to the right and left of the sleeve.

4- and 1-Meter Visual Acuity Lanes

A distance of 4 meters (13 feet and 1.5 inches, or 157.5 inches) is required between the subject's eyes and the visual acuity chart for the 4-meter test, and a distance of 1 meter (39 and 3/8 inches) is required for the 1-meter test. The room for visual acuity testing must have, in addition to the 4-meter lane, space for the visual acuity box (and possibly a stand) and space for the subject.

- Wall-mounted box: In addition to the 4-meter lane, 7 inches (17.8 cm) must be allowed for the depth of the box plus space for the subject to sit or stand.
- Stand-mounted box: In addition to the 4-meter lane, 13 inches (33 cm) must be allowed for two of the stand's casters to touch the rear wall (or a line marked on the floor when there is no wall) plus space for the subject to sit or stand.

Marking the Distance

4 Meters

- If the chair and visual acuity box are permanently affixed, distance measurements need to be made only once and no floor marks are needed to ensure the correct distance.
- If the box is mounted on the wall but the subject's chair is not permanently affixed, the 4-meter distance of the subject's eye from the chart must be marked clearly and permanently.

- If the box is mounted on a movable stand, the 4-meter distance must be marked clearly and permanently. The location and orientation of the box must be rechecked each time a new chart is put in place or the box is touched. When the stand touches the rear wall of the room, two of the five casters should touch the wall.

1 Meter

- The 1-meter distance is measured from the eye of the subject, who is seated comfortably in a chair with his or her back firmly placed against the chair's back, to the center of the second (for testing the left eye) or fourth letter (for testing the right eye) of the third line of the chart. A stick, one meter long, should be used to confirm the distance for each subject.

Visual Acuity Procedure

- Visual acuity will be measured at each study visit.
- Visual acuity should be measured for each eye AFTER refraction. Visual acuity should NOT be recorded during the refraction procedure.
- It is very important that the examiner is not aware of the patient's clinical records, in order to minimize bias. Therefore, the visual acuity examiner will not have access to the patient's previous clinical examination or treatment results.
- Visual acuity is tested separately for each eye (one eye at a time). The patient's untested eye will be completely covered with a patch, to block out all light from entering this eye. The examiner must constantly ensure that this eye remains occluded at all times.
- The patient is instructed to read each letter on the chart starting with the largest line, at the 4-meter distance.
- The patient will show the orientation of the tumbling "E" with the hand that they are not using to occlude the untested eye. If the patient cannot identify the orientation of a letter, they are encouraged to guess. **Only one response is allowed per letter.**
- The examiner must ensure that the patient does not squint (creating a pin-hole effect) or lean forward (reducing the distance to the chart).
- Once a patient has given a response for a letter and has moved on to provide a response for the next letter, any corrections of previous response will not be accepted.
- However, if the patient has given a response for a letter and has not yet moved on to provide a response for the next letter, a correction of the previous response is accepted.
- If the subject gives two possible responses for a letter, tell the patient to commit to one answer. **The examiner CANNOT, at any time, give the patient any indication as to whether a response is correct or incorrect.**
- If 3 or fewer letters are identified correctly on any row from Row 3 or below, STOP testing on that row.
- In the case that the patient reads less than 10 letters at 4 meters, move the patient or the chart so that there is a distance between the two of 1 meter.
- Visual acuity will then be retested at this 1 meter distance.
- Only the first 6 rows of letters need to be read at 1 meter.
- If less than 10 letters are read at 1 meter, then the examiner must proceed to Low Vision Testing, starting with Count Fingers testing. If the patient does not adequately Count Fingers (see below), proceed to Hand Motion. If the patient does not adequately recognize Hand Motion (see below), then proceed to Light

Perception.

Testing of Count Fingers Vision

In testing for count fingers vision, the examiner's hand presenting 1, 2, or 5 fingers is held steady at a distance of 1 meter directly in front of the eye being examined. The fellow eye is completely occluded with a patch. Refractive correction should not be used. A light should be shown directly on the hand from behind the subject and room lights should be turned on. The examiner's fingers should be presented in random order and repeated 5 times. Eccentric viewing should be encouraged. If the subject correctly identifies three of the five presentations, then count fingers vision is noted. If not, then the subject must be tested for hand motion vision.

Testing of Hand Motion Vision

The examiner's hand with all fingers spread out should be extended $\frac{1}{2}$ meter directly in front of the eye being examined. The fellow eye should be occluded with a patch. Refractive correction should not be used. A light should be shone directly on the hand from behind the subject and room lights should be turned on. The examiner's hand should be moved in an up-and-down direction (vertically) or in a side-to-side direction (horizontally) at a constant speed of approximately one back and forth presentation per second. The subject is instructed that the examiner's hand will be presented and they will have to respond to the question: "What am I doing with my hand?" This should be repeated five times. Four out of five correct responses indicate that hand motion vision is present. If the subject does not correctly identify four out of five, then you must test for light perception.

Testing for Light Perception

The indirect ophthalmoscope is used as the light source for testing light perception. Room lights should be off. The opposite eye must be completely patched. No correction should be used. From a distance of $\frac{1}{2}$ meter with the light source turned up to maximum intensity, the light from the indirect ophthalmoscope is directed into the subject's eye four times. The subject is asked to respond when the light is "on". Light Perception is recorded if the examiner is convinced the subject sees the light. Otherwise, the vision should be recorded as "No Light Perception".

Scoring Best Corrected Visual Acuity

On the Visual Acuity Forms, the examiner will circle all letters read correctly. Letters read incorrectly or not read at all will be left unmarked. At the end of each row of letters, the examiner will write down the total number of letters read correctly on the line provided. If visual acuity was not tested at 1 meter, the examiner will indicate this on the form.

After each measurement of visual acuity, the biostatistician will calculate the score for the visit. The visual acuity score is defined as follows:

- If 10 or more letters of the first line are read correctly at 4 meters, the 4 meter visual acuity score is equal to the number of letters read correctly at 4 meters plus 30.
- If 3 or fewer letters of the largest line are read correctly at 4 meters, the visual acuity score is equal to the number of letters read correctly at 1 meter.
- If 3 or fewer letters are read at 1 meter, then low vision testing must be

performed. (This result, count fingers, hand motion, light perception, or no light perception, will be used for the analysis by converting into a logMAR score according to Visual Acuity Calculation Table).

The highest attainable 4-meter visual acuity score is 100.

The Snellen equivalent, defined as the Snellen ratio corresponding to the most difficult line for which the subject read at least 4 of 5 letters correctly, will also be entered by the examiner on the 4-meter Visual Acuity Form (Section A.5).

The data entry staff will enter the number correct on each row at 4 meters, and if applicable, 1 meter and low vision testing results (They will not enter which letters the examiner circled, i.e., which letters the patient identified correctly.). Coordinating center personnel will double check the data entered by the examiner and data entry staff.

5.2.3.B Visual acuity training and certification

The goal of the certification process is to standardize methodology for refraction and visual acuity measurement. All visual function examinations must be performed by study-certified technicians. The principal investigator at each site is responsible for ensuring that the appropriate personnel are identified, trained and certified. A qualified visual function examiner (SL) from the Clinical Coordinating Center (Proctor Foundation) will certify the rooms and technicians at each site.

Technicians are expected to perform the refraction and visual acuity tests on at least one and possibly more non-study subjects according to protocol requirements. The examiner will determine whether or not the candidate executes the study protocol accurately for each procedure. A checklist (Visual Acuity/Refraction Certification Form, Section B.1) containing required procedures will be used to facilitate this process.

Room certification will be performed and recorded (Room Certification Form, section B.2) to ensure that all study rooms meet illumination, equipment, and distance requirements. Logs should be kept to document dates of light box bulb replacement.

Certification is valid for a period 18 months (\pm 2 months) from the date of certification. The process should begin as soon as possible, as technicians must be certified before the first study subject is seen. **A minimum of two certified technicians** are required at each site. The visual acuity measurement schedule may be found on the Study Forms Completion Schedule.


5.3. Ophthalmic procedures

5.3.1. Grading Cataracts

The study ophthalmologist will grade cataracts at every clinical exam based on the Age-Related Eye Disease Study (AREDS) clinical lens grading system (Chew et al., 2010). Pupils must be dilated maximally and lenses should be examined at the slit lamp for the presence and severity of three types of opacity: nuclear, cortical and posterior subcapsular. For each type of opacity, the examiner should compare the lens being examined with the AREDS 2008 Clinical lens opacity standard photographs, of increasing severity. In each series, "1" indicates clinical presence, "2" indicates clinical significance, and "3" indicates severe occurrence. Half grades may be given, for example if a nuclear opacity was thought to be half way between the first and second standard photographs, a decimalized grade of "1.5" could be assigned.

The study ophthalmologists will refer to laminated photos of the scale in real time when making the clinical assessment. If no cataract is present, he/she will indicate this on the clinical exam form.

The following categories of severity are present for all types of opacity (nuclear, cortical and posterior subcapsular): <1, 1, 1.5, 2, 2.5, >3.



*Clinical grading adapted from: Chew EY, KIM J, Sperduto RD et al. Evaluation of the Age-Related Eye Disease Study Clinical Lens Grading System AREDS Report No. 31. Ophthalmology 2010; 11; 2112-2119.

5.3.2. Grading inflammation

Slit lamp examination and dilated fundusoscopic exam are important parts of our study: assessments of anterior chamber cells and vitreous haze will determine the patient’s course of treatment. All of our study physicians are fellowship-trained uveitis specialists who have participated in prior uveitis studies.

The study ophthalmologist at each site will be required to perform an eye examination at each study visit. This examination should be similar to that performed in the routine care of uveitis patients. Several components will be assessed in detail per study protocol. The grading schemes to be used for these assessments are adapted from the Standardization of Uveitis Nomenclature (SUN) Working Group.²

Anterior Chamber Cells

SUN Working Group Grading Scheme for Anterior Chamber Cells

Grade	Cells in Field*
0	<1
0.5+	1-5
1+	6-15
2+	16-25
3+	26-50
4+	>50

*Field size is a 1mm by 1mm slit lamp beam. Grading should be done with the highest magnification and illumination and conducted in a completely dark room, prior to dilation.

Anterior Chamber Flare

Anterior Chamber Flare will be assessed by slit lamp exam but will not be part of our study criteria for controlled inflammation.

SUN Working Group Grading Scheme for Anterior Chamber Flare

Grade	Description
0	None
1+	Faint
2+	Moderate (iris and lens details clear)
3+	Marked (iris and lens details hazy)
4+	Intense (fibrin or plastic aqueous)

*Adapted from: Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis: I. Anterior Uveitis. AM J Ophthal 1964;47:155-170; Grading should be conducted in a completely dark room

Vitreous Cells

There is currently no accepted standard for grading vitreous cells, which will not be part of our study criteria for controlled inflammation. However, we will collect this information using the grading scheme below, which is adapted from the MUST trial:

Grade	Cells in Field*
0	No cells
0.5+	0 to 5 cells
1+	6-10 cells
2+	11-20 cells
3+	21-50 cells
4+	>50

*Field size is a 1mm by 0.5mm beam; Grading should be conducted in a completely dark room; These cells are graded by slit lamp exam after dilation.

Vitreous Haze

Vitreous haze will be assessed using an indirect ophthalmoscope set at mid-power and a 20D lens. Fundus examination will be done with the last view being the area around the optic disc. The examiner should then compare this view to the photograph (Figure 1) and determine the level of vitreous haze. The National Eye Institute System for grading vitreous haze will be used for all primary and secondary outcome measures. Additionally, vitreous haze will be assessed separately on the 9-point grading scale recently published by Davis et al., known as the Miami scale. The examiner should compare the vitreous haze view with the Miami photograph. An exploratory analysis will correlate measurements from the NEI and Miami scales. Clinical measurements of vitreous haze will also be compared to objective assessments done by grading of fundus photos by the reading center.

If the physician thinks that the grading of vitreous haze is affected by a significant media opacity (i.e. a dense/mature cataract) they should indicate on the Clinical Exam Form that they cannot make a reliable judgment of vitreous haze due to the opacity.


Figure 1: National Eye Institute system for grading vitreous haze

Grade	Description
0	Clear
0.5+	Slight blurring of optic disc margin Normal striations and reflex of nerve fiber layer cannot be visualized
1+	Opacities without obscuration of retinal details
2+	Few opacities resulting in mild blurring of details of optic nerve and retinal vessels
3+	Optic nerve head and retinal vessels significantly blurred but still visible
4+	Dense opacity obscuring optic nerve head

*Grading should be conducted in a completely dark room; From Nussenblatt et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92:467-471.



Figure 2: Miami 9-point system for grading vitreous haze



Miami Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol;150:637-641 e1.

Grading Retinal/Choroidal Inflammation

Assessment of active inflammation of the retina and choroid should be based on the clinical exam and ancillary testing if needed for certain diseases (i.e. fluorescein angiogram, fundus photography, B-scan ultrasound). Please refer to the table in Appendix F for imaging required for assessing uveitis activity by disease.

Active vasculitis posterior to the equator qualifies as active inflammation, but according to SUN criteria should be confirmed with a fluorescein angiogram. Macular edema in isolation is not sufficient to qualify as active inflammation, but a bullous serous retinal detachment, with any amount of accompanying vitreous, retinal or choroidal inflammation would qualify as an active inflammation. In addition, per protocol, if patients have $\geq 1+$ anterior chamber inflammation, vitreous haze and/or other retinal/choroidal lesions aside from macular edema, that would qualify as active as well.

5.3.3. Inter-observer variation of ocular inflammation

At Baseline (Phase I and Phase II) the 6th month study visit (Phase I and Phase II), the 12th month study visit (Phase I), or at treatment failure (whichever is earlier), inter-observer agreement on slit lamp observations and funduscopic exam will be assessed. Coordinators will arrange for two certified study physicians to measure anterior chamber cells, anterior chamber flare, vitreous cells, vitreous haze, and retinal/choroidal lesions at the Month 6 and 12 visit or at declaration of treatment failure. The inter-observer variation will be reported. The primary study ophthalmologist's measurements will be used for primary analysis.

5.3.4. Training and certification of ophthalmologists and study coordinators

All exams must be performed by uveitis specialists. The study protocol and classification system for grading inflammation will be reviewed by Dr. Acharya (or another study ophthalmologist from Proctor Foundation) with the investigators at all sites. An open-book exam on the study protocol will be administered, and a score of 80% is needed for

certification to participate in the trial. For investigators with scores less than 80%, additional instruction and a re-test will be done. Prior to study start, each site investigator will grade inflammation on 5 uveitis patients and scores will be compared to the Proctor investigator's scores. If a discrepancy of greater than 1 grade in any of the measurements occurs, then additional patients will be graded until there are 5 consecutive patients where the grade is within 1 level for each of the measurements (i.e. anterior chamber cells, vitreous haze, and retinal/choroidal lesions). If both graders assess each area to have 0 inflammation in a particular patient, that patient would not count towards the 5 patients needed to complete the training. This grading assessment will be done prior to initiation of the trial and yearly thereafter. Duplicate measurements of inflammation will also be collected at the 6 and/or 12-month study visits. Inter-observer agreement will be reported.

The study protocol will be reviewed with all study coordinators by coordinating center personnel. An open-book exam on the study protocol will be administered, and a score of 80% is needed for certification to participate in the trial. For coordinators with scores less than 80%, additional instruction and a re-test will be done.

5.4. Optical coherence tomography

We will be using spectral-domain optical coherence tomography (SD-OCT) in this study to monitor the effects of treatment by measuring macular thickness and changes in macular thickness. We will be utilizing the Heidelberg Spectralis SD-OCT unit for all study assessments. Each site must have access to the Heidelberg Spectralis unit at the time of study initiation and must continue to use that same scanner for all patients for the duration of the study. If Heidelberg Spectralis is not available, the Zeiss Cirrus SD-OCT may be used.

5.4.1. Required patient assessments—Heidelberg Spectralis

For our study, one of each of the following scans is required for each eye:

- **20° x 20° High Speed Volume scan centered on the macula**
 - 20° x 20°
 - 49 sections
 - 16 frames (ART)
- **7-Lines scan centered on the macula**
 - 30° x 5°
 - 7 sections
 - 25 frames (ART)

5.4.2. Scan procedures—Heidelberg Spectralis

Procedures for Obtaining Scans

General Guidelines

- Scans may be obtained if the patient's pupils are not dilated. However, pupil dilation prior to obtaining scans is encouraged
- Clean chin rest and forehead rests
- Adjust table and chin rest height to ensure patient comfort
- Make sure that patient is aligned straight; slight face turns to the left or right may decrease scan quality

Click on the Preset “**Dense**” scan icon on the screen to obtain the 20° x 20° volume scan. Please make sure that the scan will have the following parameters:

- 20° x 20°
 - 49 sections
 - 16 frames (ART)
- Pull the camera all the way back
 - Move the instrument toward the patient slowly, taking care not to alarm patient and to not touch the patient’s eyes or eyelashes with the instrument
 - Ask patient to fixate on the blue light on the inside of the machine
 - Remind patient not to follow the movement of the red scan lines
 - If patient is having trouble focusing on fixation light, you may need to help the patient direct his/her gaze by using external fixation targets
 - Focus in on the circular black and white retinal reflex
 - Move the camera forward so that the fundus image comes into view and fills the screen
 - Use the focusing knob to obtain maximum brightness and clarity of the image
 - Ensure that the image is maintained in the **upper third** of the screen
 - Click “Acquire”
 - Repeat for next eye

Click on the “**7 Lines**” Preset Scan icon

This scan will have the following parameters:

- 30° x 5°
 - 7 sections
 - 25 frames (ART)
- Focus image as described above
 - Click “Acquire”
 - Repeat for next eye
 - **Please review scans for completeness and quality. A good quality scan should have a score of at least 20. Please repeat any scans that are not complete or of poor quality.**

5.4.3. Obtaining retinal thickness data—Heidelberg Spectralis

- After closing the acquisition window, double click on the volume scan.
- Select “Thickness Map” tab
- Record central subfield thickness of each eye on data sheet
- Print out copy of scan for patient file

Be sure to complete analysis of data and record information on data collection form as soon as possible. This will ensure that the treating physician will be able to use the SD-OCT results in real time to determine if macular edema is present or not.

5.4.4. Saving/Exporting data—Heidelberg Spectralis

Saving Data

- All scans should be saved and archived at each study site on the Heidelberg SD-OCT unit.
- Even if your clinic saves all scans onto a server, please follow the instructions

below to save all scans for FAST study patients onto an external hard drive.

- After obtaining scans, highlight all study scans together, right click and choose “Export as E2E”
- Click on the “Anonymize data” box in order to ensure patient confidentiality
- In the “Export File” field: Name the E2E file as “Patient Study ID-Visit Number-Date of visit”, example “2H003-M6-17NOV2014”
- In the “Last Name” field: Type in the Patient’s Study ID and Visit, example “2H003 M6”

The screenshot shows the 'Export Options' dialog box. The 'Destination' section has an 'Export file' field containing 'D:\2H003 M6 17NOV2014.E2E' and a 'Browse...' button. Below it is a checkbox for 'Use file name prefix' which is unchecked. The 'Patient' section contains fields for 'Last name' (2H003 M6), 'First name' (56664149), 'Patient ID' (56664149), and 'Date of birth' (10/05/1993). A checkbox for 'Anonymize data' is checked, with a black arrow pointing to it from the right. Below this are two sections: 'Last Name' with radio buttons for 'Fixed' (selected) and 'PatientID', and 'First Name' with radio buttons for 'PatientID' (selected) and 'First letter only'. The 'Location' section has an 'Institute' field with the text 'ops'. At the bottom are 'OK' and 'Cancel' buttons.

- Save the “E2E” data onto a removable hard drive separate from the main unit; this raw data may be requested from each site at a later date.
- Please ensure that your removable storage drive(s) is/are HIPAA compliant as defined by your institution

Exporting E2E Data to Reading Center

- Create a folder on the desktop and/or on a removable drive for each patient visit: Label this new folder with “Study-SiteID-Patient Study ID-Visit Number- Date of visit”, example: “FAST-UCSF-2Q001-M1-10AUG2012”
- Place the E2E file into the folder
- Complete a “FAST Study Transmittal Form” (electronic copy or scan completed paper form) and add into the created folder
 - In the “Clinic ID” field of the Transmittal Form, please enter the 4-letter code for your clinic. Contact coordinating center if you have any questions regarding your Clinic ID code.

- If images cannot be obtained or are of poor quality, please provide comments on the Transmittal Form
- Compress the folder into “ZIP” format.
- Upload the ZIP folder to the Uveitis Reading Center server:
 - Username: [REDACTED]
 - Password: [REDACTED]

5.4.5. Required patient assessments—Zeiss Cirrus

For our study, one of each of the following scans is required for each eye:

- **Macular Cube Scan**
- **5 Line Raster scan centered on the macula**

5.4.6. Scan procedures—Zeiss Cirrus

Creating Patient Files

To ensure patient confidentiality, patient ID only will be used. Patient name and other identifying information will not be used on the scans. Therefore, when setting up the patient file, please follow the instructions below:

- In the Last Name field, enter study name: FAST
- In the First Name field, enter patient’s unique study number
- For Date of Birth, always use 1/1/2000
- Click proper field in gender section
- In Patient ID field enter patient’s unique study ID number, example: “1Q001”

Procedures for Obtaining Scans

General Guidelines

- Scans may be obtained if the patient’s pupils are not dilated. However, pupil dilation prior to obtaining scans is encouraged
- Clean chin rest and forehead rests
- Adjust table and chin rest height to ensure patient comfort
- Make sure that patient is aligned straight; slight face turns to the left or right may decrease scan quality
- Ensure that the camera is pulled all the way back
- Move the instrument toward the patient slowly, taking care not to alarm patient and to not touch the patient’s eyes or eyelashes with the instrument

Select “**Scan Macular Cube 512x218 HD**” default in the upper panel of the Acquire screen

- In the Iris Viewport, center the scan beam through the pupil by clicking on the pupil center or using the X-Y controls
- Focus the iris image using the chinrest arrows
- Center the fundus image in the Fundus Viewport
- Click on “Auto Focus”
- Use small arrows to focus manually
- Click “Optimize”
- Ask patient to blink right before image capture
- Click “Capture”
- Review scan; if acceptable, click “Save”

- If not acceptable, click “Try Again”

Repeat above steps to acquire “5 Line Raster HD” default Scan

- If patient is having trouble focusing on fixation light, you may need to help the patient direct his/her gaze by using external fixation targets
- Ensure that the scan image is maintained in the **upper half** of the screen
- Please review scans for completeness and quality. Signal strength should be at least 5 or higher. Please repeat any scans that are not complete or of poor quality.

5.4.7. Obtaining retinal thickness data—Zeiss Cirrus

- Obtain Macular Thickness analysis
- Obtain 5 Line Raster analysis
- Record central subfield thickness on data sheet

Be sure to complete analysis of data and record information on data collection form as soon as possible. This will ensure that the treating physician will be able to use the SD-OCT results in real time to determine if macular edema is present or not.

5.4.8. Saving/Exporting data—Zeiss Cirrus

- All scans should be saved and archived at each study site on the Zeiss Cirrus SD-OCT unit. This raw data should also be saved onto a separate removable hard drive so that it is available for export and review at a later date.
- The following images should be uploaded to the server of the Uveitis Reading Center for review.
 - Under *Records* select *Export Exams*
 - Browse to folder where to save files
 - Search for the subject to export
 - Under *Exam Export* select the *Eye(s)* and *Exam Type* for the visit you want to export
 - Select *Export*
 - Label the file with patient’s unique study ID, visit number, and date of visit, example: “FAST_1Q001_BL_10AUG2012_IB”
 - Fill out transmittal form
 - Compress the folder containing the image files for both eyes and the Transmittal form in ZIP format
- Upload the ZIP folder to the Uveitis Reading Center server:
 - Username: [REDACTED]
 - Password: [REDACTED]

5.4.9. OCT operator qualifications

Prior to the study start date, at least 2 personnel who will be responsible for obtaining SD-OCT scans at each site should be identified. These individuals should have prior experience with operation of either the Heidelberg SD-OCT or Zeiss Cirrus SD-OCT instrument for routine clinic purposes. Personnel from the coordinating center will go to each

site before that start of the trial to meet with these technicians to review all required OCT procedures specified in our protocol. OCT operators must be able to demonstrate ability to obtain quality scans as well as knowledge of the study protocol.

5.5. Fundus Photography

Color fundus photography will be performed at baseline, 6 months, 12 months or treatment failure. Photos will include fundus reflex images and non-stereoscopic fundus images. Images should be uploaded to: <http://eyehealthusf.org/upload/index.php> according to instructions in UPRC manual.

Vitreous haze will be graded according to the NEI and Miami scales by masked graders. Photographers will need to be certified by the Uveitis Photograph Reading Center prior to obtaining photos for our study. Please see UPRC manual (Appendix E) for instructions on certification and obtaining study photos.

5.6. Laboratory measurements

Hematology and serum chemistry will be monitored in all patients prior to enrollment and throughout participation in the study. Each of the participating sites has an accredited onsite laboratory where all blood draws and laboratory measurements will be performed. The following will be measured and recorded on the Laboratory Report Form (Section A.8) for each:

Hematology

- Hemoglobin and/or hematocrit
- Platelet count
- White blood cell count (WBC)
 - % neutrophils; % lymphocytes
 - CD4 lymphocyte count (*UCSF, AEH, KKESH sites only, at Baseline, Month 3, 6, & 12*)

Serum Chemistry

- SGOT (AST)
- SGPT (ALT)
- Creatinine
- Serum or urine pregnancy test

Laboratory measurements used for baseline visits should be collected 4 weeks prior to enrollment. Those used for follow-up visits may be collected at any time within the study visit window. Laboratory measurements must be collected at each study visit.

All abnormal values will be reported on the Adverse Event Checklist (Section A.10) and monitored for resolution on the Adverse Event Log. Abnormalities which result in a non-serious adverse event (i.e. AST or ALT increasing to twice the upper limit of normal) will result in immediate stopping of study medications. As these abnormalities are often reversible, patients will be allowed one month to regain eligibility. If the lab results have returned to normal within one month, patients may be re-administered the study drug according to protocol. Labs can be checked prior to one month, and if normal, treatment can resume. Otherwise, treatment failure will be declared and patients may be treated according to best medical judgment of physician. They should still be followed for their 6th months visit and be treated according to the best medical judgment of their physician.

Laboratory abnormalities which meet the designated threshold of a severe adverse event (SAE) will result in immediate stopping of study medications, and should be reported on the Serious Adverse Event Narrative form (Section A.12). Treatment failure will be declared, and patients will be treated according to the best medical judgment of their physician, but still follow-up for 6 months. If a lab SAE occurs, patients will not switch to Phase II.

6. Adverse events

6.1. Non-serious adverse event (AE) *see the adverse event checklist (Section A.10)

Non-serious adverse events may include any unfavorable medical occurrences in patients who have ever received study medication, regardless of any causal relationship with treatment. Examples may include*:

- Increased intraocular pressure (>24 mm Hg)
- Abnormal lab findings (≥ 2 times but < 5 times the upper limit of normal AST or ALT, rise in creatinine to ≥ 1.5 to < 2 mg/dL, reduction of white blood cell count to below 2.5)
- Concurrent accident or illness
- Increase in the frequency and severity of symptoms of a pre-existing condition
- Side effects such as gastrointestinal upset, nausea, vomiting, fatigue

6.2. Serious adverse event (SAE) *see the adverse event checklist (Section A.10)

Serious adverse events include any medical occurrence that results in the following outcomes, or any other adverse event classified as severe*:

- ≥ 5 times the upper limit of normal AST or ALT
- Death
- Non-elective surgery or hospitalization for any reason
- Myocardial infarction or stroke
- Life-threatening adverse drug experience or any life threatening event
- Persistent or significant disability or incapacity
- Cancer
- Seizure
- Congenital anomaly/birth defect
- Disability or permanent damage
- Required intervention to prevent permanent impairment/damage

6.3. Adverse event reporting

Non-serious and serious adverse events will be recorded at each study visit on the appropriate form (Adverse Event Checklist and Log, Sections A.10-A.11). An adverse event log will be maintained for each patient to record the onset and resolution of any adverse events. The Adverse Event Checklist will initially be completed by the study coordinator while meeting with the patient at the beginning of each study visit. If there are any reported symptoms (not only severe symptoms), the study physician will review them with the patient while remaining masked to determine if any action is needed.

In case of a Serious Adverse Event (SAE), the Serious Adverse Event Narrative Form (Section A.12) will be completed by the Investigator and submitted to the Medical Monitor, Dr. Jeremy Keenan [REDACTED], Principal Investigator Dr. Nisha Acharya [REDACTED] and the Coordinating Center Manager [REDACTED] within 24 hours of the SAE. Information recorded on this form will include the nature of the

event, date of onset, date of resolution, date of notification to Medical Monitor, and action taken. The Medical Monitor will review, sign, decide if the serious adverse event was related to the study drug, and collect additional information if needed.

If any serious adverse event other than a laboratory abnormality occurs, treatment failure cannot be declared until the Medical Monitor judges that the SAE is related to the study drug. This will require the investigator notifying the Medical Monitor about the event, and the Medical Monitor contacting the investigator regarding his determination. The Medical Monitor will determine two things: 1) whether this is a true treatment failure because the SAE is likely related to the study drug, and 2) whether it is safe to switch the patient to Phase II. If it is not safe to switch the patient will be treated with best medical judgment and still be followed for 6 months.

If the investigator thinks the SAE is related to the study drug, he/she can stop the study medication anytime (including prior to determination of treatment failure by the medical monitor). If the investigator thinks treatment failure is likely (prior to hearing from the Medical Monitor) they should obtain all study assessments, which would be collected at a treatment failure visit. However, the investigator will wait to complete the Treatment Assessment Form and officially declare treatment failure, until they are instructed to do so by the Medical Monitor.

Any significant study drug-related adverse events will be reported by the coordinating center to the FDA and CHR office as appropriate. The principal statistician will inform the DSMC of serious adverse events by arm every six months.

6.4. Patient death

Any patient death that occurs during the study will be reported by the study center's Study Coordinator to the Medical Monitor within 24 hours. The study arm of any deceased patient will be made available to the DSMC by the DCC if appropriate.

7. Data collection and management

This section discusses how the data will be collected from the different Study Centers, entered into the computer database and stored, and transferred to the Data Analysis Committee under the supervision of the Data Coordinating Center (DCC). The data management plan described below is similar to what we are already using for our NEI-funded SCUT and MUTT clinical trials, which enroll patients at Proctor/UCSF, and at Aravind Eye Hospital in India. Proctor/UCSF is the clinical and data coordinating center for these trials.

7.1. Data collection forms

The data collection forms are derived from the Steroids for Corneal Ulcers Trial, the Mycotic Ulcer Treatment Trial pilot and main trial, and the FAST pilot trial initiated as a precursor to this proposed study. These forms have been extensively field-tested by UCSF and Aravind investigators.

Study personnel at each site will be given specific training for each form for which they will be responsible. Paper forms for each patient will be completed by study personnel (study physicians, refractionists, etc.) on paper in real time when the patient is being

assessed. Teleconferences and site visits will be held periodically for all users of the forms to review procedures and address questions.

7.2. Data review

Data will be reviewed in real time, as the patient is being assessed. The study coordinator will verify with the personnel filling out the forms that they are complete. Before scanning to be sent to Proctor for data entry, the forms will be reviewed and cross-checked for consistency and completeness by the study coordinator within **24 hours** of completing the form. If the forms are not filled out completely, the study coordinator will contact the person responsible for completing the form to provide the missing data, or clarify any inconsistent data. The study coordinator or investigators who filled out the form are the only people who are authorized to add missing data or make any changes to the study forms. All changes should be made with a red ink pen, and then signed and dated. Further investigation may be conducted if certain fields or personnel are associated with a higher rate of paper form errors.

7.3. Data entry

Once the completed study forms have been reviewed and approved by the study coordinator, the study coordinator will scan and email the forms to the study email address [REDACTED] **within 10 days** of the patient visit. All data will be entered into the official electronic research data capture service at UCSF: REDCap. Each study form will be double entered by two independent data entry operators at Aravind. The data entry manager will merge the entries, checking for any inconsistencies or errors. The goal is for both data entries and data merging to occur within 10 days of receiving the completed forms in order to prevent the accumulation of un-entered forms. The database program contains an entry module for each form, prompting the user to enter the data in the same order as the form and clearly indicating each question.

7.3.1. Data entry errors

The data entry manager will compare double-entered study data using the automated feature in REDCap. Wherever there is a mismatch, an error file will be generated with relevant data such as the form, field name, visit name, and data for which discrepancy is found. The data entry manager will then contact the data entry operators to verify the forms and re-enter the data. Discrepancies and missing values will be assessed by the data entry manager, and resolved by queries sent to the study coordinator and appropriate observers (clinician, refractionist, etc). A logfile will preserve the date and time of any changes, together with who entered the changes.

7.3.2. Data consistency and validity

A database data quality assessment program will be created in R programming software to help prevent inconsistencies or invalid data. The database program will check for the following errors: (1) improper entry of the patient ID based on the checksum, (2) data fields that are out of range, (3) inconsistent or illogical entries, (4) incompleteness, and (5) numerical values that are far outside the range of those previously entered. The software will create an error file with relevant data such as the form identification, field names and the data. Automated checks will be made to ensure consistency and that each variable in the analysis set has in-range values (protecting against negative ages, spelling errors in

categorical factors, and similar errors). The DCC will conduct regular checks of the data at each site and will contact the study coordinator about any errors in order to resolve the inconsistencies and have the data entry operators enter the correct data.

7.3.3. Data preparation and cleaning

Data sets for analysis will be produced in Microsoft Excel® worksheets (downloaded from the REDCap system) containing a single header line whose variable names match the REDCap database. Each analysis set will be in the form of a rectangular table in which each column corresponds to a single variable and each row to an observation. All missing values will be coded explicitly using the string “NA” (as used in the R software). Codes for categorical variables (such as 1 for male, and 2 for female) will be avoided in favor of self-documenting character strings (such as Male, Female) whenever possible.

A detailed codebook will be prepared, containing for each variable, (a) the form from which the variable derived, (b) the text of the question, (c) all possible values for the variable, and (d) summary statistics for the variable. Note that all codes and character strings that represent categorical factors will be clearly defined in the codebook. Units for each continuous variable (e.g. logMAR) will be unambiguously indicated for each variable. Each release of the analysis set will be accompanied by the corresponding version of the codebook. Version numbering with dates will be strictly observed.

7.3.4. Monitoring

We will maintain a record of (1) changes to the initial entries on database forms, and (2) changes made to all entered data. Database errors include (a) missing information, (b) erroneous information that was initially entered, and (c) errors arising from difficulties with the forms themselves. Quality assurance reports will summarize the number of each of these. Most importantly, we will closely monitor the waiting time between the collection of the initial form and the entry of the data. If entry times exceed 30 days, then this will trigger a response, which may include investigation, retraining, and even reassignment.

7.4. Data analysis

Following data checks by the data analyst, the Data Analysis Committee will be responsible for analyzing the data. At designated time points, it will be merged the unmasked data with the randomization list, perform statistical analyses and prepare reports.

Standard report-generation software included with the R statistical and data analysis package will be used to ensure consistency of the codebook and analysis set at all times.

Data monitoring reports will be prepared based on analysis data sets. These will be prepared using report-generation software. Monitoring reports will include (a) recruitment reports for each center, (b) compliance reports, (c) retention reports, and (d) data quality reports. These will be reviewed by the DCC on a monthly basis, and communicated to the study sites on a monthly basis.

7.5. Data storage and security

Paper forms will be maintained in locked file cabinets in locked rooms only accessible to research staff at each study site. All PDFs of forms will be sent to the study coordinator at

Proctor. They should be sent through a secure email and saved on a secure server.

All electronic storage will be subject to standard security procedures in compliance with established enterprise information security standards. Each computer will be hardware-firewalled and will not be accessible outside the Local Area Network. Hard-disk encryption will be used for each machine, and the machine will not be accessible without a network account and password. Only one individual at each site will have password access to the machine; new accounts may be provided by the local network administrator only with the approval of the DCC. Accounts will be immediately deactivated for data entry or other personnel who leave the study. The computer used for data entry and storage will be kept in a physically locked room, and only authorized study personnel will be able to access this machine. All individuals who access the server room will be logged as to time and date. At each center, the complete database (including all data tables as well as change logs) will be backed up weekly on the server and weekly on a CD/DVD, which will be kept at a safe, locked cabinet. Temperature logs will be maintained for the server room and reported.

The database at the DCC will be stored on a SQL server located at 95 Kirkham Street, San Francisco, CA and three sets of backup copies on CD/DVD will be kept. The server is hardware-firewalled and also uses hard-disk encryption; it is inaccessible outside the Proctor network and cannot be physically accessed by anyone other than the network administrator. Other visitors must be accompanied by an information security professional and the visit will be logged. All data will be protected with passwords and the computer/server on which the data is stored and the backup copies on CD/DVD will be located in a lock-secured facility. Each back-up file will be archived offsite. In the event of disruption due to unforeseen circumstances, all materials needed to continue will be available from the offsite archive.

8. Quality control

With the help of the Data Coordinating Center and the Data Analysis Committee, the Clinical Coordinating Center will evaluate the quality of study activities (clinical examination, treatment compliance, refraction, etc.).

8.1. Medication storage and expiry

Study medications will be stored at room temperature. The expiration dates of the treatment kits will be regularly monitored and all expired study medicine will be discarded appropriately.

8.2. Periodic reports

The Study Coordinators will send weekly reports to the clinical coordinating center, on the number of eligible patients screened, the number of patients enrolled, reasons for ineligibility, and the number of patients who have come back for follow-up visits. This will be used to monitor the enrollment/follow-up progress and any protocol violation in enrollment. The CCC will send monthly reports to all investigators with a summary of overall enrollment and breakdown of enrollment at each site.

When a site visit or training/certification is conducted at a study site, a report will be prepared and sent to the Executive Committee.

The minutes of the DSMC meeting will be circulated electronically among the investigators and the members of the DSMC after each meeting.

8.3. Data management, security and quality assurance

See Section 7.

8.4. Monitoring compliance

Patients will be asked to record missed doses in individual treatment calendars and to bring them with their medication to each follow-up visit. The study coordinator will collect details of the number of doses missed by the patient and record these in the medication log. In addition study coordinators will conduct pill counts at each visit.

8.5. Certification

For training and certification process, see Sections 5.2.3.

8.6. Data audits

Samples of data forms will be audited at each site to ensure consistency between the source documents and data entry. Patient charts will also be reviewed two times a year to confirm adherence to the protocol.

9. Duties and responsibilities of staff

9.1. Ophthalmologist

- Note: whenever possible, the primary study ophthalmologist should be the same person across all a patient's study visits, for consistency of measurements
- Responsible for enrolling study subjects
- Provide information for completing the clinical examination forms
- Obtain written consent from the subjects with the help of study coordinator
- Initiate study medication as per the randomization
- Responsible for the care of the patient throughout the course of the study
- Manage adverse events

9.2. Clinical Trial Manager

- Ensure the execution of the study as per the protocol
- Arrange training of the ophthalmic assistants, and refractionists
- Coordinate with the collaborating centers
- Prepare monthly reports regarding recruitment and follow-up progress
- Handle correspondence between centers
- Maintain IRB approval and renewals
- Communicate with central pharmacy regarding drug orders and distribution to sites

9.3. Study Coordinator

- Make sure that appropriate patients are screened and enrolled in to the study (including obtaining appropriate assent/consent)
- Prepare weekly reports regarding recruitment and follow-up progress
- Send reminders to study patients for follow-up visits
- Meet with the patient at each study visit, prior to the study ophthalmologist to help maintain masking

- Assist ophthalmologist, ophthalmic assistants, and refractionists with conforming to study procedures
- Verify data forms for completion and collect missing information
- Send study forms for prompt data entry
- Maintain stock of and dispense study medications

9.4. Data Analyst

- Develop data entry programs specific to the study forms under the supervision of DCC
- Monitor the flow of forms from the coordinator
- Supervise data entry operators for any errors or omissions
- Develop consistency checks
- Communicate with study coordinators and data entry operators to correct any mistakes in study forms and data entry
- Transfer data as and when requested by the DCC
- Back up all data appropriately

9.5. Data Entry Operator

- Enter all data from study forms when submitted by the study coordinator
- Verify inconsistencies in the forms and send them for correction to the study coordinator
- Perform double entry to ensure accurate recording

9.6. Biostatistician (Proctor)

- Review data for quality control purposes
- Prepare reports for DSMC
- Lock database at completion of study after database is cleaned
- Conduct analyses at the conclusion of the study
- Prepare randomization list and distribute the list to a pharmacist and non-masked, senior physicians at the study sites in case of emergency.

9.7. Ophthalmic Assistants

- Obtain patient information
- Measure preliminary vision
- Assist ophthalmologist in the clinical examination/enrollment of the subject
- Counsel and motivate patients to return for scheduled follow-up visits

9.8. Refractionists

- Perform manifest refraction as specified by protocol of both eyes at each visit
- Measure and record best spectacle-corrected visual acuity at each visit
- Enter visual acuity (number of letters read and Snellen equivalent) on the form

9.9. OCT Operators

- Perform OCT photography as specified by protocol of both eyes at all visits

9.10. Fundus Photographers

- Perform fundus photography as specified by protocol of both eyes at the baseline, 6 months, 12 months or treatment failure visits

9.11. The Reading Center

- Complete grading of vitreous haze from images of fundus photography
- Process OCT images

10. Study Organization

10.1. Executive Committee

The Executive Committee will be chaired by Dr. Acharya at the Proctor Foundation and will include Dr. Lietman and Dr. Porco. This committee will act as the administrative and executive arm of the clinical trial and will meet once a month to provide overall oversight for the study and make decisions on day-to-day operational issues. The role of the Executive Committee includes monitoring study progress and data collection process, supervising the Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC) for overall quality control, evaluating and adopting changes in study procedures as necessary, communicating with and implementing recommendations from the Data and Safety Monitoring Committee, making executive decisions on the allocation of resources, establishing policies on publications and authorship, and approving and overseeing ancillary studies.

10.2. Clinical Coordinating Center (CCC)

Dr. Acharya will also be responsible for directing the CCC, located at the Proctor Foundation/UCSF. The responsibility of the CCC includes oversight and coordination of the clinical implementation of the trial at all sites. Specifically, this includes roles such as maintaining an up-to-date manual of operations, obtaining human research approvals from Institutional Review Boards, conducting training and certification of all personnel including physicians and refractionists, supervising preparation and dispensing of study medication, ensuring proper masking, and monitoring protocol adherence and recruitment. The CCC will monitor the recruitment progress with weekly reports from each of the study sites. It will also organize twice yearly site visits to conduct chart reviews, training and certification of study personnel and monthly phone calls with study investigators to review enrollment, retention and any other study-related issues. The coordinating center will be responsible for training/certifying study refractionists and managing the refraction protocol. Dr. Jeremy Keenan will serve as medical monitor of the trial. He will receive all reports of serious adverse events from all study sites, ascertain whether further information is needed, and convey that information to the DSMC. As with our current NEI-funded studies, the study coordinator at Proctor/UCSF will serve as the manager of the coordinating center and will assist with many of the clinical coordination activities listed above and also check in weekly by email with the study coordinators at each site to discuss any study-related issues.

10.3. Uveitis Photograph Reading Center (UPRC)

The Reading Center at University of South Florida, run by Dr. Brian Madow, will receive OCT and fundus photos from all study sites. Grading of OCT and fundus photography will be conducted by trained personnel. They will assess type of macular edema, presence of

epiretinal membrane, and evaluate vitreous haze using the NEI and Miami scale fundus photos. They will also be responsible for monitoring quality of images.

10.4. Data Coordinating Center (DCC)

The DCC including, Dr. Lietman and Dr. Porco, is responsible for supervising data collection, data management, data quality control, data analysis, event adjudication, and training and certification of study site staff in the data management systems. The DCC will also be responsible for coordinating and supporting the activities of the Data Safety Monitoring Committee, including preparing interim and final data reports and organizing meetings with the Data Analysis Committee. The DCC will also be responsible for the dissemination of datasets for use by the Data Analysis Committee and other investigators. The DCC will meet weekly to monitor the progress and quality of data entry/management and address any issues. The DCC will be in close contact with the data analysts and data entry operators to ensure quality assurance of data entry. See MOP for further information on data management (Section 7).

10.5. Data Analysis Center (DAC)

Dr. Porco will direct the Data Analysis Committee with assistance from the data manager. The primary functions of the DAC include designing a statistical analysis plan, preparing and distributing randomization lists, performing data analysis, and coordinating publications and presentations. The Committee is responsible for obtaining data from the Data Coordinating Center, performing unmasked data analyses and for preparing reports for the Data and Safety Monitoring Committee, and at the conclusion of the study, for the Principal Investigator. The DAC will also be responsible for conducting the prespecified interim analysis (when 1/3rd and 2/3^{ds} of the primary outcome data has been collected) and also for providing data to the DSMC to evaluate the stopping guidelines.

10.6. Data Safety and Monitoring Committee (DSMC)

The Data Safety and Monitoring Committee (DSMC) is independent and NEI-appointed, with experts from diverse fields including ethics, biostatistics, epidemiology, ophthalmology, and international health care, and include at least one member of the NEI staff as an ex officio member. The committee will meet for the first time before the study begins. Only after the DSMC reviews and approves the protocol will patients be enrolled. We anticipate the group will meet regularly throughout the study and review information on data quality, enrollment, patient retention, and study outcomes, etc. Committee members will be unmasked and receive reports of the data with ARM information at two interim time-points (when 1/3rd and 2/3^{ds} of the primary outcome has been collected). They will also receive reports of serious adverse events from the principal statistician, every 6 months.

10.7. Editorial Committee

The Editorial Committee is composed of the principal investigator Dr. Acharya and co-investigators Dr. Rathinam, Dr. Anuradha, Dr. Suhler, Dr. Lim, Dr. Arellanes, Dr. Goldstein, and Dr Dhibi. This committee has the responsibility to assist in the preparation of the primary study results and to review secondary manuscripts produced by the study investigators. They have the responsibility to ensure the completion of the primary manuscript (Specific Aim 1) in a timely manner and direct its submission for publication.

10.8. Study Sites

Under the supervision of the CCC, Dr. Rathinam will direct the Indian centers, Dr. Suhler will direct the Oregon center, Dr. Arellanes will direct the Mexico City center, Dr. Lim will direct the Melbourne center, Dr. Goldstein will direct the Chicago center, Dr. Dhibi will direct the Riyadh center, and Dr. Acharya will direct the San Francisco center.

10.9. Pharmacy

The UCSF Pharmacy can handle high volume orders and provide quick turn-around time to ensure a steady supply of medications over the course of the trial. They have participated in a number of clinical trials and will be able to package and bottle the drugs to fit the specifications of the study protocol. The UCSF Pharmacy will prepare all of the study medications for the trial.

10.10 Study Communications

The study coordinator at the Proctor Foundation will be responsible for ensuring that communication between all facilities and committees is conducted seamlessly. Communication between study personnel at the Proctor Foundation and investigators at other sites will be performed by extensive use of secure email. Much of the communication will be through email, but we have found that regular, international, conference calls are valuable and that regular, face-to-face meetings are mandatory. Members of the CCC and the DCC at the Proctor Foundation will visit sites every 4-6 months through the duration of the study to discuss details of the study and monitor quality control.

11. Bibliography

1. Nussenblatt RB. The natural history of uveitis. *Int Ophthalmol* 1990;14:303-8.
2. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. *Br J Ophthalmol* 1996;80:332-6.
3. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. *Ophthalmology* 2004;111:491-500; discussion 500.
4. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. *Br J Ophthalmol* 1996;80:844-8.
5. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. *Ophthalmologica* 2004;218:223-36.
6. Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. *Br J Ophthalmol* 1992;76:137-41.
7. Smit RL, Baarsma GS, de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. *Int Ophthalmol* 1993;17:71-6.
8. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. *Am J Ophthalmol* 1996;121:35-46.
9. Mercanti A, Parolini B, Bonora A, Lequaglie Q, Tomazzoli L. Epidemiology of endogenous uveitis in north-eastern Italy. Analysis of 655 new cases. *Acta Ophthalmol Scand* 2001;79:64-8.
10. Das D, Bhattacharjee H, Bhattacharyya PK, et al. Pattern of uveitis in North East India: a tertiary eye care center study. *Indian J Ophthalmol* 2009;57:144-6.
11. Rathinam SR, Namperumalsamy P. Global variation and pattern changes in epidemiology of uveitis. *Indian J Ophthalmol* 2007;55:173-83.
12. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. *Am J Ophthalmol* 2000;130:492-513.
13. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. *Ophthalmology* 2008;115:1826-32.
14. Siepmann K, Huber M, Stubiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. *Graefes Arch Clin Exp Ophthalmol* 2006;244:788-94.
15. Teoh SC, Hogan AC, Dick AD, Lee RW. Mycophenolate mofetil for the treatment of uveitis. *Am J Ophthalmol* 2008;146:752-60, 760 e1-3.
16. Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. *Ophthalmology* 2005;112:1472-7.
17. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. *Ophthalmology* 1999;106:370-4.
18. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. *Lancet* 1998;352:35-6.
19. Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. *Ophthalmology* 2003;110:1061-5.
20. Choudhary A, Harding SP, Bucknall RC, Pearce IA. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. *J Ocul Pharmacol Ther* 2006;22:168-75.
21. Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. *Ocul Immunol Inflamm* 2001;9:35-40.
22. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. *Ophthalmology* 1999;106:111-8.
23. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with

juvenile idiopathic arthritis. *J Rheumatol* 2005;32:362-5.

24. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for Ocular Inflammatory Diseases. *Ophthalmology* 2009.
25. Holz FG, Krastel H, Breitbart A, Schwarz-Eywill M, Pezzutto A, Volcker HE. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. *Ger J Ophthalmol* 1992;1:142-4.
26. Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low-dose methotrexate therapy for ocular inflammatory disease. *Ophthalmology* 1992;99:1419-23.
27. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. *Ophthalmology* 2009;116:797-801.
28. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate Mofetil for Ocular Inflammation. *Am J Ophthalmol* 2009.
29. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. *Ophthalmology* 2008;115:1416-21, 1421 e1.
30. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol* 2005; 140: 509-16.
31. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. *Ophthalmology* 1985;92:467-71.
32. Manual of Operations: Age Related Eye Disease Study, 2000.
33. Sherring AK. A Practical Guide on Refraction, 1999.

Protocol Revision History

Version

1. Protocol 2.0, 26 September 2012

Revisions in response to feedback from the first DSMC meeting.

- Changed the primary regression analysis to only having treatment arm and site as predictors

2. Protocol 2.1, 1 March 2013

Changes made based on recommendations from our Indian investigators.

- In the inclusion criteria, changed the abnormal threshold for hemoglobin levels to be less than or equal to 9. Previously we had less than or equal to 10, but we would like to set the levels to be more relevant to the Indian population, as their normal levels are frequently between 9 and 10.
- Added windows for Week 2 visit to be plus or minus 3 days.
- Clarified on the study form completion schedule that laboratory test will be done at the week 2 visit (we have previously indicated this in text, but not in the completion schedule).
- Added adverse event checklists for Week 2 in the study form completion schedule.

3. Protocol 2.2, 1 May 2013

Changes made in light of a new reading center and responses from site investigators.

- Added information on a reading center we are collaborating with at University of South Florida.
- In the exclusion criteria, added "planning on getting surgery within the next 6 months"
- Added laboratory assessments for Phase I (6-12 months) at months 7, 8, 10 and 11 and updated the study form schedule to reflect this.
- Modified the wording of the thresholds for the non-serious and serious laboratory events.

4. Protocol 2.3, 22 July 2013

Changes made to reflect the moratorium placed on research with Indian collaborators by the NIH. In order to continue enrollment for the trial, we added new centers.

- Added two new study sites: the Centre for Eye Research Australia in Melbourne, Australia, and Asociacion Para Evitar la Ceguera in Mexico City, Mexico.
- Modified the study timeline to move the data collection and enrollment period back by three months.
- Added the clinicaltrials.gov NCT number.

5. Protocol 2.4, 19 August 2013

Changes reflecting a new source of study drug and new centers.

- Modify the procurement source of our medications from Leiter's pharmacy to the UCSF pharmacy, which can provide medication at a cheaper price. UCSF's pharmacy will purchase and package the medications instead.
- Add Northwestern University in Chicago, IL as a new site.

- Remove the section in the protocol that states medication bottles will be identical and will not carry the medication name. Instead we will have the medication name on the bottles and will keep them in an opaque bag during the study visit to ensure masking of the study doctors (observers).
- Change wording to clarify that double data entry will take place at Proctor Foundation, and all other sites will send secure PDFs to the study coordinator at Proctor.
- In the exclusion criteria, add "ocular condition (besides uveitis) anticipated to dictate treatment course"

6. Protocol 2.5, 1 October 2013

Change reflecting investigator questions on the safety of using NSAIDs during the trial

- Changed the contraindications section on the consent form to allow use of non-steroidal anti-inflammatory medications in combination with methotrexate. We will change it to previously approved language: "Non-steroidal inflammatory drugs (NSAIDs) are contraindicated and should not be taken at the same time as high doses of methotrexate. These drugs taken together may cause bone marrow problems, leading to increased risk of infection, aplastic anemia and gastrointestinal toxicity. The dosage of methotrexate used in this study is not expected to lead to such problems, but you should inform your doctor if you are currently taking any NSAIDs."

7. Protocol 2.6, 2 December 2013

Change to clarify inclusion/exclusion criteria

- In the exclusion criteria, added "periocular or intravitreal corticosteroid injection in the past 4 weeks"

8. Protocol 3.0, 24 March 2014

Changes to include reportable diseases and to allow use of an ETDRS letter chart. Collaborators found enrollment criteria too stringent, changes to inclusion/exclusion criteria to facilitate enrollment

- Added the hepatitis B full panel of tests as part of the study screening. We will add information on reportable diseases to our consent form (Hepatitis B and HIV)
- Changed the vision testing protocol from Tumbling E charts to ETDRS letter charts.
- In the inclusion criteria, changed the duration of a recently failed steroid taper from the past 14 days to the past 4 weeks
- In the exclusion criteria, changed the time limit for abnormal AST, ALT, and CBC labs from within 14 days of enrollment to within 4 weeks of enrollment
- In the exclusion criteria, changed the time limit for abnormal tuberculin skin test, or interferon-gamma release assay, a chest radiograph, RPR/VDRL, FTA-ABS, or other treponemal tests, Hepatitis B surface antigen and Hepatitis C antibody tests from within 60 days of enrollment to within 90 days of enrollment

9. Protocol 3.1, 8 May 2014

Changes to broaden enrollment criteria. New criteria were devised in a lab meeting within the Proctor group and then refined at an investigators' meeting where all the collaborating site PIs were present.

- Changed the enrollment criteria from:

- Active inflammation within the last 90 days, defined by the presence of **any of the following** (in at least one eye) according to SUN criteria:
 - ≥ 2+ anterior chamber cells
 - ≥ 2+ vitreous haze
 - active retinal or choroidal lesions

- **At least one** of the following criteria must be met before or at enrollment:
 - 1.) Active inflammation after 4 weeks of high-dose (1 mg/kg prednisone equivalent) corticosteroid treatment or 4+ weeks after periocular or intravitreal corticosteroid injection
 - 2.) Treatment with oral corticosteroids resulting in a reduction of inflammation, followed by an increase in inflammation (of at least 1 grade in anterior chamber cells or vitreous haze or a change of non-active to active retinal/choroidal lesions) when corticosteroid is tapered, in the 4 weeks prior to enrollment
 - 3.) Known uveitic condition* necessitating corticosteroid-sparing immunosuppressive treatment according to SUN criteria**

To:

- Active inflammation within the last 180 days, defined by the presence of any of the following (in at least one eye) according to SUN criteria:
 - ≥ 2+ anterior chamber cells
 - ≥ 2+ vitreous haze
 - active retinal or choroidal lesions

- **At least one** of the following criteria must be met before or at enrollment:
 - 1.) Active inflammation after 4 weeks of high-dose (1 mg/kg prednisone equivalent) oral corticosteroid treatment
 - 2.) Treatment with oral corticosteroids resulting in a reduction of inflammation, followed by an increase in inflammation (of at least 1 grade in anterior chamber cells or vitreous haze or a change of non-active to active retinal/choroidal lesions) when corticosteroid is tapered, in the 180 days prior to enrollment
 - 3.) Treatment with ³10mg/day oral prednisone or equivalent over at least the past 90 days prior to enrollment
 - 4.) Long-acting corticosteroid injection 4 weeks to 180 days prior to enrollment
 - 5.) One of the following uveitic conditions necessitating corticosteroid-sparing immunosuppressive treatment:
 - Behcet's disease with posterior segment involvement
 - Multifocal choroiditis with panuveitis
 - Serpiginous choroidopathy
 - Birdshot retinochoroidopathy
 - Diffuse retinal vasculitis
 - VKH with bullous serous retinal detachments and/or choroidal detachments

- Sympathetic ophthalmia

10. Protocol 3.2, 29 July 2014

Changes made to add a new center.

- Added King Khaled Eye Specialist Hospital in Riyadh, Saudi Arabia as another enrollment center

11. Protocol 3.3, 12 December 2014

Changes made to clarify enrollment criteria and steroid taper.

- Clarified that goal of steroid taper in Phase I is to maintain at 7.5 mg/day of oral prednisone, not lower (subject to clinician's judgment)
- In inclusion criteria, clarified that Acute Vogt- Koyanagi-Harada syndrome (VKH) that is active for at least 4 weeks qualifies a patient as being in need of immunosuppressive therapy for the purposes of the trial.
- Changed timeline of initial assessments. Because the eyes of patients who visit an ophthalmologist and begin taking prednisone often are quiet by the time of the next visit, and because this trial requires inflammation at enrollment, we will allow the enrollment eye exam and visual acuity assessment to take place up to seven days before the baseline visit date.

12. Protocol 3.4, 13 January 2015

Changes to clarify inclusion/exclusion criteria

- In exclusion criteria, removed HIV from list of specimens that must be collected for laboratory measurements *within 60 days prior to enrollment*. "Evidence of active tuberculosis, HIV infection, syphilis, or hepatitis B or C" remains an exclusion criterion, however, HIV testing is per investigator discretion based upon risk factors discovered upon examination.

13. Protocol 3.5, 6 April 2015

Cleaned up erratum in typing and references

- Changed all mentions of "qd" to "daily" for clarity
- Standardized all "bid" to "BID"
- Clarified that every site does NEI-VFQ but Indian sites also do IND-VFQ
- Changed "Davis scale" to preferred name of Miami scale
- Clarified that injection for persistent ME allowed in first 90 days of follow-up applies to both Phase I and II.
- Specified NEI vitreous haze grading scale for assessment of vitreous haze component of inflammation at enrollment
- Corrected page numbers in table of contents
- Corrected old references to 14 day and 60 day lab result windows to 4 week and 90 days, respectively.

14. Protocol 4.0, 30 April 2015

Changes to reflect

- Updated data entry staff location to “Madurai” from “Proctor”
- Removed month 6 from Phase 1 months 6-12 window table
- Corrected a typo on page 70 section 7.4: “recruitment reports four” to “recruitment reports for”

15. Protocol 4.1, 26 June 2015

Updated exclusion criteria to facilitate enrollment based on a discussion from an Investigator’s Meeting on May 2, 2015 and discussions with the DSMC.

- Amend the current exclusion criterion that excludes patients with prior immunosuppressive therapy (IMT) other than corticosteroids to allow patients who had been on IMT more than 12 months prior to enrollment without previous adverse events and to exclude those known to have had inefficacy, safety, or tolerability issues with methotrexate or mycophenolate mofetil or prior biologic therapy use. The exclusion criteria previously referenced "prior immunosuppressive therapy other than *prednisone*" but now references "*corticosteroids*." Prednisone is the most common corticosteroid used to treat noninfectious uveitis. However, there are other forms of corticosteroids available and we wanted to be inclusive. Since in practice use of another type of corticosteroid other than prednisone does not affect a patients ability to start IMT, so we wanted to be inclusive and wanted to be sure we did exclude patients if they had been on another form of a corticosteroid. The exclusion criteria was then changed from:
 - Prior immunosuppressive therapy other than prednisone

To:

- Prior immunosuppressive therapy other than corticosteroids in the past 12 months
 - Prior intolerability or safety issues with methotrexate or mycophenolate mofetil
 - Prior failure to control ocular or other inflammation using methotrexate or mycophenolate mofetil
 - Prior biologic therapy at any time
- Changed the required timeline of turning in forms to data entry 10 days instead of 7 days

16. Protocol 4.2, 21 September 2015

Changes to study sites

- Added Aravind Eye Hospital – Pondicherry as new study site

17. Protocol 4.3, 2 October 2015

Changes to clarify protocol

- Added back in Zeiss Cirrus in OCT procedures

- Changed wording for Tumbling E (not “alternative” protocol) in visual acuity procedures

18. Protocol 4.4, 26 February 2016

Clarified requirements for lab tests

- Added clarification on lab-related adverse event thresholds for treatment failure due to safety in Section 2.5.2: “If lab results remain at or above the threshold of a non-serious adverse event for 28 days, this is classified as a serious adverse event and treatment failure will immediately be declared.”
- Clarified that the CD4 lab test is required only at AEH, KKESH and UCSF sites at Baseline, Month 3, 6, and 12 (Section 4.3.4, 4.4.2, 5.6)

19. Protocol 4.5, 6 January 2017

Changed randomization protocol and clarified eligibility for phase II.

- Removed randomization list holders from Section 2.4 and added explanation of new process to randomize patients with secure online REDCap database. Study coordinators will perform randomizations on the online database and emergency contact personnel will have access to the database in case of an emergency to look up treatment assignments for current patients who have been randomized.
- Added a statement (Section 4.1.2) instructing investigators to contact the coordinating center if they believe a patient would benefit from being treated in Phase II of the trial but is not able to enter Phase II within the two-week window. In exceptional cases, permission may be granted for the patient to enter Phase II outside of the two-week window.
- Removed Clinical Eye Exam form and Secondary Clinical Eye Exam Form from the Baseline Phase II column of the study form completion schedule. These forms/assessments will no longer be required if a patient enters Phase II on a different day than the Phase I Treatment Failure visit.
- Added a paragraph explaining the process for randomizing patients using the online REDCap database as Section 4.3.2